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ABSTRACT 
 
Hypertension is an important modifiable risk factor for cardiovascular and 
cerebrovascular diseases. Its high prevalence combined with the morbidity and mortality 
associated with secondary complications make it a major public health concern.  
 
One of the important recent advances in hypertension research is an understanding 
that hypertension often may have a developmental origin. Birthweight is associated with 
hypertension across the lifespan and adult cardiovascular disease, such that those at both ends 
of the spectrum are at increased risk. Nonetheless, birthweight is a relatively crude surrogate 
of fetal growth and it may be that quantification of body composition, such as percentage 
body fat, may more accurately identify the “at risk” individual. A causative mechanism 
linking birthweight and risk of cardiovascular disease is yet to be identified but may involve 
changes to the structure and function of organs including the placenta which may impair 
development and predispose individuals to later cardiovascular disease.  
 
Aims   
The aims of this thesis were to investigate the associations between placental function, 
body composition and cardiovascular autonomic function. To achieve these aims, the 
following associations were tested in three settings: 
1. the relationship between maternal factors, placental factors, inflammation and infant 
body composition   
2. the associations of infant body composition and late preterm birth with cardiovascular 
autonomic function 
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3. the association of body composition with autonomic functions in the child and 
adolescent 
 
Results  
The study detailed in chapter three is a cross sectional study that investigated the 
relationship between maternal factors, placental function and perinatal inflammatory 
exposure on the outcome infant fat mass in a cohort of 136 full term infants. This study found 
that infant fat mass was associated maternal factors (pre-pregnancy weight, maternal age and 
parity) and placental factors (weight and surface area). A mediation model was employed to 
determine whether placental function (placental weight) may potentially mediate the 
association of maternal factors, specifically; pre-pregnancy weight and age. Our mediation 
analysis revealed selected maternal factors associated with infant fat mass differed from those 
that were associated with placental weight. Such that only 25-35% of these effects of 
maternal pre-pregnancy weight and maternal age on newborn fat mass was mediated by 
placental weight.  
The studies detailed in chapters four and five is a cross sectional study that 
investigated the effect of infant body composition on cardiovascular autonomic function. 
Chapter four details whether vascular autonomic function, specifically blood pressure 
variability and baroreflex function, differ by newborn percentage body fat and prematurity in 
a cohort of 70 infants, of which 8 were late preterm. Furthermore, this study has introduced a 
possible new non-invasive measure of autonomic regulation of the myocardium, the dP/dtmax 
variability of arterial pressure. This study found little evidence for altered autonomic function 
of vasomotor function and cardiac contractility in these groups, with the exception of infant 
with high body fat who showed reduced baroreflex sensitivity. Furthermore, across the entire 
body fat spectrum (n=62), there was a nonlinear association between newborn body fat and 
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spontaneous baroreflex sensitivity that was independent of birthweight. Chapter five details 
the effect of infant body fat percent on cardiac autonomic control and whether body fat 
percent is a better predictor of alterations in cardiac autonomic control in a cohort of 132 
infants, 37-42 week’s gestation. Cardiac autonomic control was assessed using heart rate 
variability (time and frequency anlaysis) in 4-minute epochs repeated up to three times. This 
study demonstrated that infants with low and high body fat percent have reduced cardiac 
autonomic control. The non-linear association of body fatness with cardiac autonomic control 
was independent of birthweight.  
The studies detailed in chapter six is a cross sectional study that describe cardiac 
autonomic function in those born late preterm. This study included 26 late preterm newborns 
at 34 and 37 completed week’s gestation and a control group of 114 newborns at 37 and 42 
week’s gestation. Cardiac autonomic control was assessed using the same methodology as 
described in chapter five. This study demonstrated that infants born late preterm have 
reduced overall cardiac autonomic control, reduced parasympathetic modulation of the heart 
and increased sympathetic modulation to the heart.  
Finally, the study detailed in chapter seven investigated the association between 
body composition and autonomic function in children and adolescents 2 to 20 years of age 
(n=72) at rest and in response to a stress test. Body composition was assessed by air 
displacement plethysomography using the BOD POD. Markers of autonomic function 
included; heart rate variability (HRV), systolic blood pressure variability (SBPV), baroreflex 
function and dp/dt variability measured for 5 minutes during rest and 4 minutes during 
moderate exercise on a cycle ergometer. This study demonstrated that at rest the association 
between body fat percent and high frequency SBPV was significantly modified by age. 
Subjects who were leaner showed increased HRV, increased cardiac parasympathetic drive 
and lower heart rates, this association was strongest among younger participants, 2-9 years.   
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In response to exercise, individuals with higher body fat percent showed increased HRV 
whereas leaner subjects showed lower HRV. The change in HRV from resting to exercise 
was only associated with fat free mass, such that those who were lean showed a reduced 
response in HRV to exercise.  
 
Conclusions  
These studies indicate different mechanism control fat mass and fat free mass in the 
newborn and that placental weight partly mediates the association of maternal factors with 
newborn body composition. The role of the placenta and factors which affect birthweight 
have gained increasing attention due to the large body of evidence linking birthweight and 
later disease. While low birthweight has previously been shown to be associated altered 
autonomic function in the infant our studies suggests that body fatness may provide 
information beyond that obtained from birthweight assessment alone.  
Previous studies have shown altered blood pressure control in those born preterm, our 
studies found altered cardiovascular outcomes even in born late preterm. Assessment of body 
composition in children and adolescents at rest and in response to an exercise test suggests 
worsening of autonomic control due to adiposity may develop over time during childhood 
and adolescence.  
Collectively, these results emphasise the implications of altered in-utero and early life 
exposures on cardiovascular outcomes. 
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CHAPTER ONE  
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HYPERTENSION  
Hypertension is defined as a systolic blood pressure ≥  140 mmHg and a diastolic 
blood pressure  ≥ 90 mmHg (1). At its early stages, hypertension rarely causes symptoms and 
therefore many people go undiagnosed.  Hypertension is an important modifiable risk factor 
for cardiovascular morbidity and mortality, affecting approximately 40% of people. Its high 
prevalence, combined with the morbidity and mortality associated with secondary 
complications, make it a major public health concern. Hypertension is an independent risk 
factor for heart failure, myocardial infarction, kidney disease, hemorrhagic and ischemic 
stroke and premature death. If left untreated, hypertension is associated with the continuous 
increases in cardiovascular risk as well as the onset of vascular and renal damage (2). 
 
 According to recent estimates by the World Health Organization, cardiovascular 
disease accounts for approximately 17 million deaths a year, accounting for one third of the 
total deaths globally. Of these, hypertension accounted for 9.4 million, being responsible for 
45% of deaths due to heart disease and 51% of deaths due to stroke (1).  
 
The increasing prevalence of hypertension is attributed to a combination of factors 
including population growth, ageing and a complex interaction between behavioral risk 
factors including unhealthy eating, physical inactivity, weight gain and exposure to persistent 
stress (2). Over the years, the number of people with hypertension rose from 600 million in 
1980 to 1 billion in the year 2008 (1). Currently, successful treatment of hypertension 
remains poor, and it may be partly due to a mechanistic mismatch with treatments targeting 
the established symptoms and not the pathophysiologic root cause. Therefore, an understating 
of the aetiology of hypertension is essential for the development of treatment and prevention 
strategies.  
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Current treatment strategies  
Following decades of research into the disease, several major risk factors have been 
unveiled which can be classified into three categories: environmental, genetic and epigenetic. 
It is thought that the complex interaction between these factors are responsible for the 
development of hypertension. Hypertension can be classified as either primary, which is of 
unknown etiology, or secondary, which arise from known underlying renal, vascular, and/or 
endocrine diseases. It is estimated that 90-95% of adult cases of hypertension are of unknown 
etiology (3).  
 
The initial approach taken to the management and treatment of hypertension involves 
lifestyle modification, including adjustment to diet, exercise, alcohol and tobacco 
consumption. Clinical trials indicate that dietary interventions that reduce saturated and total 
fat, that are rich in fruits and vegetables, and with abstinence of alcohol consumption and 
tobacco use can successfully lower blood pressure by as much as 11 mm Hg in individuals 
with hypertension (4). However, due to poor patient adherence to a strict diet and the 
complex and multi factorial nature of hypertension, a pharmaceutical approach is necessary 
in the majority of patients in the real-world environment.  
Unfortunately, current pharmaceutical approaches have also had limited success. A 
number of studies indicate most patients fail to achieve systolic blood pressures below 140 
mmHg (5-7). The proportion of patients achieving target blood pressures below 140/90 
mmHg ranges from a maximum of 27% in the USA to a minimum of 3% in Zaire (8).  
 
These issues associated with treatment may be circumvented by the development of 
novel anti-hypertensive agents. The development of such novel agents will be informed by a 
more comprehensive understanding of the aetiology and pathophysiology of hypertension.  
Hasthi U Dissanayake  Introduction 
 
4 
BLOOD PRESSURE REGULATION 
Over 90% of patients with hypertension receive a diagnosis of hypertension with 
unknown aetiology, also known as primary hypertension. This diagnosis is commonly 
followed by suboptimal therapeutic outcomes and reduced therapeutic compliance. An 
understanding of normal control of blood pressure can inform on the likely disease processes 
contributing to primary hypertension.  
Indeed, in otherwise healthy people, blood pressure is tightly regulated to ensure 
constant perfusion of various tissues and to meet metabolic demands, while remaining low 
enough to avoid structural damage to tissues. Blood pressure regulation is a complex 
physiologic function involving multiple systems.  
Local mechanisms act to regulate blood flow via the opposing actions of acute 
vasoconstriction and vasodilatation, and changes to the number and caliber of blood vessels 
supplying a tissue. Endothelial autocrine secretions play a vital role in inducing 
vasoconstriction and vasodilation. The renal-endocrine system is a chronic mechanism, 
controlling blood pressure over weeks and months via fluid balance and salt homeostasis; 
these mechanisms will not be discussed in this thesis as they are beyond the scope of the aims 
of this thesis.   
 
In addition to these local mechanisms, global control of blood flow is mediated via 
the autonomic nervous system which can be divided into sympathetic and parasympathetic 
nervous system. The sympathetic nervous system is central to the control of blood pressure 
via direct adjustments to cardiac output and total peripheral resistance and indirect 
adjustments to blood volume via changes to renal function. The parasymapthic nervous 
system contributes mainly to the regulation of cardiac function.
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Autonomic innervation of the heart  
Although cardiac automaticity is intrinsic to pacemaker tissue, the heart is innervated 
by vagal (parasympathetic) and sympathetic fibers. Furthermore, heart rate and rhythm are 
largely under the control of the autonomic nervous system (9).   
 
Postganglionic sympathetic neurons innervate the atria, ventricles and conduction 
system of the heart. The sympathetic modulation of the heart is mediated by the release of 
epinephrine and norepinephrine. Activation of -adrenergic receptors upregulates cyclic 
AMP initiating protein kinase A mediated phosphorylation of membrane proteins and 
increases L-type calcium and pacemaker current (9). The end point is an acceleration of the 
slow diastolic depolarization resulting in an increase in heart rate (positive chronotropy), 
contraction of the myocardium (inotropy) and conduction velocity of atrioventricular node 
(dromotrophy).  
 
 The parasympathetic influence on the heart is mediated by cholinergic efferent vagal 
fibers, predominantly innervating the sinoatrial and atrioventricular nodes (10). However, 
there is some overlap in the anatomical distribution where the atrial muscle is also innervated 
by vagal efferent fibers and the ventricular myocardium sparsely innervated by vagal 
efferent.  The release of acetylcholine by the vagus nerve inhibits hyperpolarization activated 
pacemaker current. The pacemaker depolarization results from a slow deactivation of the 
delayed rectifier current resulting in diastolic depolarization. Furthermore, acetylcholine acts 
on muscarinic acetylcholine receptors to increase cell membrane potassium conductance, 
slowing the speed of depolarization acting to slow the heart rate (9). Under normal resting 
condition, vagal tone prevails and heart period variations are mainly dependent on vagal 
modulation (11, 12). 
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Oscillations in heart period  
Efferent sympathetic and parasympathetic activity to the sinus node is largely 
synchronous to each cardiac cycle and can be affected by central (vasomotor and respiratory 
centers) and peripheral (oscillations arterial pressure and respiratory movements) oscillations 
(13). These oscillations generate rhythmic fluctuations which manifest as short and long-term 
oscillation in the heart period and the analysis of these fluctuations may provide insight to the 
state and function of (a) the sympathetic and parasympathetic efferent activity, (b) the central 
oscillators, (c) the sinus node, and (d) humoral factors.  
The modulatory effect of neural activity on the sinus node has been possible by 
spectral analysis of heart rate variability. Measures of heart rate variability have been utilized 
as tools to measure cardiac autonomic function in the studies represented in this thesis and 
methodologies will be covered in relevant chapters.  
 
Autonomic innervation of the vasculature   
In contrast to the heart, most arteries and veins receive only sympathetic innervation, 
while capillaries receive no innervation. Sympathetic adrenergic nerves tonically release 
norepinephrine activating 1 and 1 adrenergic receptors located on blood vessels. This tonic 
activation maintains vascular tone. The activation of vascular sympathetic nerves causes 
vasoconstriction of arteries and veins and contraction of vascular smooth muscles.  
 
Baroreceptor reflex  
The baroreceptor reflex is a rapid, homeostatic reflex which buffers fluctuations in 
blood pressure caused by everyday behaviors including stress, postural changes and physical 
activity (14, 15).   Adequate buffering is crucial for regulating blood flow and maintaining 
gaseous and nutrient exchange with tissues.  
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Blood pressure changes are detected by mechanoreceptors known as baroreceptors 
located in the aortic arch and carotid sinus, Figure 1. These stretch receptors are activated 
when distended and send action potentials to the central nervous system which propagates 
signals through the autonomic nervous system. The end result is adjusting total peripheral 
resistance via vasodilatation and reducing cardiac output through negative chronotropic and 
inotropic regulation of the heart, Figure 2. 
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Figure 1. Location and innervation of arterial baroreceptors. Blood pressure changes cause a 
conformational change in baroreceptors resulting in changes to the neuronal firing. The 
Herine nerve and a branch of the glossopharyngeal nerve carries signals from the carotid 
baroreceptors and the vagal nerve carried signals from the aortic baroreceptors. Adapted from 
Klabunde, RE (16). 
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Figure 2. An increase in arterial pressure increases baroreceptor firing. Autonomic neurons 
within the cardiovascular control centre (medulla) respond by decreasing sympathetic nerve 
activity to the heart and blood vessels and increases parasympathetic activity to the heart, 
resulting in decreasing cardiac output (CO), heart rate, (HR), stroke volume (SV) and total 
peripheral resistance (TPR) ultimately reducing arterial pressure. Adapted from Klabunde RE 
(16). 
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NON-INVASIVE ASSESSMENT OF AUTONOMIC FUNCTION  
The autonomic nervous system plays a key role in maintaining homeostasis by 
continually adjusting the function of organs in response to ongoing changes in the internal 
and external environment. Disruption to these homeostatic mechanisms may be a mechanistic 
contributor to the pathophysiology of disease.  
The ability to reliably quantify dynamics of the autonomic nervous system is crucial 
for investigating diseases associated with autonomic dysfunction. Traditionally, the 
assessment of autonomic activity requires the use of invasive techniques such as measuring 
muscle sympathetic nerve activity using microneurography or measuring cardiac 
noradrenaline spillover to plasma using isotope dilution techniques. However, the use of 
these invasive methods limits their widespread use, particularly in otherwise healthy 
individuals including infants and children. The strong consensus that autonomic dysfunction 
may be pivotal in the development of hypertension has encouraged the development of 
quantitative non-invasive markers of autonomic activity.  
 
In this thesis, autonomic function was assessed using the following techniques: (i) 
time and frequency analysis of heart rate variability, (ii) frequency analysis of blood pressure 
variability, (iii) spontaneous baroreflex sensitivity, (iv) baroreflex effectiveness index and a 
potential new marker of autonomic regulation of the myocardium (v) dP/dtmax variability of 
arterial pressure. These measures are all conducted post-hoc from electrocardiography and 
blood pressure waveforms.  
 
Heart rate variability 
Measures of heart rate variability (HRV) represent one of the most promising markers 
of cardiac autonomic function. ‘Heart rate variability’ is the conventionally accepted term to 
describe variations in both RR intervals and instantaneous heart rate.  
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Variations in heart rate can be evaluated using a number of methods. In the studies 
described in this thesis, HRV was calculated with time and frequency domain methodology. 
Details are provided in the relevant chapters, but in brief, key time domain measures included 
standard deviation of the NN interval (SDNN), and the square root of variance, an estimate of 
overall HRV (9). The square root of the mean squared differences of successive NN intervals 
(RMSSD) and the standard deviation of the difference between adjacent NN intervals 
(SD∆NN) as a marker of vagal modulation of the heart (17).  
 
The autonomic nervous system mediates oscillations in heart rate and blood pressure 
at two main frequencies; high and low. Frequency domain analysis of HRV are determined 
by performing a fast Fourier transformation from an ECG trace, which enables the separation 
of the fluctuations into three pre-determined frequency components: very low, low and high 
frequency. The very low frequency ranges between 0-0.04 Hz, low frequency in the ranges of 
0.04 to 0.15 with high frequency depending on the rate of respiration (18). Time and 
frequency analysis of heart rate variability has been used in a number of studies as a simple 
tool for both research and clinical studies (9), including those in infants and children with 
different phenotypes (19, 20). 
 
Components of heart rate variability  
Two frequency bands are shown to be related to autonomic function; low frequency 
reflects both sympathetic and parasympathetic modulation and high frequency reflects 
parasympathetic modulation to the heart (19, 20).  
Efferent vagal activity contributes largely to the high frequency component. This is 
seen in clinical and experimental observations using autonomic maneuvers such as 
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muscarinic receptor blockage, electrical vagal stimulation and vagotomy (13, 21, 22). More 
debated is the interpretation of the low frequency component, considered as a marker of 
sympathetic modulation by some (13, 23-25) and by others, as a marker of both sympathetic 
and parasympathetic influence (21, 26). Consequently, the low to high frequency ratio is 
thought to be a marker of cardiac sympathetic balance (9).  
The physiological basis of the very low frequency component is less well understood 
but may reflect changes in vasoactive hormone levels or thermoregulatory mechanisms (27).  
 
It is important to recognize that heart rate variability measures autonomic modulations 
to the heart rather than the mean level of autonomic modulation. Therefore, autonomic 
withdrawal as well as a saturating high level of sympathetic modulation leads to diminished 
heart rate variability.  
 
Blood pressure variability  
Blood pressure can vary significantly over minutes throughout the course of the day, 
for example, changes in the beat to beat blood pressure variation in response to physiological 
or psychological stimuli, or in response to sleep and wakefulness. However, spontaneous 
blood pressure variations also occur independent of behavior (28). These fluctuations of 
blood pressure are the result of complex interactions between a number of mechanisms 
including mechanical influences of ventilation, cardiac vascular neural regulation, arterial 
stiffness, humoral and endothelial factors or genetic factors.  However, when applied in the 
frequency domain, analysis can provide insight into integrated cardiovascular regulation (29).  
 
Similar to heart rate variability, frequency analysis of beat to beat fluctuations in 
systolic blood pressure can be examined. The low frequency band of blood pressure 
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variability is regarded as an index of sympathetic modulation of the systemic vasculature and 
therefore total peripheral resistance (19, 30). The role of the high frequency component of 
blood pressure variaibility in autonomic regulation is less clear. However a recent study 
indicates that it may be linked to respiratory modulation of sympathetic vasomotor tone (31). 
Frequency analysis of blood pressure variability has been applied in a number of studies 
including the infant and child with different phenotypes (19, 32).  
 
Baroreflex sensitivity  
The sensitivity of the baroreceptor reflex is a measure of how much heart rate changes 
for a given change in arterial blood pressure. Traditional measures of baroreflex sensitivity 
are derived using invasive techniques, whereby vasoactive drugs are injected to produce 
changes in blood pressure, plotting the resultant heart rate or pulse interval response against 
blood pressure (33). More recently, the analysis of baroreflex sensitivity has been undertaken 
using computer-based techniques without the use of vasoactive drugs.  
The sequence method scans the blood pressure wave form and identifies sequences of 
consecutive increases or decreases in systolic blood pressure followed by a progressive 
lengthening or shortening of heart rate or pulse interval over a period of four or more beats. 
This relationship is then plotted and fitted with a linear regression. The slope of the 
regression between systolic blood pressure and pulse interval or heart rate values in each 
sequence are indicative of baroreflex sensitivity (34).   
 
Studies indicate that beat to beat changes in heart rate do not correspond to the fluctuation in 
systolic blood pressure in the same window, Figure 3. These delays are a result of different 
velocities of vagal and sympathetic regulation (35). Studies in infants indicate a delay of 
approximately two seconds for changes in heart rate in response to a change in blood pressure 
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(36), however no delays are found conversely in older children or adults. Therefore, the use 
of delays should be considered when identifying the relationship with corresponding heart 
rate or pulse intervals, and the relationship should be plotted for each delay in the neonate. 
Results obtained utilizing the sequence method are consistent with those obtained using 
traditional methods of vasoactive drugs. Previous studies have used the sequence technique to 
determine baroreflex sensitivity in the infant, child and adult (34, 36, 37). Similarly, this 
method was used in our studies to determine baroreflex sensitivity in the infant, child and 
adolescent. 
Hasthi U Dissanayake  Introduction 
 
15 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Visual representation showing beat to beat interval (BBI) does not respond to 
changes in systolic blood pressure (SBP) in the same window. Adapted from Malberg et al 
(35). 
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Baroreflex effectiveness index  
In healthy individuals, the baroreflex is not always activated in response to every 
fluctuation in blood pressure. These sequences are interspersed with progressive systolic 
blood pressure changes that are not coupled with a reflex modulation. The presence of these 
uncoupled sequences may indicate that even in healthy individuals, the baroreflex may not be 
totally effective in inducing responsive changes to blood pressure fluctuations, despite being 
continuously involved in cardiovascular homeostasis (34).  
 
This phenomenon can be quantified as the baroreflex effectiveness index and is 
determined as the ratio of the number of identified baroreflex sequences against the total 
number of systolic blood pressure ramps observed for a given period of time (34). It can be 
calculated using the formula below and may be useful in understanding baroreflex function 
between different phenotypes.  
 
𝐵𝐸𝐼 =
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑃𝐼/𝑆𝐵𝑃 𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒𝑠 
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑒𝑟 𝑜𝑓 𝑆𝐵𝑃 𝑟𝑎𝑚𝑝𝑠 
 
 
dP/dtmax variability 
Estimated arterial dP/dtmax has been reported to be a surrogate measure for evaluating 
changes in left ventricular contractility (Rhodes et al., 1993). Although dP/dtmax of the arterial 
pressure waveform is affected by preload and arterial compliance (38), studies indicate a 
strong correlation between ventricular and arterial dP/dtmax. Furthermore, arterial dP/dtmax 
may offer a valuable methodology for non-invasive assessment of myocardial contractility 
(39-41). 
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A major influence on ventricular contractility is the autonomic nervous system (42). 
A study part of this thesis has introduced a possible new index of autonomic control of 
myocardial contractility, dP/dtmax variability. It is possible that sympathetic modulation of the 
ventricular myocardium may be reflected in the low frequency component of dP/dtmax 
variability, as the maximum rate of change in arterial pressure is related to the force of 
ventricular contraction. Accordingly, frequency analysis of dP/dtmax variability can be 
performed similar to systolic blood pressure variability, Figure 4. 
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Figure 4: Example of blood pressure waveform (A) recorded in a control 
newborn (B) calculated dP/dt waveform and (C) dP/dtmax derived from the blood pressure 
waveform. dP/dtmax coincides with the maximum upstroke of the blood pressure waveform 
during systole. Applying frequency analysis over the dP/dtmax waveform enables the 
separation of fluctuations into individual frequency components.  
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AUTONOMIC ASSESSMENT DURING EXERCISE  
Exercise testing has become a routine procedure in testing impairment of functional 
capacity in people with cardiac problems. Exercise is a form of physiological stress inflicted 
upon the body inducing a cardiovascular response. These tests can be useful in identifying 
individuals at risk of cardiovascular disease and interpretation of hemodynamic data. 
Furthermore, in some patients’ cardiovascular disorders or the hypertensive phenotype may 
be unveiled only when challenged with an acute stressor.  
 
In the context of programming, low birthweight children show decreased diastolic 
function and exercise induced cardiac fatigue after prolonged exercise (43) and very low 
birthweight premature children show limited functional capacity during exercise (44). 
However, other studies have found little differences in exercise performance between small 
for gestational age and appropriate for gestational age children (45). To date there are only a 
few studies that have investigated a cardiovascular response to exercise in those born small or 
large for gestational age.  
 
Numerous exercise protocols and exercise machines have been used for paediatric and 
adolescent exercise testing. Each of these methods have their unique advantages and 
disadvantage. Cycle ergometry was used in our exercise testing protocol as our testing 
required an accurate blood pressure waveform and electrocardiogram and use of a bicycle is 
preferred over a treadmill for acquisition of these type of measurements (46).  A disadvantage 
of using cycle ergometry is that not all subjects, especially in the paediatric population, are 
accustomed to cycling therefore premature muscular fatigue may prevent individuals from 
reaching their maximal effort. The complete exercise protocol used in this thesis for exercise 
testing is described in Chapter seven.  
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Cardiac autonomic function during dynamic exercise   
 The autonomic nervous system plays a crucial role in initiating cardiovascular 
responses to exercise. These changes ensure the increased metabolic demand is met. During 
exercise, there is a well characterised decrease in cardiac parasympathetic activity and an 
increased sympathetic activity to the renal, cardiac and splenic regions which results in an 
increased heart rate, cardiac output, stroke volume and helps redistribute blood flow to 
skeletal muscles (47).  
 
The autonomic nervous system regulates cardiac function during exercise, these 
include regulation of cardiac contraction (inotropic), heart rate (chrontopic) and rate of 
myocardial relaxation (lusitropy) (48). In humans our understanding of cardiac autonomic 
control during exercise is mainly based on studies that have utilised heart rate variability 
analysis which has been validated in children and adolescents analysis (49-53) and or giving 
pharmacological antagonists that act on cardiac autonomic receptors (48). A number of 
studies have investigated the effect of exercise on heart rate variability, with both the 
intensity and duration of exercise being involved. Nevertheless, the literature indicates that 
on average heart rate variability is reduced (in time and frequency analysis) during exercise. 
With regard to sympathovagal balance, cardiac parasympathetic activity appear to be reduced 
during exercise, but normalised units of low frequency power (a measure of cardiac 
sympathetic and parasympathetic modulation) increases during low to moderate exercise and 
decreases during high intensity exercise (54-57). However, there are some conflicting results 
to these changes (58-60).  
When utilising frequency analysis of heart rate variability during dynamic exercise it 
is important to consider the frequency ranges, especially the high frequency range. Typically, 
a high frequency band of 0.15-0.40 Hz is used, however during exercise this band may not be 
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suitable as higher respiratory frequency are observed during exercise. Therefore, different 
low (i.e 0.18 Hz) (61, 62) and upper limits (i.e 0.35, 0.50 or 0.80 Hz) (55, 58, 62) have been 
used during exercise.  
 
Baroreflex function during dynamic exercise   
The arterial baroreflex resets and functions around the prevailing heart rate and blood 
pressure during dynamic exercise (63-66). The resetting of the baroreflex is brought about by 
neural signals from higher brain centres and sensory afferents from active skeletal muscles 
(67). With the resetting of the baroreflex to a higher operating point, baroreflex sensitivity is 
reduced  (68-71). This reduction is seen as the operating point of the baroreflex is shifted 
away from the point of maximum sensitivity, located at the centre of the baroreflex function 
curve, figure xx, (69).  These changes are thought to occur due to an exercise induced 
reduction in cardiac parasympathetic activity (69). Collectively, measuring autonomic 
reactivity to exercise may provide some insight to autonomic stress reactivity in different 
phenotypes.  
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DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE  
 
The “Barker hypothesis” 
The ‘Barker hypothesis’ posits that suboptimal in utero conditions may permanently 
alter the growth and maturation of fetal tissue, leading to long-term changes in structure and 
physiological function that may influence risk of disease in later life(72-74). This concept is 
commonly known as fetal programming and is a core component in the field of 
developmental origins of health and disease.  
 
This concept arose from epidemiological observations made by Barker and colleagues 
which showed geographical distribution of infant mortality in England closely matched the 
distribution of death rates from coronary heart disease decades later (75). The most 
commonly registered cause of infant death during this time was low birthweight. This 
observation led to the hypothesis that individuals with a low birthweight who survived 
infancy and childhood in those regions may be at an increased risk of coronary heart disease 
later in life.  
 
Following this initial observation made by Barker and Osmond, a number of other 
studies have found evidence consistent with this hypothesis, showing a strong association 
between low birthweight and increased risk of later cardiovascular disease (75-81).  
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Fetal growth and adult cardiovascular disease: a life course perspective 
Impaired fetal growth due to maternal malnutrition or placental insufficiency is a 
well-established risk factor for increased cardiovascular morbidity and mortality in adulthood 
(82). Reduced fetal growth is frequently accompanied by systemic growth restriction 
resulting in changes to the structure and function of key organs which control blood pressure. 
These adaptive changes prepare the infant to similar conditions postnatally, ensuring its 
survival, giving rise to a thrifty phenotype. If these individuals are exposed to a high caloric 
diet in postnatal life, they may be at an increased risk of developing metabolic disorders such 
as type II diabetes and abdominal obesity. Indeed, a number of studies describe an 
association between low birthweight and higher risk of hyperlipidemia, type 2 diabetes and 
greater central distribution of fat (72, 83, 84), all risk factors for cardiovascular disease.  
 
Animal models provide further evidence for an association between fetal growth 
restriction and adult cardiovascular disease. A number of prenatal manipulations including 
maternal under nutrition, glucocorticoid exposure, hypoxia and placental obtrusion show 
cardiovascular programming in the rat, sheep, pig and guinea pigs (85-87).  
 
Since the observations made by Barker and colleagues, this field of research have 
evolved to encompass a number of other environmental insults in addition to undernutrition.   
 
With the growing obesity epidemic, attention has recently been directed towards 
maternal over nutrition. There is accumulating evidence in humans that those born large for 
gestational age may also be at increased risk of developing cardiovascular and metabolic 
disease in later life. For example, those born large for gestational age show increased systolic 
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blood pressure and obesity as children (88-91) as well as adverse cardiometabolic health as 
children and adults (92-94). 
Furthermore, there is accumulating evidence from a number of animal studies 
supporting the hypothesis that increased maternal weight, obesity or a high fat diet during 
pregnancy is associated with obesity and hypertension in the offspring (95-100).  
 
Collectively, it is becoming increasingly evident that those born small or large for 
gestational age may be at increased risk of later cardiovascular and metabolic disease. 
However, it is important to understand that although programming of cardiovascular disease 
can begin in utero, programming can also occur in postnatal life, particularly during infancy 
while plasticity of organs and tissues remains high. This can occur due to premature births 
(101-103), growth trajectories (104-107) or changes in nutrition composition (108, 109).  
 
Therefore, given the high prevalence of cardiovascular disease, targeting established 
cardiovascular disease in the adult is no longer effective in ameliorating the growing burden. 
It is therefore important to consider a life course perspective, an approach based on the 
premise that the aetiology of chronic diseases begins decades prior to their clinical 
presentation, and that they can be prevented and controlled at multiple stages of the life 
course. This requires an understanding of the behavioral, biological and psychosocial 
processes across the life course of an individual (110), in order to enable interventions to be 
developed and implemented to prevent clinical disease outcomes.  
 
Developmental plasticity is highest in early life and declines over the life course 
which results in increased susceptibility to disease due to a reduced ability to adapt to new 
stimuli, Figure 5. Although the greatest risk of disease is in adulthood, risk factors for 
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diseases accumulate over an individual’s life course. Identifying these early risk factors and 
phenotypes are imperative and enables risk stratification and the development of nutritional 
and lifestyle interventions. A number of maternal factors including dietary intake, body 
composition and stress can affect fetal development. These changes encountered in utero may 
predispose the exposed individual to later cardiovascular risk. Similarly, nutrition and 
development during infancy and childhood will influence risk of disease at a later stage. 
Therefore, early intervention, such as during early childhood, may have a greater impact on 
reducing disease risk than interventions implemented later in life, figure 5.  
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Figure 5. Life course perspective of disease risk. Nonlinear increase in disease risk as 
plasticity decreases and accumulative effects of adverse stimuli over the life course. Early 
intervention reduces risk trajectories. Adapted from Hanson et al (111).  
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Fetal growth and adult cardiovascular disease: plausible mechanisms  
As described in the previous section, there is a strong association between birthweight 
and risk of adult cardiovascular disease. However, it is unlikely that birthweight itself is the 
cause of increased cardiovascular risk, but simply a crude marker of other process that are 
occurring. To date, it is unclear whether developmental alterations in the kidney, vasculature 
or the brain causes increased risk of cardiovascular disease in those born small or large for 
gestational age. A number of studies show altered structural and functional changes to the 
kidney and vasculature in programming studies.  
 
Early studies focused on the kidney as a key site for programming of hypertension. In 
humans, low birthweight is accompanied by a reduced nephron number (112, 113). These 
studies provide a plausible evidence-based mechanism linking low birthweight with poor 
blood pressure control, and subsequent hypertensive disorders. Other studies, however, have 
failed to demonstrate a link between reduced nephron number and hypertension (114, 115).  
 
Vascular function studies in low birthweight individuals show decreased vascular 
compliance (116), endothelial dysfunction (117), impaired endothelial-dependent and 
independent vasodilation at birth, 3 months of age, childhood and adult life  (118-120). Low 
birthweight individuals also show structural changes to the vasculature. These include; 
increased arterial and large artery stiffness (121), increased aortic wall thickening (122), 
reduced compliance and aortic size (123), carotid atherosclerosis (117, 124) and narrowing of 
coronary arteries (125). More recently, young adults born large for gestational age show 
increased carotid intima-media thickness, a marker of subclinical atherosclerosis (92) as well 
as newborns (93).  
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AUTONOMIC NERVOUS SYSTEM AND PROGRAMMING OF 
HYPERTENSIVE DISEASE  
 
Animal models  
 Experimental studies with animal models have played an important role in investigating the 
roles of maternal nutritional manipulations and placental insufficiency in driving alterations to 
autonomic activity as a mediator of the increased blood pressure in adulthood (126-132).  
 
 Studies looking at a maternal low protein diet found alterations in catecholamine 
metabolism in 12-week-old rat offspring from mothers fed a low protein diet during pregnancy 
and lactation, consistent with an increased sympathoadrenal activity during the fed state (133). 
A study designed to measure renal sympathetic nerve activity in protein restricted rats found 
increased renal sympathetic nerve activity in response to stress and not during resting 
conditions.   
 
 Studies looking at neuronal activity have shown increased levels of corticotropin-releasing 
hormone RNA expression in the paraventricular nucleus (PVN) of humans with primary 
hypertension (134), in spontaneously hypertensive rat (135), and in the hypothalamus of 
hypertensive rats programmed via maternal undernutrition (136). These studies indicate a 
possible role of the PVN in the pathogenesis of hypertension in humans and in animal models. 
The PVN is a neuronal nucleus located in the hypothalamus, which is activated in response to 
stress and physiological changes. Neurons projecting from the PVN have important functions 
in regulating the autonomic nervous system. A study by Navarrete and colleagues (2007) 
investigated the excitatory connections of the PVN neurons between offspring from mothers 
given a restricted diet and those from a control diet found, offspring of undernourished mothers 
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exhibited increased neuronal activity in the PVN and locus coeruleus with an increased systolic 
pressure compared to their control counterparts. Furthermore, they tested the effect of 
microinjecting 1-adrenoceptor antagonist prazosin into the PVN and corticotropin-releasing 
hormone into the locus coeruleus. Microinjecting prazosin into the PVN decreased neuronal 
activity and systolic blood pressure in the undernourished offspring; whereas microinjection of 
corticotropin-releasing hormone into the locus coeruleus stimulated neurons and increased 
systolic blood pressure in control rats. Taken together, two alternatives are possible for the 
effects observed; (i) desensitization of corticotropin-releasing hormone receptors due to 
hyperactivity in undernourished offspring and/or (ii) neurons are already fully active in the 
undernourished offspring and are insensitive to any further excitation via exogenous 
corticotropin-releasing hormone  (136). This study points to the possibility of a hyperactive 
PVN- locus coeruleus loop in offspring of mothers given an undernourished diet. This 
hyperactive loop could potentially be responsible for increased stimulation of the sympathetic 
nervous system and therefore, the hypertensive state of these undernourished rats (136). 
 
 Initial studies directed their focus on maternal/fetal under-nutrition and low birthweights. 
However, in light of the obesity epidemic, attention has recently been shifted to the role of 
maternal over-nutrition in programming of hypertension. There is now substantial evidence 
from animal studies supporting the hypothesis that maternal overweight, obesity or high fat 
dietary intake is associated with obesity and hypertension in the offspring (137-140). 
Furthermore there is evidence suggesting raised sympathetic activity may be mechanistically 
involved in programmed hypertension (137, 141). A study by Samuelsson et al (137), showed 
hypertension and increased sympathetic activity in juvenile rat offspring (30 days of age) and 
as young adults (90 days) from mothers fed an obesogenic diet during pregnancy. Moreover, 
administration of  and -adrenergic blockers reduced blood pressure to levels comparable to 
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control rats. In addition, these offspring developed hypertension and increased sympathetic 
activity as juveniles, prior to the onset of overt obesity. Therefore, this suggests changes to 
autonomic activity and hypertension arise as a direct consequence of in utero exposure to 
maternal obesity. A study by Rudyk and colleagues (141), determined the effects of a high fat 
diet in the absence of maternal obesity on cardiovascular and autonomic function in rats during 
rest and in response to an acute stressor. Resting blood pressures were similar between groups 
although offspring from mothers fed a high fat diet showed heightened cardiovascular response 
to stress with a prolonged recovery period. Following salt loading, these rats showed a 
heightened nocturnal blood pressure and an increased low/high frequency ratio of HRV. This 
suggests that a high fat diet during pregnancy, in the absence of maternal obesity, results in 
altered sympathetic control and hypertension in the offspring, secondary to an acute stress 
response (141).  
 
 Similarly, a study in rabbits investigating the effects of a maternal high fat diet on blood 
pressure and renal sympathetic nerve activity found that offspring from a maternal high fat diet 
had higher MAP, HR and renal sympathetic nerve activity at four months of age compared to 
their control counterparts. Furthermore, in response to an acute stressor, the high fat offspring 
exhibited an exaggerated sympathetic response. However, it is difficult to dissociate whether 
the increased sympathetic activity seen in the high fat offspring are due to excess visceral fat 
found in these offspring, or due to the direct programming of the sympathetic nervous system 
due to a maternal high fat diet (142). 
 
In addition to the increased consumption of diet high in fat, there is also a growing trend 
in the consumption of beverages high in sugar. Despite the known adverse effects of high sugar 
beverages on cardiovascular and metabolic health, their effects on the developing fetus have 
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not been studied extensively. In pregnant mice, obesity induced by feeding a diet rich in animal 
fat and sugars resulted in hypertension and increased fat mass in the offspring (143). The same 
investigators subsequently examined the effects of a maternal diet with high sugar content in 
isolation and found that it induced significantly higher blood pressures in both male and female 
offspring at three months of age (144). Furthermore, both male and female offspring showed 
increased LF:HF ratio in their HRV and raised renal noradrenalin, suggesting that the 
hypertension may be due to increased sympathetic tone. 
 
Studies in Humans  
Chapter two of this thesis details studies investigating the autonomic nervous system 
and programming of hypertension in humans.  
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PLACENTAL FUNCTION  
The placenta is a key organ that connects the growing fetus to the uterine wall and 
facilitates the transfer of nutrients, gas exchange, waste elimination, and thermoregulation. In 
addition, the placenta metabolises a number of substrates, produces key hormones that affect 
pregnancy, fetal growth and metabolism, as well as protect the fetus from infection and 
maternal diseases (145). These different functional properties of the placenta can be 
categorized into different systems. These include transport and metabolism, protection and 
endocrine.  Any functional changes to the placenta directly affect the fetus, altering its ability 
to adapt and respond to the intrauterine environment, ultimately affecting fetal growth (145).  
 
The Placenta and programming of disease  
The developmental origins of health of disease concept involves early environmental 
exposures and other influences during gestation, and their links with postnatal predisposition 
of an individual to disease in later life. The placenta plays a key role in these processes and it 
is possible that the links between nutritional and endocrine factors with later disease are 
mediated via placental health and control mechanisms. The evidence linking the placenta to 
later disease is based on placental weight (146). Placental weight is strongly correlated with 
the weight of the newborn, and as fetal weight increases throughout gestation, so does 
placental weight.  
 
Several studies have shown that placental weight is associated with increased risk of 
hypertension in later life (82, 146, 147). However, studies in children show inconsistent 
associations with blood pressure (148). Moreover, studies report an association between 
increased blood pressure levels with low and high placental weight in relation to birthweight 
(149, 150). However, placental weight is directly associated with the placental surface area 
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available for nutrient and oxygen exchange. Studies in animals indicate that if ewes are 
undernourished during mid pregnancy, the placenta can expand, thereby increasing its surface 
area allowing for increased nutrient exchange from the mother (151, 152). However, these 
changes were only seen in those who were well nourished at time of conception. A study 
including 2003 subjects found reduced placental weight and area to be associated with 
hypertension but not reduced placental thickness (148).   
 
Fetal nutrition depends partially on maternal nutrition, metabolism and maternal 
nutrient stores. A number of studies indicate maternal factors such as diet, body composition, 
body mass index, maternal blood glucose and lifestyle influence placental size and therefore 
fetal development (148, 153, 154). Maternal factors may affect fetal development via the 
placenta by modifying placental metabolism and nutritional transport or, independent of 
placental tissue (i.e. nutrients enter the fetal circulation directly) (154). Several studies 
indicate that both maternal and fetal factors affect transport capacity, ultimately altering 
placental function and amount of glucose, amino acid and fatty acid transported to the fetus 
(154-156).  
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Early life inflammation  
More recently, infection and early life inflammation, which can affect the placenta, 
have been proposed to contribute to increased cardiovascular risk. Many of the early life risk 
factors such as poor intrauterine growth, maternal obesity, diabetes, hypercholesterolaemia 
and smoking are associated with an increased inflammatory state (157). Moreover, 
inflammation plays a central role in the development of atherosclerosis and cardiovascular 
disease, and therefore, early life inflammatory events and infection may predispose these 
individuals to increased cardiovascular risk.  
 
To date, there are a limited number of studies that have investigated the role of 
perinatal inflammation and infection on cardiovascular risk. A perinatal inflammatory 
exposure most commonly elicited in response to an infection within the uterus during 
pregnancy can result in a maternal (chorioamnionitis) and fetal inflammatory response, both 
of which can be histologically identified within the placenta (158). It is possible that a 
perinatal infection or inflammatory exposure may affect developing organs such as the heart 
and blood vessels (159), contributing to pathways underpinning epidemiological associations 
between poor intrauterine growth and adult cardiovascular disease.  
 
Animal models of chorioamnionitis show associations between chorioamnionitis and 
hemodynamic changes (157), with reduced cardiac function (160), impaired myocardial 
contractility and relaxation (161), increased cardiac afterload and reduced cardiac output in 
fetal mice (162), reduced ventricular contractility and reduced cardiomyocyte numbers in 
fetal sheep (163).  
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In human newborns, increased abdominal aortic intima-media thickness, a marker of 
preclinical atherosclerosis, is associated with increased inflammatory mediators in the 
amniotic fluid (164) and in maternal (165) and umbilical cord plasma (166). A study in 
preterm infants showed that histological chorioamnionitis is associated with increased serum 
high-sensitivity C-reactive protein during their first week after birth, and a non-significant 
trend towards an adverse lipid profile. However, measures of aortic intima-media thickness 
and blood pressure in these infants showed no association with chorioamnionitis. The short 
duration and the late on set of chorioamnionitis later in the gestational period may be 
insufficient to induce changes to arterial structure. Nevertheless, follow up studies of these 
infants may unveil altered risk trajectories (167).  
 
Collectively, altered placental function via maternal factors or a perinatal 
inflammatory exposure may affect fetal growth and development and predispose the 
individual to later cardiovascular and metabolic risk. However, the mechanisms which 
ultimately mediate these changes are largely unknown.  
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BIRTHWEIGHT PHENOTYPE  
Normal fetal growth is imperative for the immediate and long-term health outcome of 
the offspring. To determine those born small or large, reference values for birthweight for 
gestational age and gender are commonly used. These population references provide 
birthweight percentiles for each gestational age with birthweights below the <10th percentiles 
defined as small for gestational age (SGA), those with birthweights from 10th to 90th 
percentiles defined as appropriate for gestational age and, those with birthweights >90th 
percentile defined as large for gestational age (LGA). Those born small or large for 
gestational age are at increased risk of developing cardiovascular disease with both groups 
showing altered metabolic function as infants, children and adults. (168). The underlying 
mechanism driving disease progression in these two distinct groups are likely different. 
 
Birthweight and birthweight percentiles have long been used by both researchers and 
clinicians to determine at risk individuals. As described extensively, early studies found 
birthweight as a predictor of infant mortality, with a ‘U-shaped’ association (see figure 6) 
(169).  
 
 However, the use of birthweight percentiles has some inherent problems. Firstly, there 
are a number of maternal variables that have an independent effect on birthweight. These 
include parity, ethnicity, weight and height, all of which program a unique predetermined 
growth potential in the fetus (170). Birthweight percentiles do not take these into account and 
therefore, does not discriminate well between a baby who is just constitutionally small who 
have met their unique growth potential, from a baby who is pathologically small who did not 
reach their unique growth potential. Similarly, babies with excess growth above their 
expected growth trajectory may be pathologically large. Distinguishing babies who are 
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pathologically small or large from “normal” is imperative as they require different types of 
care and using a single birthweight percentile does not differentiate between these babies.  
 
Second, the quality of growth is important as two babies of the same sex may have the 
same birthweight but have a very different body composition. Available fat stores in the baby 
are crucial for delivering an energy supply post birth especially prior to establishment of 
breastfeeding (171). Those infants categorized as “normal” based on their birthweight, but 
who have failed to reach their growth potential and have low fat content, may be a group that 
would specifically benefit from body fatness assessment in the early postnatal period. 
 
 
Figure 6. Birthweight-specific mortality curves. Fetal and infant mortality is highest at 
the lowest birthweights but falls sharply as birthweight increases and rises again for 
those with the highest birthweights. Adapted from Wilcox AJ et al (169)
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Newborn body composition 
 Body composition describes the percentage of muscle, fat, bone and water in an 
individual. Therefore, two people of the same weight and sex may look very different as 
different type of tissue in the body take up different amounts of space in the body. Muscle 
tissue takes up less space than fat tissue, therefore leanness is determined by both weight and 
body composition.  
 
Body composition is a key component of health and it is realized that several aspects 
of body composition especially percentage body fat and the amount of lean mass are 
important indicators of health outcomes and physical status in infants, children and adults. A 
study conducted at the Royal Prince Alfred Hospital, Sydney, showed that percentage body 
fat was a better indicator of neonatal morbidity compared to birthweight (172).   
 
There are several techniques available to measure body composition. These include 
dual-energy X-ray absorptiometry, hydrostatic weighting, measurement of total body water 
using isotope dilution as well as multicompetent models (173). However, these techniques 
have practical limitations as they are time consuming, invasive and may involve some 
radiation and therefore cannot be easily applied in a neonatal or child population.  
 
The commercially available system known as the PEA POD (COSMED, Concord, 
CA, USA), utilizes the air-displacement plethysmography technique to measure body 
composition.  The use of the PEA POD offers a number of advantages over other measures as 
it is a fast, automated, safe, noninvasive measure and can be applied in the neonate (174)  
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Briefly, air displacement plethysmograph uses whole body densitometry to determine 
body composition. Using the pressure and volume relationship of Boyles Law, the volume of 
the neonate situated inside a chamber is derived. Using measures of body volume and body 
mass permits calculation of body density (175). Once whole-body density is known, 
estimates of percentage fat, fat mass and fat free mass can be determine using an equation 
such as those derived by Siri (176):  
Percent Fat = 495/density – 450 
 
These equations are integral to the software of the device. Mass of the neonate is 
easily obtained using the integrated electronic scales within the PEA POD measured to the 
nearest 0.1g (175). The PEA POD device has been validated in the neonate, and is the a quick 
noninvasive method for body composition assessment in infancy (174) 
 
Measures of body composition, fat mass and lean body mass utilizing the PEA POD 
have refined the assessment of fetal growth. This has enabled body fat percentiles charts to be 
created according to gestational age and gender, table 1 (177).  Infant body composition 
measurements are now routinely conducted as part of general care at the Royal Prince Alfred 
Hospital, Sydney.  
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Table 1: Newborn body fat percentiles according to gestational age and sex, adapted from 
Hawkes CP et al  (177).  
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Child and adolescent body composition  
Over the past four decades there has been a tenfold increase in the number of obese 
children and adolescents (aged five to 19 years). Worldwide, this increase was from 11 
million in 1975 to a staggering 124 million in 2016 (178). Furthermore, an additional 213 
million were classified as overweight in 2016 (178).  
 
Children as young as 3 years of age who are overweight show increased inflammatory 
markers compared to those with normal weight (179). Hypertension, dyslipidemia and 
dysglycemia are already seen in children with obesity. Furthermore 19% to 38% of these 
children also present with the metabolic syndrome (180, 181). This increasing trend of 
obesity among children and adolescents poses a great risk for the long-term health of these 
individuals as obesity tracks strongly, such that approximately 70% of 6-9 year old children 
with obesity will have obesity as adults (177).  
 
Currently, body mass index (BMI) is widely used to identify children and adolescents 
with high adiposity, those between the 85th and 95th percentile (sex and age adjusted) are 
classified as being overweight and those with a BMI greater than the 95th percentile are 
classified as being obese (182). Similar to birthweight percentiles, BMI cutoffs are 
population based and may not reflect individual growth patterns. A study investigating the 
use of BMI in the prediction of cardiovascular disease risk factor clustering in a biracial 
sample of children and adolescents found, identifying risk of metabolic syndrome for a given 
BMI differed significantly between white and black obese adolescents (183). Furthermore, 
children and adolescents may also be classified as having a normal weight and BMI, but may 
in fact have increased adiposity which increases their risk of cardiometabolic diseases. These 
limitations associated with the use of BMI have led to the use of body composition 
Hasthi U Dissanayake  Introduction 
 
42 
measurements as a tool to accurately identify individuals at risk of developing obesity-related 
disease.  
 
The BOD POD (COSMED, Concord, CA, USA) is an air displacement 
plethysmograph, similar to the PEA POD but validated for assessment of body composition 
in older children and adults(173, 184-186).  
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AIMS  
Birthweight is associated with hypertension across the lifespan and adult 
cardiovascular disease, such that those at both ends of the spectrum are at increased risk. 
Nonetheless, birthweight is a relatively crude surrogate of fetal growth and it may be that 
quantification of body composition, particularly body fatness, may more accurately identify 
the “high risk” individual. Causative mechanisms linking birthweight and risk of 
cardiovascular disease likely involve changes to the structure and function of organs 
including the placenta, which may impair development and predispose individuals to later 
cardiovascular disease.  
 
The aims of this thesis were to investigate the association between placental function, 
body composition and cardiovascular autonomic function. To achieve these aims, the 
following associations were tested in three settings: 
1. the relationship between maternal factors, placental factors, inflammation and infant 
body composition   
2. the associations of infant body composition and late preterm birth with cardiovascular 
autonomic function 
3. the association of body composition with autonomic functions in the child and 
adolescent.  
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ABSTRACT  
Hypertension is an important modifiable risk factor for cardiovascular and 
cerebrovascular diseases. Its high prevalence, combined with the morbidity and 
mortality associated with secondary complications, make it a major public health 
concern. Despite decades of research, over 95% of all cases of hypertension remain of 
unknown etiology, necessitating that treatments target the established symptoms and 
not the cause. One of the important recent advances in hypertension research is an 
understanding that hypertension often may have a developmental origin. A substantial 
body of evidence indicates that exposure to an adverse intrauterine environment 
during critical periods of development may predispose an individual to develop 
hypertension later in life. A causative mechanism has yet to be identified, but may 
include epigenetic modifications, and/or alterations in renal, vascular or autonomic 
cardiovascular functions. This review will present evidence regarding changes in 
autonomic activity as a possible causative pathophysiological mechanism underlying 
the development of programmed hypertension.  
 
In man, low birth weight is the best-known risk factor for hypertension of 
developmental origins, although this is a broad surrogate measure for intrauterine 
adversity. This review will include clinical studies across the lifespan that have 
investigated autonomic function in groups that include; individuals with fetal growth 
restriction and those born preterm.  A determination of whether altered autonomic 
function is seen in these individuals in early life is imperative, as hypertensive disorders 
that have their origins in utero, and that can be identified early, will open the door to 
risk stratification, and the development of new strategies that prevent or specifically 
target these mechanisms. 
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INTRODUCTION  
Cardiovascular and cerebrovascular diseases are a major cause of morbidity 
and mortality worldwide. According to the most recent reports from the World Health 
Organisation (1), 15 million people died from cardiovascular diseases in 2015; 
estimated to rise to 23 million deaths annually by 2030 (2). Hypertension is an 
important modifiable risk factor for cardiovascular and cerebrovascular diseases (3), 
affecting approximately 40% of people (2). In total, hypertension accounts for 9.4 
million deaths worldwide every year (2).  The World Health Organisation estimates 
that globally hypertension is responsible for at least 51% of deaths due to stroke and 
45% of deaths due to heart disease. In the USA, it is estimated that the health care 
costs attributed to hypertension in 2010 were in excess of 90 billion dollars (4) .  
 
Successful treatment of hypertension remains poor, and it has been argued that 
this is partly due to a mechanistic mismatch, with treatments targeting the established 
symptoms and not the upstream pathophysiologic root cause. Despite decades of 
research into its aetiology, an important proportion of hypertension remains 
categorised as “essential” hypertension, i.e. without unknown cause(5) .  A 
meaningful proportion of essential hypertension may have neurogenic origins, in 
particular relating to sympathetic nervous system activity.  
 
A substantial body of epidemiological and experimental evidence indicates 
that exposure to an adverse intrauterine environment during critical periods of 
development may predispose an individual to develop cardiovascular disease later in 
life. Indeed, it has been argued that a meaningful proportion of cases of primary 
hypertension may have a programmed or developmental origin (6, 7), with putative 
Hasthi U Dissanayake   Chapter Two: A Review 
 
47 
mechanisms including epigenetic modification, changes to nephron number, 
glucocorticoid levels, endothelial dysfunction, activation of the renin-angiotensin 
system (RAS), and autonomic dysfunction (8). This review will present evidence 
regarding autonomic activity as a possible causative pathophysiological mechanism 
underlying the development of programmed hypertension.  
 
AUTONOMIC NERVOUS SYSTEM AND HYPERTENSION 
The autonomic nervous system has important functions in the control of blood 
pressure via direct regulation of cardiac output and total peripheral resistance, and 
indirect regulation of blood volume via alterations to renal function. A key 
characteristic of hypertension, a major contributor to most cardiovascular diseases, is 
elevated sympathetic nerve activity (9). Raised sympathetic nerve activity is 
established during childhood in some humans prior to the development of clinical 
hypertension. Moreover, evidence for raised sympathetic activity has been observed 
in normotensive subjects considered at increased risk of developing hypertension, 
such as children with a familial history of hypertension (10), those with borderline 
hypertension, and also in those with white-coat hypertension (11-13), suggesting that 
raised sympathetic activity precedes clinical hypertension, and supporting a causal 
role of sympathetic dysfunction in the etiology and pathophysiology of hypertension. 
Children with a family history of hypertensive disorders also exhibit decreased 
baroreflex sensitivity (10), a related yet distinct, pathway consistent with a 
predisposition to developing hypertension. Furthermore, there is convincing evidence 
from studies measuring noradrenaline spillover and using direct neural recordings that 
raised sympathetic nerve activity is present in both overt hypertension and in 
borderline hypertension (11, 14-17). Such “neurogenic hypertension” has been 
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reported to account for at least 50% of all cases of high blood pressure (18). Studies 
also suggest that essential hypertension, and particularly resistant hypertension, is 
characterized by raised sympathetic cardiovascular drive (19-21), with both showing 
pronounced sympathoinhibition in response to anti-hypertensive interventions. On 
average, people with hypertensive disorders also have lower cardiac parasympathetic 
nerve activity (22) (23). Taken together, these data indicate that there is a strong 
neurogenic component associated with the pathophysiology and etiology of 
hypertension.  
 
These clinical studies are supported by evidence from experimental studies, in 
particular those utilizing the spontaneous hypertensive rat (SHR), which have been 
important in establishing a causal link between sympathetic over-activity and 
hypertension. Jude and colleagues (1976), (24)  showed this link in early studies, 
where, sympathetic nerve activity and blood pressure were shown to increase rapidly 
as SHRs aged, and by five weeks of age, both blood pressure and sympathetic nerve 
activity were significantly higher than values observed in normotensive strains of rats 
(24). When sympathetic ganglionic transmission was reduced via hexamethonium 
administration in SHRs, both sympathetic nerve activity and mean arterial pressure 
were reduced to a level comparable with normotensive controls (24).  
 
AUTONOMIC NERVOUS SYSTEM AND PROGRAMMED 
HYPERTENSION 
 The mammalian nervous system begins its development during fetal life and 
continues after birth. Accordingly, both intrauterine and postnatal exposures may 
affect and alter the development of neural components. There is a wealth of 
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epidemiological evidence indicating raised blood pressure can be influenced by in 
utero exposures (8), specifically an inverse association between birth weight and risk 
of hypertension and cardiovascular disease in later life, such that those with the 
lowest birth weight are at highest risk of these cardio-metabolic diseases (25, 26). In 
particular, those with fetal growth restriction, including mild to moderate forms, are at 
the highest risk of heart disease and type 2 diabetes, whilst those born preterm birth 
have evidence of raised blood pressure (27, 28). These infants are exposed to distinct 
early life exposures that may infer risk via distinct pathways, including reduced time 
to develop prior to birth, and/or insufficient nutrient availability due to malnutrition or 
impaired utero-placental perfusion. To better understand these underlining 
mechanisms, it is important to understand whether altered autonomic function is due 
to prematurity or growth restriction alone and whether there is an additive effect in 
those born premature with low birthweight.  
 
Evidence for altered autonomic function in individuals born SGA or growth 
restricted  
 A number of studies have investigated the relationship between fetal growth 
restriction and altered autonomic function, from the perinatal period through to 
childhood and adult life. However, studies in  the term born, growth restricted infant 
is limited, a study by Galland and colleagues 2006, found increased sympathetic 
activity and reduced tachycardiac response to head-up-tilt test at 1-3 months in infants 
born small for gestational age (29). This association appears to persist into 
adolescence and adulthood. Amongst twins, the duration of the cardiac pre-ejection 
period, a marker of sympathetic control of heart rate (30, 31), was shorter in the twin 
with lower birth weight (30); accounting for 63-84% of the association of birth weight 
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with raised blood pressure in this group.  In young adults born SGA, direct recording 
of sympathetic nerve traffic using microneurography demonstrates increased 
sympathetic nerve activity (32), independent of metabolic factors including central 
adiposity, BMI and glucose tolerance. It has thus been proposed that augmented 
sympathetic activity may manifest during early development, in those with impaired 
fetal growth, as a plausible mechanism underlying the observed increased risk of 
hypertension (32, 33).  
 However, not all studies have consistently found increases in sympathetic nervous 
system activity in people born small (Table 1). A study measuring muscle 
sympathetic nerve activity during rest and in response to a cold pressor test in people 
born with a low birth weight aged 20-30 years found they had lower sympathetic 
nerve activity (34). Furthermore, blood pressure and heart rate were similar between 
low birth weight and healthy birth weight subjects, with no evidence of endocrine 
differences between the two groups. The functional consequence of the decreased 
muscle sympathetic nerve activity in low birth weight subjects remains unclear and it 
is unlikely that the altered sympathetic outflow to the muscle beds is a contributing 
factor for the higher prevalence of hypertension seen in low birth weight subjects. 
However, other branches of the sympathetic nervous system, such as the renal or 
cardiac branch, which control blood pressure, cannot be excluded as these branches 
may indeed exhibit higher activity.  
 
 In addition, other studies have found changes to the autonomic nervous system 
without an increase or decrease in the sympathetic or parasympathetic branch but 
showing some autonomic dysfunction. A study assessing heart rate variability a 
marker of cardiac autonomic control found lower heart rate variability, depicting 
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diminished cardiac autonomic control in IUGR children (35). Similarly, a study by 
Rakow and colleagues (2013) showed decreased heart rate variability in 9 year 
children who were small for gestational age (36).  
Taken together, the evidence indicates that people born with impaired fetal growth 
show altered autonomic activity, putatively predisposing these people to the 
development of hypertension and CVD in later life.  
 
Evidence for altered autonomic function in individuals born preterm  
 As early as the first week postnatal, there is evidence that cardiac parasympathetic 
activity is lower in preterm infants, without alteration in cardiac sympathetic activity 
(37, 38). At 5-6 months postnatal, both cardiac sympathetic and parasympathetic 
activity are lower in preterm infants during quiet sleep, but not during active sleep 
(39), with evidence of reduced sympathetic vasomotor activity in the same infants at 
2-4 weeks. Consistent with this observation other studies have also shown, preterm 
infants exhibit reduced vascular autonomic control, quantified by a reduced baroreflex 
sensitivity (40) whereby prematurity impairs the normal maturational increase in 
barorefelx sensitivity (41). The baroreflex is the most important nervous system 
regulatory mechanism of blood pressure homeostasis. Impaired sensitivity of the 
baroreflex in these individuals at an early age may place them at an increased risk of 
cardiovascular instability. Studies investigating autonomic stress responses using 
postural change test found increased sympathetic response to a head-up tilt test in 
preterm, growth restricted infants (42, 43). It is possible that the hypertensive 
phenotype of raised sympathetic activity is only unveiled when infants are challenged 
with a physiological stressor. Whether such effects persist into childhood and later life 
is unknown.  
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  Impaired fetal growth is an important risk factor for preterm birth; yet with 
potentially opposing effects on autonomic activity. Studies investigating prematurity 
per se found, day old infants born preterm with fetal growth restriction showed 
reduced cardiac autonomic activity as well as reduced cardiac sympathetic activity 
compared to their preterm appropriate for age counterparts. These differences seen at 
postnatal day one did not persist into infancy 1-6 months later. A similar study in 9-
year-old children by the same authors found preterm appropriate for gestational age 
children showed increased parasympathetic activation and blood pressure changes 
related to respiration compared to term appropriate for gestational age counterparts. It 
appears these children have a heightened parasympathetic response to respiratory 
related blood pressure fluctuations, however this is counterintuitive as increase 
parasympathetic activation is known to be protective of cardiovascular disease (44) 
and diminished parasympathetic control is known to increase the risk of malignant 
cardiac arrhythmias and hypertension (38). Other studies in children of similar age 
found an overall reduction in cardiac autonomic function (36), the overall suppression 
of cardiac autonomic function may be indicative of an impaired capacity of this group 
to adapt to changes in the internal and external environment which may contribute to 
increase risk of later hypertension and cardiovascular disease.
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ANIMAL MODELS OF PROGRAMMED HYPERTENSION  
 Following the strong associations made between low birth weight and increased 
cardiovascular risk, a number of animal models of programmed hypertension have 
been studies in the hope of understand the pathophysiological mechanisms. Rat pups 
with low birth weight show significantly higher blood pressure as adults compared to 
their normal birth weight litter mates (7), illustrating a consistent neonatal phenotype 
with that of humans. A number of in utero insults have been found to reduce birth 
weight and program hypertension in animal models; maternal protein restriction, 
global food restriction, placental insufficiency and hypoxia, to name a few (45).  
 
 Animal models examining the effects of prenatal undernutrition on offspring 
autonomic nervous system function has found altered autonomic function with the 
resetting of the baroreflex to a higher set point, increase epinephrine levels, raise 
catecholamine levels, increase sympathetic and decrease parasympathetic nervous 
system activity (46). Similarly studies replicating models of IUGR by placental 
insufficiency accompanied by adult cardiovascular disease has shown that bilateral 
renal denervation completely abolished established hypertension in the adult offspring 
(47). This suggests that increased renal sympathetic nerve activity contributes to the 
maintenance of established hypertension in this model of IUGR (47). A study by 
Ojeda and colleagues (2007) (48) highlighted that early renal denervation in juvenile 
rats (4 weeks of age) normalized arterial pressure in IUGR offspring. Furthermore, 
renal noradrenalin content was increased in IUGR offspring compared to controls 
(48). Similarly, a study by Jansson and Lambert (1999) (49), found increased 
sympathetic nerve activity with no changes to blood pressure in IUGR offspring. It is 
possible that these rats may represent a pre-hypertensive state, therefore studies in the 
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older rat is required to determine if these rats develop hypertension.  
Accordingly, there is good experimental evidence to support altered autonomic 
activity seen in growth restricted individuals.  
 
 The exact mechanisms that link impaired fetal growth with changes in autonomic 
nervous system activity remain poorly described. It is unlikely that low birth weight is 
the cause of adverse subsequent health outcomes, but simply a surrogate observation. 
Instead growth restriction reflects systemic restriction of growth including adaptations 
to counteract the stress by altering structure and function of physiological systems 
related to blood pressure control. Increased sympathetic activity, higher peripheral 
vascular resistance, and lower coronary and cerebral arterial resistance are believed to 
initiate these adaptive changes. Whilst these adaptive changes are important for short-
term survival of the growth restricted fetus, these changes may subsequently raise 
long term risk of cardio-metabolic disease.  
 
 Collectively a number of human and animal models demonstrate altered autonomic 
function following fetal growth restriction and or prematurity. In the context of 
human studies this is seen throughout the lifespan from infancy to adulthood, (Table 
1). However, to date, it is unclear which branch of the autonomic nervous system is 
increase or decrease. These differences described may be attributed to different 
methodology employed to measure autonomic control over specific tissues as well as 
heterogeneity between study populations and participant characteristics. Furthermore, 
many studies detailing autonomic activity in small babies have been unable to 
specifically differentiate between the effects of growth restriction, constitutional 
smallness, and prematurity. Furthermore, birth weight is a widely used, albeit 
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relatively crude, surrogate of fetal growth. Birth weight percentiles are unable to 
differentiate between the constitutionally small but well-nourished infant who has met 
their genetic growth potential, from an under-nourished infant of the same weight, 
whose intrauterine environment has restricted their growth trajectory. Therefore, 
defining alterations in fetal growth is problematic leading to heterogeneity within and 
between study populations. Future studies should take this into consideration. 
Furthermore, methodological differences between studies may also contribute to the 
discrepancies seen.  
Indeed, preterm birth, constitutional smallness, and fetal growth restriction appear to 
have distinct associations with later hemodynamic and vascular health (27, 28, 50). 
These differences may relate to the distinct etiologies, with implications for human 
populations in developing countries, where maternal malnutrition is an important 
contributor to fetal growth restriction, and in more developed nations where placental 
insufficiency is a relatively more important risk factor for impaired fetal growth.  
 
CLINICAL IMPLICATIONS  
Hypertension is a complex condition, with multiple risk factors and 
pathophysiological pathways involved. The concept of developmentally programmed 
hypertension further our understanding of this disease, yet adds to the complexity. 
Infants born growth restricted are among the tiniest and most vulnerable babies, and 
medical advances in the last decades have enabled the first generation of these babies 
to reach adulthood, but leaving them with an increased risk of hypertension and later 
cardiovascular disease.  
Countering a component of hypertensive disorders that has its origins in utero will 
open the door to the development of new strategies that prevent or specifically target 
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these mechanisms. Nonetheless, the exact mechanisms by which in utero exposures 
alter autonomic activity and subsequent blood pressure remain relatively poorly 
described.  The remarkable similarity of hemodynamic phenotype in offspring 
exposed to these distinct exposures suggests the possibility that there may be an 
overarching signal influencing programming in these studies.  
In light of the growing number of hypertensive patients it is important to consider a 
neurogenic origin of hypertension and its exact mechanism, which may enable the 
development of novel anti-hypertensive agents, which entail more specific targets. 
Furthermore, low birth weight is a known risk factor for later hypertension with 
evidence for altered autonomic control. However, currently, there are no clinically 
established strategies to prevent cardiovascular events in those born growth restricted 
or preterm. Future studies should look to establish effective pharmacological and 
nutritional approaches in the management of blood pressure in those born growth 
restricted or preterm. Appendix two contains a published book chapter evaluating a 
nutritional approach, omega-3 polyunsaturated fatty acid and offspring blood 
pressure.  
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Table 1. Autonomic cardiovascular control in infants, children and adults born preterm, SGA or IUGR  
Reference Participants 
GA (weeks) at 
birth 
PNA at 
investigation 
and duration 
of recording 
HR BP 
Overall heart 
rate variability 
Sympathovagal 
balance 
Vascular 
autonomic 
control 
Response to 
stressors 
Preterm vs term 
Patural et al. 
2004 
 
 
23 preterm 
8 term 
*All BW AGA 
28 to 37 
>37 
PT: Theoretical 
full-term age 
(38 – 41) 
Term: 1st wk of 
life 
5 minutes 
during quiet 
sleep 
 
N/A N/A =  parasympathetic N/A N/A 
IJzerman et 
al. 2003 
 
32 dizygotic 
twin pairs 
37 
monozygotic 
twin pairs 
21 dizygotic 
twin pairs 
24 
monozygotic 
twin pairs 
 
>37 
 
>37 
 
<37 
 
<37 
17.0  1.7 y 
 
16.0  1.8 y 
pre-ejection 
period 
RSA 
=  N/A  sympathetic 
= parasympathetic 
 
N/A  sympathetic 
at rest, 
reacting time 
task and during 
mental 
arithmetic 
 
Yiallourou et 
al. 2013 
 
25 preterm; 
BW (600 – 
2061g) 
31 term; BW 
(2900 – 4250g) 
 
28 – 32 
38 – 42 
2 – 4 weeks, 2 
– 3 mo, 5 – 6 
mo 
5 – 8 min (QS 
& AS) 
N/A N/A   sympathetic 
 parasympathetic 
*at 5 – 6 mo (QS) 
 BPV (HF)  
 BPV (LF) 
*(2 – 4 w) 
 
 
N/A 
Andriessen et 
al. 2005 
16 Preterm G1; 
BW (1333  
277 g) 
10 Preterm G2; 
BW (1872  
468 g) 
6 Full term; 
BW (3220  
565 g) 
 
29.3  1.4 
32.9  1.2 
38.4  1.7 
 
4.7  2.7 d 
3.3  1.5 d 
3.8  2.1 d 
192-s-long 
segments 
N/A N/A   parasympathetic  Total BPV 
 BPV (HF) 
N/A 
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Mathewson et 
al. 2014 
 
30 ELBW; BW 
<1000 g 
47 NBW; BW  
2500 g 
27.9  2.4 
>37 
23.0  1.3 y 
ELBW, 23.5  
1.0 y NBW at 
(T1) duration 
2min. 31.8  
1.6 y ELBW, 
32.3  1.4 y 
NBW, (T2); 
duration 6min 
 
N/A N/A = (heart period)  respiratory sinus 
arrhythmia 
N/A N/A 
 
 
 
 
 
Patural et al. 
2007 
39 preterm; 
BW (504-1750 
g) 
19 full term; 
BW (2680 – 
3640 g) 
 
28  2 
40  2 
 
 
0-14 days 
0-7 days 
15 min 
recordings 
 
 
 
 
N/A  = 
 
 
N/A N/A 
Van Reempts 
et al. 1997 
21 preterm + 
CIUSTR; BW 
(720-2113 g) 
30 preterm 
control; BW 
(813-2380 g) 
 
32.8 
30.9 
2-126 days 
2-86 days 
15s, 30s and at 
1,2,3,4,5 min 
N/A N/A N/A N/A N/A Tilt test:  HR 
 
Schäffer et al. 
2008 
27 IUGR <5th 
percentile 
27 AGA 10th to 
90th percentile 
 
34.3-41.7 
34.3-42 
 
PNA not given 
24h Holter 
recording 
= N/A = = N/A N/A 
Term 
Boguszewski 
et al. 2004 
 
12 term AGA 
9 term SGA 
normal stature 
8 SGA short 
stature 
*Term SGA 
(BW below -2 
SD score for 
healthy 
newborns) 
 
 
 
> 37 20-25 y 
postganglionic 
MSNA 
= = N/A  sympathetic 
 
N/A N/A 
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Galland, et al. 
2006 
 
27 SGA <10th 
percentile 
23 AGA >25th 
percentile 
 
39  1 
40  1 
 
1 and 3 mo, 
daytime sleep 
study, duration 
4 h 
= N/A =  sympathetic 
 parasympathetic 
N/A Reduced 
tachycardiac 
response to 
head-up-tilt 
Weitz et al. 
2003 
13 Term LBW; 
BW (<2500g) 
13 Term NBW; 
BW (3200-
3700) 
>37 
 
20 – 30y 
postganglionic 
MSNA 
= = N/A  sympathetic 
 
N/A = sympathetic 
response in 
response to 
inspiratory 
apnea & cold 
pressor test 
 
Aziz et al. 
2011 
33 normal; BW 
(3530  0.48g) 
20 IUGR-1; 
BW (2290  
0.19g) 
17 IUGR-2; 
BW (2290  
0.19g) 
 
39.15  1 
38. 95  1 
 
 
8.96  0.72 y 
9.31  0.62 y 
 
24h ECG 
recordings 
N/A N/A  normal vs 
IUGR-1 
 
= normal vs 
IUGR-2 
= 
 
N/A N/A 
Spassov et al. 
1994 
10 IUGR <3rd 
percentile 
16 AGA 10th to 
75th percentile 
 
 
GA not given 
conceptional 
age at study 
37-41) 
2-10 days 
4 hours 
 N/A   parasympathetic N/A N/A 
Mixed preterm and term 
Rakow et al. 
2013 
 
 
31 preterm; 
BW (965  202 
g) 
27 term SGA; 
BW (2441  
334 g) 
28 terms; BW 
(3503  515 g) 
 
26.7  2.1 
39.3  1.4 
39.6  1.0 
 
 
9.6  0.3 y 
9.8  0.3 y 
9.8  0.2 y 
 
24h ECG 
recordings 
N/A N/A  normal vs 
Preterm 
 
 normal vs 
SGA 
 
= 
 
 
 
 
 
N/A N/A 
Cohen et al. 
2017 
25 preterm 
FGR 
22 preterm 
19 term AGA 
*n changed 
during each 
follow-up 
24-35 
25-35 
37-41 
Day 1, 1mo, 
6mo 
Day 1, 1mo, 
6mo 
N/A, 1mo, 6mo 
 PT FGR vs 
PT AGA at 
1day during AS 
&QS 
= across 3 
groups at 1mo 
and 6mo 
 PT FGR vs 
PT AGA at 
1day during AS 
& QS 
 PT FGR vs PT 
AGA at 1day 
during AS & QS 
= BRS 
across 
groups 
during AS & 
QS 
N/A 
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Yiallourou et 
al. 2017 
 
18 preterm, 
FGR 
15 preterm, 
AGA 
20 term, AGA 
30  1 
30  1 
40  0 
 
9  0.5 y 
9  0.5 y 
9  0.5 y 
2min epochs 
from overnight 
recording in AS 
and QS 
 
= 
 
= N/A  parasympathetic 
(PT AGA vs term) 
 
 
 
 
 BPV (HF) 
(PT AGA vs 
term) 
 
N/A 
Souza et al. 
2017 
100 children 
Prematurity 
(%) 
:10 PT, 90 
Term 
 
Not specified 8.85  1.82 y 
 
Positively 
correlated with 
BMI 
Positively 
correlated with 
BMI 
Inverse 
correlation with 
BW 
N/A  parasympathetic N/A N/A 
Cohen et al. 
2008 
 
16 preterm- 
IUGR BW 
<10th percentile 
16 preterm 
AGA 
29 term AGA 
32  2 
31  2 
40  1 
 
0-2 weeks 
post-term age 
preterm 
(IUGR and 
AGA) vs 
term 
 preterm 
(IUGR and 
AGA) vs 
term 
N/A N/A N/A  sympathetic 
response to tilt 
test 
 Preterm 
(IUGR and 
AGA) vs term; 
 preterm 
IUGR vs 
preterm AGA 
 
GA, gestational age; PNA, postnatal age; HR, heart rate; BP, blood pressure; BW, birth weight; SGA, small for gestational age; AGA, appropriate for gestational age; IUGR, intrauterine growth 
restricted; CIUST, chronic intrauterine stress; ELBW, extremely low birth weight; LBW, low birth weight; NBW, normal birth weight; FGR, fetal growth restricted; PT, preterm; N/A, not available; MSNA, 
muscle sympathetic nerve activity; QS, quiet sleep; AS, active sleep; BMI, body mass index; BPV (HF), high frequency component of blood pressure variability; LF:HF, low frequency to high frequency 
ratio;  
 
 increase or  decrease between specified groups, = no differences between specified groups  
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ABSTRACT 
Aim: The objective of this study was to assess whether maternal characteristics, placental 
size or histological chorioamnionitis was associated with newborn body composition. 
Furthermore, we sought to determine whether placental weight may mediate the association 
of maternal pre-pregnancy weight and age with newborn body composition.  
 
Methods: A cross sectional study was conducted at Royal Prince Alfred Hospital, Sydney, 
Australia. This study included 136 healthy singleton term born newborns. Recruitment was 
stratified by newborn body fat percentiles (sex and gestational adjusted). Body fat was 
assessed by air displacement plethysmography. A maternal (chorioamnionitis) and fetal 
(chorionic and umbilical vasculitis, funisitis) inflammatory response were classified 
according to Redline criteria.  
 
Results: Maternal pre-pregnancy weight, parity, labour, placental weight and surface area 
were associated with newborn fat mass and fat free mass. Gestational diabetes and maternal 
age was associated with newborn fat mass but not fat free mass. There was no association 
between histological chorioamnionitis and newborn body composition however spontaneous 
onset of labour was strongly associated with the presence of histological chorioamnionitis. 
Only 25 to 31% of the association of maternal weight and age with newborn fat mass was 
mediated via the placenta.  
 
Conclusions: Maternal factors associated with newborn fat mass and fat free mass differed, 
indicating that different mechanisms control fat mass and fat free mass. Our mediation 
analysis suggests that placental weight partly mediates the association of maternal factors 
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with newborn body composition. Histological chorioamnionitis was not associated with 
newborn body composition.  
 
Key words: placenta, chorioamnionitis, newborn body composition 
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INTRODUCTION  
The in-utero environment has a profound influence on fetal development. Sub-optimal in-
utero conditions may permanently alter the fetal tissues and organs, changing structure and/or 
physiological function, and consequently predisposing individuals to later cardiovascular 
disease (1). A large body of epidemiological evidence supports an association between low 
birth weight and adult cardiovascular disease (2-6). However, birth weight, is a relatively 
crude marker of fetal growth and nutrition and does not discriminate well between “normal” 
small babies and “pathologically” small babies who have failed to meet their growth 
potential. The same issues arise with defining normally large babies from those who have 
excessive growth above their expected growth trajectory, also a population at later risk of 
cardiovascular disease. Measurement of newborn body composition, comprising lean and fat 
mass, may be a better discriminator of “pathologically” small or large babies. Indeed, 
measures of fat mass appear to be more associated with the intrauterine environment and 
maternal nutritional status and correlate better with neonatal morbidity (7). Lean body mass 
on the other hand is less variable and largely reflects genetic components such as parental 
size. 
 
Fetal growth is determined by a number of factors, including growth potential related to 
genetic factors and maternal factors such as stature, nutrition and metabolism, endocrine 
factors, placental perfusion and function, and the fetal response to growth factors and 
nutrients (8). Placental function, which regulates nutrient supply to the fetus, is a key 
determinant of fetal growth and can be modified by both maternal and fetal factors (9). 
Nutrient transfer is dependent upon the available surface area and thus placental size. 
Placental weight is used as a crude marker of placental size and is correlated closely with 
birth weight (10). Studies have found placental weight and the placental weight to birth 
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weight ratio to be predictive of maternal disease, perinatal morbidity and mortality, as well as 
childhood growth and development (11-15). Moreover, placental size and placental weight 
ratio are associated with adult chronic disease outcomes including diabetes, hypertension, 
coronary artery disease and cerebrovascular incidents (12, 13).  
 
Chorioamnionitis is a perinatal inflammatory exposure most commonly as a response to an 
ascending intrauterine infection. This affects the chorionic plate and fetal membranes, 
triggering a maternal inflammatory response. Severe cases of chorioamnionitis can elicit a 
fetal inflammatory response affecting the umbilical vessels (16). Studies show 
chorioamnionitis and evidence of persisting systemic inflammation (17, 18). An early life 
inflammatory event may prime the innate immune system and elicit a heightened 
inflammatory response to future insults. Inflammation plays a central role in the development 
of cardiovascular disease, and those born small or large for gestational age show increased 
risk (2). Therefore, it is possible that a perinatal inflammatory event may contributing to 
pathways underpinning epidemiological associations between poor intra-uterine growth and 
adult cardiovascular disease. 
 
Accordingly, we aim to assess whether maternal characteristics, placental size or placental 
inflammation is associated with newborn body composition. Furthermore, we sought to 
determine whether placental weight may mediate the association of maternal pre-pregnancy 
weight and age with newborn body composition.  
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MATERIALS AND METHODS  
Ethical Approval  
This study was conducted in accordance with the standards set by the 2013 version of the 
Declaration of Helsinki and was approved by the Sydney Local Health District ethics 
committee and The University of Sydney Human Ethics committee (HRECH/14RPAH/478). 
Participation was voluntary, and informed written consent was collected from the parents of 
the newborn.  
 
Participants  
This is a sub-study of a larger cross-sectional study investigating newborn body composition 
and markers of cardiovascular risk. We recruited a total of 189 full term newborns on the 
basis of their body fat percentage from the postnatal wards and Neonatal Unit at Royal Prince 
Alfred Hospital, Sydney between April 2015 and September 2017 as part of a larger study. 
Eligible subjects were well singleton newborns between 37 and 42 completed weeks 
gestation who had body composition measured within 24 hours of birth. Exclusion criteria 
were major congenital abnormalities and newborns on respiratory support. Of the 189 full 
term newborns recruited, placental reports were available in 136 full term newborns and were 
categorised according to established body fat percentiles (19).  
Gestational age was calculated from first trimester ultrasounds or date of last menstrual 
period if no early ultrasound was performed.  
 
Body composition and anthropometry  
Newborn body composition was assessed by air displacement plethysmography using the 
PEAPOD (COSMED, Concord, CA, USA). Air displacement plethysmography is a non-
invasive, validated technique for assessing body composition in newborns (20) and utilises 
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whole body densitometry by accurately measuring the mass and volume of the newborn by 
calculating fat mass, fat free mass and percentage body fat using software integral to the 
PEAPOD. Newborn weight was measured by the integrated electronic scales within the 
PEAPOD measuring to the nearest 0.1g. Newborn volume was calculated by applying Boyles 
law, relating pressure changes to a given change in volume of air.  
 
Data collection  
Maternal and newborn characteristics were collected directly from the mothers and electronic 
medical records. Maternal body mass index (BMI) was calculated using pre-pregnancy 
weight and height. Parity was coded as P1 for first pregnancy >20 weeks’ gestation and P2+ 
for those with one or more pregnancies >20 weeks’ gestation. Newborn birthweight, head 
circumference and length and were measured as per the Royal Prince Alfred Hospital 
Neonatal Early Assessment Program (21).  
 
Placental collection and examination 
Placentas that were not required to be sent for formal pathological examination and those not 
taken home were stored in a 4C temperature-controlled fridge for 48 hours. After 
recruitment and consent, placentas were sent to pathology. Placental examination was 
performed according to the Perinatal Society of Australia and New Zealand Guidelines by an 
Anatomical Pathologist at the Tissue Pathology and Diagnostic Oncology Department of 
Royal Prince Alfred Hospital. In our cohort, 74 placentas were sent for placental histological 
examination according to New South Wales Policy documents detailing Maternity 
Indications for placental histological examination at time of birth (22). The other 62 placentas 
were sent to pathology as per study protocol (22).  
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A Maternal (chorioamnionitis) and fetal (chorionic and umbilical vasculitis, funisitis) 
inflammatory responses (23) were classified according to Redline criteria for stage (between 
1-3) and grade (1 or 2) (16). In our cohort 55 placentas had a reported Redline stage and 
grade which was reviewed by an anatomical pathologist, 81 of the placental reports were 
given a Redline stage and grade by a researcher using the same standardised diagnostic 
terminology for Redline stage and grade (16). Of these, 20 reports were cross-checked further 
by a neonatal clinician experienced with placental reporting and review and no changes were 
made.  
 
Placental weight and placental weight to birth weight ratio  
Placental weights were measured at pathology with fetal membranes trimmed according to 
the Amsterdam guidelines (24). Placental weight to birth weight ratio was calculated by 
dividing the placental weight (g) by birth weight (g).   
 
Placental surface area  
Assuming an elliptical surface area, placental surface area was calculated as 𝑚𝑎𝑥𝑖𝑚𝑎𝑙 ×
 𝑙𝑒𝑠𝑠𝑒𝑟 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 ×  𝜋/4 (25).  
 
Statistical analysis  
Statistical analysis was performed using SPSS (Statistical Package for Social Sciences, IBM 
Corp, version 23). Data expressed as mean and standard deviations. Associations of maternal 
and placental factors associated with newborn fat mass were determined by Pearson’s 
correlation and multivariable linear regression for continuous variables and by logistic 
regression for categorical variables. Each variable in the multivariable models was adjusted 
for newborn sex and gestational age.  
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We used a simple mediation model derived from multivariable linear regression to determine 
whether placental weight may mediate the association of maternal factors (particularly 
maternal pre-pregnancy weight and age) with newborn fat mass (26). Separate mediation 
models were conducted for each maternal factor. Beta coefficients and 95% confidence 
intervals were calculated for all models. The 95% confidence intervals for the indirect effect 
were calculated using the bootstrapping method with 10,000 replications. The mediation 
analysis was performed by the SPSS macro PROCESS (26). Percent mediation (PM) was 
calculated as the percent of the total effect accounted for by the indirect effect.  
 
RESULTS  
Participants  
Placental reports were available in 136 full term newborns across body fat percentiles; ≤10th 
(n = 25), >10th to ≤25th (n = 21), >25th to ≤50th (n = 24), >50th to ≤75th (n = 17), >75th to 
≤90th (n = 22), >90th (n = 27) (Table 1). The 74 placentas sent up front did not have 
significant placental abnormalities and therefore has not affected outliers. 
 
Factors associated with newborn fat mass and fat free mass  
Maternal factors associated with newborn fat mass in unadjusted analysis were pre-pregnancy 
weight (r = 0.227, P = 0.01), maternal age (r = 0.211, P = 0.01) and parity (r = 0.178, P = 
0.02). These effects remained similar when adjusted for sex and gestational age of the 
newborn. Gestational diabetes mellitus and type of labour were also associated after 
adjustment (Table 2).  In our unadjusted analysis, only pre-pregnancy weight was associated 
with newborn fat free mass (r = 0.241, P = 0.003). These effects remained similar when 
adjusted for sex and gestational age with parity and labour also being associated after 
adjustment (Table 2). 
Hasthi U Dissanayake  Chapter Three 
 
75 
Placental factors associated with newborn fat mass in unadjusted analyses were, placental 
weight (r = 0.472, P < 0.0001) and placental surface area (r = 0.263, P = 0.01). Similarly, 
placental weight and placental surface area were both associated with newborn fat free mass 
(r = 0.323, P < 0.0001), (r = 0.225, P = 0.004). These remained similar when adjusted for sex 
and gestational age (Table 2).  
 
Maternal factors associated with placental weight and histological chorioamnionitis  
In our unadjusted analyses only maternal age was associated with placental surface area (r = 
0.147, P = 0.04), however, after adjusting for newborn sex and gestational age this 
association was no longer significant (Table 3). Parity was associated with the presence of 
chorioamnionitis and a fetal inflammatory response, furthermore spontaneous onset of labour 
was associated with chorioamnionitis. These remained similar after adjustment for sex and 
gestational age (Table 4).  
 
Mediation analysis  
A mediation analysis was performed to determine whether placental weight, may account for 
a proportion of the shared variance between selected maternal factors and newborn fat mass. 
Figure 1 provides a visual representation of the mediation model. Maternal factors included 
in the mediation model were maternal pre-pregnancy weight and maternal age and are 
displayed in (Figure 1.) 
 
This analysis revealed that the association of maternal pre-pregnancy weight and maternal 
age with newborn fat mass did not appear to be solely mediated by placental weight, (Figure 
1). The mediator (placental weight) accounted for PM = 0.31 and PM = 0.26 percent of the 
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total effect of maternal pre-pregnancy weight and maternal age with newborn fat free mass, 
although these indirect effects did not reach statistical significance, (Figure 1).   
 
DISCUSSION  
The placenta is vital in normal fetal growth in utero. Most studies assessing placental 
structure or function assess the relationship with birth weight. Birth weight however is a 
relatively crude marker of baby’s morbidity risk and in recent years various methods of 
assessing body composition appear to correlate better (7). There are few studies assessing 
placental factors and newborn body composition.  We found, placental weight and surface 
area, to be associated with both newborn fat mass and fat free mass. Our mediation analysis 
indicates that an estimated 25 to 31% of the associations of maternal weight and age with 
newborn fat mass are mediated via placental weight. This study found no evidence for an 
association between chorioamnionitis with newborn fat mass or fat free mass.  
 
Maternal pre-pregnancy weight, age, parity, gestational diabetes and labour were positively 
associated with newborn fat mass. Conversely, newborn fat free mass was associated with 
maternal pre-pregnancy weight, parity and type of labour but not gestational diabetes or age.  
Newborn fat mass may be a better indicator of energy supply and growth of the fetus than 
birth weight as increased neonatal fat may be found in normal weight neonates. Furthermore, 
neonatal fat mass is thought to better reflect the intrauterine environment and energy supply 
in the last trimester better whereas lean mass is more reflective of genetic influences (27). 
The differentiated effects may suggest that the mechanisms controlling fat mass and fat free 
mass are different.  
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Maternal factors may affect fetal growth by modifying placental nutritional transport. The 
transport capacity depends on total surface area as well as the efficacy of transporters. In our 
study both placental weight and surface area was associated with newborn fat mass, table 2. 
We hypothesised that the association of selected maternal factors with newborn fat mass may 
be mediated via the placenta, specifically, placental weight. This hypothesis was somewhat 
supported by our mediation analysis. Although the indirect pathway via placental weight did 
not reach statistical significance, we suspect this is primarily due to limited statistical power. 
It possible that other mechanisms that we were unable to assess may be involved. Future 
studies with a larger sample size would quantify the strength of these mediation pathways, 
and also to expand such pathways to include maternal total weight gain during pregnancy.  
 
There is increasing evidence that an early life inflammatory exposure may prime the innate 
immune system, subsequently resulting in a heightened inflammatory response in the future 
(17). This may contribute to pathways underpinning epidemiological associations between 
poor intra-uterine growth and increased cardiovascular risk.  We found no evidence for an 
association between chorioamnionitis and newborn body composition. However, in line with 
previous studies, spontaneous onset of labour was associated with chorioamnionitis, 
furthermore spontaneous onset of labour was positively associated with newborn fat mass 
and fat free mass. Longitudinal studies investigating infants exposed to chorioamnionitis is 
need. Larger studies should also look to exclude laboured placentas as these placentas may 
appear to be more.  
 
We acknowledge the limitations of this study, including a relatively small sample size and 
restricted assessment of maternal factors that may influence the placental. Subsequent 
research in this field should include measurement of gestational weight gain and maternal 
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body composition. However, to our knowledge this is the first study to assess maternal 
factors, placental size and inflammation and newborn fat mass and the first to attempt to 
delineate direct and indirect associations.  Future studies should address these limitations in 
terms of breadth of data and sample size, in order to better elucidate the causal pathways that 
underpin the observed associations and inform further on the putative mechanisms linking 
perinatal exposures with later cardio-metabolic risk.  
 
In conclusion, this study found that maternal factors associated with newborn fat mass and fat 
free mass differed. These differentiated effects suggest that the mechanisms controlling fat 
mass and fat free mass may be different. Placental weight and surface area was strongly 
associated with newborn fat mass and fat free mass. Interestingly only 25 – 31% of the effect 
of maternal pre-pregnancy weight and maternal age on newborn fat mass was mediated by 
placental weight. This study found no evidence for an association between chorioamnionitis 
and newborn body composition.  
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Table 1: Participant characteristics  
Maternal characteristic  
n = 136 
Value 
Age, y 33.7 (3.9) 
Ethnicity, n (%)  
   Asian  34 (25) 
   Caucasian 89 (65) 
   Middle Eastern 4 (3) 
   Other  8 (6) 
   Not stated  1 (1) 
Maternal smoking, n (%) 4 (3) 
Maternal pre-pregnancy BMI, (Kg/m2) 23.7 (4.4) 
Maternal pre-pregnancy weight, (kg) 63.7 (12.8) 
Gestational diabetes mellitus, n (%) 22 (16.2) 
Hypertension, n (%) 4 (2.9) 
OGTT 2 hours, (mmol/L) 5.9 (1.5) 
Parity, n (%)  
     P1  85 (63) 
     P2+ 51 (38) 
Mode of delivery, n (%)  
     Normal  76 (55.9) 
     Instrumental 25 (18.4) 
     Caesarean 35 (25.7) 
Labour, n (%)   
     Spontaneous 71 (52.2) 
     Induced 42 (30.9) 
     No labour 23 (16.9) 
Newborn characteristics 
n = 136 
Value 
Gestational age, (weeks) 39.2 (1.1) 
Female, n (%) 69 (50.7) 
Length, (cm) 49.7 (2.3) 
Head circumference, (cm) 34.7 (1.5) 
Birth weight, (g)  3385 (540) 
Body fat, n (%)  10.8 (5.4) 
Body fat, (g)  405 (351) 
Fat free mass, (g) 89.2 (5.3) 
Fat free mass, (g)  2944 (483) 
Data presented as mean (SD) for continuous variables and n (%) for 
dichotomous variables. N = 136, except for maternal BMI (n = 124), 
pre-pregnancy weight (n = 130), and 2 hours oral glucose tolerance 
test (OGTT) (n = 125).  
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Table 2: Maternal and placental factors associated with newborn body composition  
 Newborn fat mass (g) 
n = 136 
Newborn fat free mass (g) 
n = 136 
  (95% CI) P value  (95% CI) P value 
Newborn sex (male) 80 (-36, 196) 0.17 -188. (-347, -30) 0.02 
Gestational age (weeks)  73 (21, 124) 0.01 92 (21, 163) 0.01 
Maternal Characteristics 
†Maternal BMI (Kg/m2) 10 (-5, 24) 0.19 8 (-11, 27) 0.40 
†Pre-pregnancy weight (kg) 6 (11) 0.01 9 (2, 15) 0.01 
†Maternal age (years) 22 (7, 36) 0.004 11 (-9, 32) 0.27 
†Parity (P1 vs P2+) 205 (89, 321) 0.01 180 (16, 342) 0.03 
†Gestational diabetes mellitus 185 (24, 346) 0.02 -14 (-238, 211) 0.91 
†OGTT, 2 hours (mmol/L) 3 (-25, 31) 0.83 -14 (-73, 46) 0.65 
Placental Characteristics  
†Placental weight (per 100g) 126 (84, 167) <0.0001 116 (54, 178) <0.001 
†Placental surface area (cm2) 1 (0.4, 2) <0.01 1 (0.4, 3) 0.01 
†Placental weight to birth weight ratio 109 (-2089, 2304) 0.92 -2316 (-5285, 653) 0.13 
†Villitis 86 (-105, 277) 0.37 180 (-80, 440) 0.17 
†Histological chorioamnionitis -90 (-211, 32) 0.15 -145(-310, 20) 0.08 
†Fetal inflammatory response  153 (-33, 339) 0.11 210 (-45, 465) 0.11 
Values are unstandardized -regression coefficients (95% CI) from multiple multivariable models. †Each 
variable is adjusted for sex and gestational age. Results shown are increase in newborn fat mass (g) and fat free 
mass in (g) per unit increase in the independent variable. BMI, body mass index; OGTT, oral glucose tolerance 
test.  
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Table 3: Maternal factors associated with placental weight and placental surface area  
 Placental weight (g) 
n = 136 
Placental surface area (cm2) 
n = 136 
  (95% CI) P 
value 
 (95% CI) P value  
Newborn sex (male) -6 (-51, 38) 0.78 -3 (-30, 23) 0.81 
Gestational age (weeks)  13 (-7, 33) 0.21 2 (-10, 14) 0.73 
†Maternal BMI (kg/m2) 1 (-4, 6) 0.66 -1(-4, 2) 0.59 
†OGTT, 2 hours (mmol/L) 3 (-12,18) 0.70 4 (-5, 13) 0.41 
†Maternal age (years) 5 (-1, 10) 0.10 3(-1, 6) 0.07 
†Parity (P1 vs P2+) 40 (-3, 85) 0.07 29 (3, 55) 0.03 
†Hypertension of 
pregnancy 
-4 (-130,123) 0.96 -41 (-114, 33) 0.28 
†Gestational diabetes -21 (-82, 39) 0.48 22 (-13, 57) 0.23 
†Pre-pregnancy weight (kg) 1.4 ( -0.3, 3) 0.10 0.4 (-0.6, 1.4) 0.44 
Values are unstandardized -regression coefficients (95% CI) from multiple multivariable model. † Each 
variable is adjusted for sex and gestational age. Results shown are increase in placental weight (g) and 
placental surface area (cm2) per unit increase in the independent variable.  BMI, body mass index; OGTT, 
oral glucose tolerance test.  
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Table 4: Maternal factors associated with chorioamnionitis and fetal inflammatory response  
 Presence of histological chorioamnionitis  
n = 49/136 
Presence of fetal inflammatory response  
n = 15/136 
 Odds ratio 
 (95% CI) 
P value  Odds ratio 
 (95% CI) 
P value  
Newborn sex (male) 0.86 (0.42, 1.75) 0.68 0.34 (0.10, 1.14) 0.08 
Gestational age (weeks)  1.29 (0.93, 1.78) 0.12 0.86 (0.53, 1.38) 0.52 
†Maternal BMI (kg/m2) 
 
0.97 (0.88, 1.06) 0.44 1.08 (0.91, 1.27) 0.38 
†Maternal age (years) 0.93 (0.84, 1.02) 0.12 0.97 (0.85, 1.15) 0.68 
†Parity (P1 vs P2+) 2.25 (0.11, 0.58) 0.001 9.45 (1.19, 74.91) 0.03 
†Hypertension of pregnancy  2.00 (0.26, 15.08) 0.50 0.22 (0.02, 2.51) 0.22 
† OGTT, 2 hours (mmol/L) 0.94 (0.73, 1.21) 0.65 1.28 ( 0.85, 1.95) 0.24 
†Gestational diabetes  
 
1.83 (0.61, 5.51) 0.28 ---#   
†Spontaneous onset of labour  3.36 (1.57, 7.17) 0.002 0.50 (0.16, 1.60) 0.25 
†Maternal pre-pregnancy weight (kg) 0.98 (0.95, 1.01) 0.23 1.04 (0.98, 1.11) 0.20 
Values are odds ratios (95% CI) from multiple multivariable model. † Each variable is adjusted for sex and gestational age. # Of the 22 
participants with gestational diabetes, there were none with a fetal inflammatory response.  BMI, body mass index; OGTT, oral glucose 
tolerance test.  
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Figure 1: Mediation models   
Figure 1: Mediation models showing the effect of maternal factors on newborn fat mass with the mediator, 
(placental weight) located causally between maternal factors and newborn fat mass. 
a) The direct effect of maternal pre-pregnancy weight when controlled for placental weight is indicated in blue.  The 
indirect effect via placental weight was B = 1.933 [95%CI -0.01,4.64]. b) The direct effect of maternal age when 
controlled for placental weight is indicated in blue. The indirect effect via placental weight was B = 5.058 [95%CI 
-0.16,12.39]. 
Placental weight (g) 
Maternal pre-pregnancy 
weight (kg) Newborn fat mass (g) 
B = 1.5, P = 0.09 B = 1.3, P < 0.001
B = 4.3 [95%CI -0.09, 8.6]  
a.
Placental weight (g) 
Maternal age (years) Newborn fat mass (g) 
B = 4.0, P = 0.15 B = 1.3, P < 0.001
B = 14.2 [95%CI  0.6, 27.8]
b.
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Abstract
Birth weight is associated with adult cardiovascular disease, such that those at
both ends of the spectrum are at increased risk. This may be driven in part by
modification to autonomic control, a mechanistic contributor to hypertension.
However, birth weight is a relatively crude surrogate of fetal growth; and new-
born body composition may more accurately identify the “at risk” infant.
Accordingly, we sought to determine whether newborns with high or low
body fat have altered autonomic control of vasomotor function and cardiac
contractility. Body fat was assessed by air-displacement plethysmography
<24 h postnatal. Measures of spontaneous baroreflex sensitivity (sBRS), blood
pressure variability (BPV), and dP/dtmax variability were compared between
newborns categorized according to established body fat percentiles: high body
fat (HBF, >90th percentile, n = 7), low body fat (LBF, ≤10th percentile,
n = 12), and normal body fat (control, >25th to ≤75th percentile, n = 23).
BPV was similar across body fat percentiles; similarly, low frequency dP/dtmax
variability was similar across body fat percentiles. sBRS was reduced in HBF
compared to controls (11.0  6.0 vs. 20.1  9.4 msec/mmHg, P = 0.03), but
LBF did not differ (18.4  6.0 msec/mmHg, P = 0.80). Across the entire body
fat spectrum (n = 62), there was a nonlinear association between newborn
body fat and sBRS (P = 0.03) that was independent of birth weight
(P = 0.04). Autonomic modulation of vasomotor function and cardiac con-
tractility in the newborn did not differ by body fat, but newborns born with
high body fat show depressed baroreflex sensitivity.
Introduction
Hypertension is an important modifiable risk factor for
cardiovascular and cerebrovascular diseases. Despite dec-
ades of research, over 95% of all cases of hypertension
remain of unknown etiology (World Health Organisation,
2013), necessitating that treatments target the established
symptoms and not the cause. A major consequence of
this is a failure of the treatment strategies currently used
in the management of hypertension with a considerable
number of patients failing to adequately control their
blood pressure (Yaxley and Thambar 2015).
A key pathophysiological hallmark of hypertension is ele-
vated sympathetic nerve activity. Importantly, raised sympa-
thetic activity has been reported in prehypertensive cohorts
such as in patients with a family history of hypertension and
may even be established during childhood (Julius et al.
1991). Thus, sympathetic overactivity precedes hypertension
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
This is an open access article under the terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
2018 | Vol. 6 | Iss. 8 | e13682
Page 1
Physiological Reports ISSN 2051-817X
and may be a pathophysiological component of the causal
pathway. Impaired baroreceptor reflex function has also
been reported in both established hypertension (Bristow
et al. 1969; Gribbin et al. 1971; Ducher et al. 2006), and in
young adults with borderline hypertension (Takeshita et al.
1975; Matsukawa et al. 1991).
One of the most important recent advances in hyper-
tension research is an understanding that hypertension
often may have a developmental origin. This concept is
based upon epidemiological studies where babies born
small had a significantly higher prevalence of hyperten-
sion and cardiovascular disease in later life (Lawlor et al.
2002). People born small for gestational age represent a
group at one end of the birth weight spectrum who are at
increased risk of cardiovascular disease in adulthood,
however, more recently those born large for gestational
age also represents a group at increased risk (Koklu et al.
2007; Skilton et al. 2014).
Birth weight is unable to differentiate between the consti-
tutionally small but well-nourished newborn who has met
their genetic growth potential, from an undernourished
newborn of the same weight, whose intrauterine environ-
ment has restricted their growth trajectory. Similarly, those
who are large for gestational age may be constitutionally
large, or have excessive fetal growth above their expected
growth trajectory. It has been proposed that groups of new-
borns with restricted or excessive growth in response to
their intrauterine environment are those at most risk of
later cardiovascular disease (Barker et al. 1993). Therefore,
utilization of newborn body composition, comprising lean
and fat mass may be a better indicator than birth weight.
Being able to measure autonomic function noninva-
sively and early detection of hypertension risk at a young
age may help both in understanding the etiology of
hypertension and identifying those at risk at a young age,
which could prove highly valuable.
Accordingly, we sought to determine whether vascular
autonomic function, specifically blood pressure variability
and baroreflex function, differ by newborn percentage
body fat and prematurity. Furthermore, this study has
introduced a possible new noninvasive measure of auto-
nomic regulation of the myocardium, the dP/dtmax vari-
ability in arterial pressure.
Methods
Ethical approval
This study was conducted in accordance with the stan-
dards set by the 2013 version of the Declaration of Hel-
sinki and was approved by the Sydney Local Health
District ethics committee and The University of Sydney
Human Ethics committee (HRECH/14RPAH/478).
Participation was voluntary, and informed written con-
sent was collected from the parents of the newborn.
Subject selection
Participants were recruited from the postnatal wards and
the neonatal unit at Royal Prince Alfred Hospital, Sydney.
Eligible newborns were singleton newborns between 37
and 42 completed weeks of gestation and those born late
preterm between 34 and 36 weeks of gestation who had
undergone routine body composition measurements. The
only exclusion criterion for this study was major congeni-
tal abnormalities and ongoing need for respiratory sup-
port in the newborn. Obstetric assessment of pregnancies
at risk of abnormal fetal growth (such as preeclampsia)
was not excluded. Gestational age was calculated from
first trimester ultrasounds.
Body composition and anthropometry
Body composition was measured in infants in the first 24 h
of life with air-displacement plethysmography (PEA POD,
COSMED USA, Inc), as part of routine clinical practice.
Air-displacement plethysmography is an age-appropriate
method for assessing body composition (Fields et al. 2015),
and has been validated in both term and preterm infants
(Ma et al. 2004; Ellis et al. 2007; Roggero et al. 2012). This
technique accurately measures body volume by the applica-
tion of Boyle’s law to the displacement of air by the infants
in a sealed chamber. Fat mass and fat-free mass are calcu-
lated by proprietary algorithms. Anthropometry was mea-
sured concurrently by two trained midwives. Weight is
measured with the integrated PEA POD scales to the near-
est gram, and head circumference to 0.1 cm. Length is
measured with a length board to the nearest 0.1 cm (Easy-
Glide Bearing infantometer, Perspective Enterprises, USA).
Newborns were categorized according to published body
fat percentiles, adjusted for gestational age and gender
(Hawkes et al. 2011).
Data collection
Maternal and newborn characteristics were collected
directly from mothers using a standardized questionnaire
and corroborated from electronic medical records.
Subjects
Blood pressure was recorded in 113 newborns, although
the measurements from 43 of these were insufficient for
analysis due to newborn- or equipment-related problems.
Failed measurements that were newborn-related occurred
when the newborn woke up during the measurement,
2018 | Vol. 6 | Iss. 8 | e13682
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failed to settle into sleep, or when the measurement was
interrupted by a member of the clinical care team. Equip-
ment-related problems occurred when the blood pressure
cuff failed to detect sufficient or continuous blood pres-
sure. Adequate blood pressure waveforms were obtained
in 70 newborns, of these 8 were late preterm newborns
and 62 were full-term newborns categorized according to
established body fat percentiles (Hawkes et al. 2011) as
follows: ≤10th percentile (n = male/female), n = 7/5;
>10th to ≤25th, n = 5/5; >25th to ≤50th, n = 5/8; >50th
to ≤75th, n = 5/5; >75th to ≤90th, n = 4/6; >90th per-
centile, n = 4/3.
To ensure equal spread across body fat percentiles for
comparisons between the full-term and late preterm
group, the full-term group was selected so that 10% of
newborns were ≤10th body fat percentile, 15% from
>10th to ≤25th, 25% from >25th to ≤50th, 25% from
>50th to ≤75th, 15% from >75th to ≤90th and 10% of
newborns >90th percentile body fat percentile. Individuals
within body fat percentiles were chosen at random.
Data acquisition
Continuous blood pressure recordings were acquired in
the sleeping newborn at 1–5 days old using a noninvasive
photoplethysomgraphic cuff (Finometer Pro, FMS, Fina-
press Medical Systems, The Netherlands), placed around
the right wrist of the newborn with the sensor positioned
over the radial artery. Blood pressure was recorded in 4-
minute intervals and repeated 1–3 times in each newborn.
Analogue outputs of blood pressure were sampled at
500 Hz using Labchart program (ADInstruments, Sydney,
Australia). Continuous blood pressure recordings were
exported to Spike2 software (version 7.18, Cambridge
Electronics Design, Cambridge, UK) and the following
waveforms were generated: systolic blood pressure (SBP),
dP/dt, and dP/dtmax of the blood pressure waveform.
SBP variability
Power spectral analysis of the systolic blood pressure
waveform provides a noninvasive method for the analysis
of autonomic nervous system modulation to vasculature.
SBPV was calculated using frequency domain methodol-
ogy on the SBP waveform sampled at 5 Hz, with linear
trend removal and by performing a Fast Fourier trans-
form (FFT, 256 point, Hanning window, zero percent
overlap) using customized algorithms in Spike2. The FFT
was performed on SBP waveform durations of 1- to 2-
min epochs repeated 3–5 times and averaged in each
infant, methodology similar to those previously published
in infants (Yiallourou et al. 2012a, 2013). Spectral bands
of SBPV were defined at 0.04–0.15 Hz for low frequency
and 0.15–1.1 Hz for high frequency. The very low-fre-
quency band was not analyzed because of the short time
period of the recordings. The high-frequency band was
based on respiratory rates in newborns at 0.5–1 Hz
(Polson et al. 2006) and the total frequency band was
defined as the range between 0 and 1.1 Hz.
The low-frequency component of SBP variability is an
established biomarker for sympathetic modulation of the
vasculature. These low-frequency oscillations of systolic
blood pressure are a result from an oscillation of the sym-
pathetic vasomotor tone and are enhanced during sympa-
thetic activation (Julien 2006).
Spectral analysis of dP/dtmax variability
Estimated arterial dP/dtmax has been reported to be a sur-
rogate measure for evaluating changes in left ventricular
contractility (Rhodes et al. 1993), and dP/dtmax variability
may represent autonomic modulation of ventricular
myocardial contractility. The arterial pressure dP/dt is
determined by the first differential of the blood pressure
waveform, and dP/dtmax, the peak rise in blood pressure
was identified using a peak detection algorithm in Spike2
(Fig. 1). Frequency analysis of dP/dtmax variability was
then performed similar to SBPV (Fig. 2). The dP/dtmax
waveform was resampled at 5 Hz, and linear trend
removal and FFT (256 point, Hanning window) was per-
formed. As the maximum rate of change in arterial pres-
sure is related to the force of ventricular contraction, the
low- frequency component of dP/dtmax variability may
reflect the sympathetic modulation of the myocardium
during systole.
Measures of low and high power for SBPV and dP/
dtmax were explored in its absolute values and using nor-
malized units (nu) as some studies indicating power spec-
tral components which are normalized for total power
may better detect sympathetic and parasympathetic pre-
dominance (Pagani et al. 1997). Normalized units were
calculated as previously described (Malik et al. 1996)
using the equation below, as an example for normalized
units of low frequency:
LF(NU) ¼ (LF=(Total Power-VLF)) 100
Baroreflex function analysis
Spontaneous baroreflex sensitivity (sBRS) was determined
using the sequence method which incorporates the identi-
fication of sequences of consecutive increases in SBP
(pressor ramps) or decreases in SBP (depressor ramps)
that are followed by a progressive lengthening (or short-
ening) of pulse interval (PI) (Polson et al. 2006). Sponta-
neously occurring changes in SBP over a period of four
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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or more beats were identified and the relationship with
the corresponding pulse interval, with delays of three,
four, and five beats were plotted. These delays were cho-
sen based on a delay of approximately 2 sec for changes
in heart rate in response to a change in blood pressure,
given that the neonatal heart rate is ~2 beats per second
(Polson et al. 2006). The slope and r2 value of the linear
regression for these plots were calculated and a barorecep-
tor mediated change in heart rate was only considered to
have occurred when the slope was positive and r2 was
>0.8 for each delay.
In addition to sBRS, baroreflex effectiveness index
(BEI) was used as an additional measure of baroreflex
function in the newborn. This is a measure of barorflex
recruitment and was determined as the ratio of the num-
ber of identified baroreflex sequences against the total
number of SBP ramps observed for a given period of time
(Rienzo et al. 2001), calculated using the formula below:
BEI ¼ Total number of pulse interval/SBP sequences
total number of SBP ramps
Statistical analysis
Statistical analysis was performed using SPSS Statistics,
version 23 (IBM Corp, Armonk, N.Y., USA).
Continuous data were expressed as mean (standard devi-
ation), and categorical data as count (percentage). Data
were visually inspected for normality, and nonnormally
distributed data was transformed appropriately. One-way
analysis of variance (ANOVA), with Dunnett correction
for multiple comparisons was applied to compare high
body fat (HBF; >90th percentile) with control (body fat
>25th to ≤75th percentile), and low body fat (LBF;
≤10th percentile) with control newborns. Full-term and
late preterm newborns were compared using indepen-
dent-samples t-test. Chi-square tests were used for cate-
gorical data. Nonlinear associations were determined by
use of quadratic terms in multivariable regression mod-
els that included participants across the entire spectrum
of body fat percent. Statistical significance was inferred
where P < 0.05.
Results
Participant characteristics
Of the total 62 full-term newborns, 7 were HBF (>90th
body fat percentile), and 12 were LBF (≤10th body fat
percentile) and 23 newborns in the control group
(>25th to ≤75th body fat percentile). Mothers who gave
birth to newborns with HBF had a greater proportion of
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Figure 1. Example of blood pressure waveform (A) recorded in a control newborn using the Finapres and (B) dP/dt and (C) dP/dtmax derived
from the BP waveform. The dP/dt waveform was generated by applying the slope function to the blood pressure waveform in Spike2. dP/dtmax
coincides with the maximum upstroke of the blood pressure waveform during systole.
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cesarean deliveries and no labor compared to controls.
Mothers in the LBF and control group were more likely
to have a spontaneous, normal (vaginal) delivery,
(Table 1).
Newborns with LBF were lighter, shorter, and had
reduced head circumference compared to controls, while
newborns with HBF were heavier, taller, and had a larger
head circumference. As expected, based on selection, new-
borns with LBF had reduced body fat compared to con-
trols, while newborns with HBF had higher body fat.
Conversely, LBF newborns had increased fat-free mass
compared to controls, while newborns with HBF had
reduced fat-free mass, (Table 1).
Maternal characteristics were not different between the
full-term and late preterm group. Late preterm newborns
were lighter, shorter, had reduced head circumference,
body fat, and reduced fat-free mass compared to full-term
newborns, (Table 2).
Autonomic function between newborn body
fat percentiles
Systolic blood pressure variability
We found no differences in overall blood pressure vari-
ability or individual frequency components of blood pres-
sure variability across body fat percentiles. Similarly, the
normalized units of low and high frequency components
were not different across body fat percentiles, (Table 3).
dP/dtmax variability
We found no differences in overall dP/dtmax, dP/dtmax
variability or individual frequency components of dP/
dtmax variability across body fat percentiles. Similarly, the
normalized units of low- and high-frequency components
were not different across body fat percentiles, (Table 3).
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Baroreflex function
Spontaneous baroreflex sensitivity (sBRS) was significantly
different between body fat percentiles (P = 0.04, Table 3).
Multiple comparisons revealed that sBRS was ~45% lower
in newborns with HBF than controls (P = 0.02), however,
no differences were seen between LBF and controls.
Across the entire body fat spectrum, there was a non-
linear association between infant body fat percent and
sBRS (P = 0.03, adjusted for gestational age and sex),
which was independent of birth weight (P = 0.04 after
adjustment). Body fat percent accounted for 13.4% of the
variance in sBRS. In comparison, birth weight accounted
for 10% of the variance in sBRS. In a model which
included birth weight, the introduction of body fat per-
cent accounted for an additional 7% of the variance in
sBRS.
The baroreflex effectiveness was similar across body fat
percentiles (P = 0.09), (Table 3).
Autonomic function between late preterm
and full-term newborns
Systolic blood pressure and dP/dtmax variability
We found no differences in overall blood pressure vari-
ability, individual frequency components of blood pres-
sure variability, or in any of the normalized units of low-
Table 1. Maternal and newborn characteristics across body fat percentiles.
LBF ≤ 10th percentile
(n = 12)
Control > 25th to ≤75th percentile
(n = 23)
HBF > 90th percentile
(n = 7) P value
Maternal characteristics
Age (years) 32  4.4 34  4.3 36  6.6 0.26
Ethnicity, n (%)
Asian 3 (25) 4 (17) 0 (0)
Caucasian 4 (33) 15 (65) 5 (71)
Middle Eastern 1 (8) 0 (0) 0 (0) 0.50
South Asian 3 (25) 3 (13) 1 (14)
Other 1 (8) 1 (4) 1 (14)
Maternal prepregnancy BMI (kg/m2) 21.9  2.6 22.8  3.5 22.8  2.3 0.71
Gestational diabetes mellitus, n (%) 2 (17) 5 (22) 1 (14) 0.88
Preeclampsia, n (%) 1 (8) 0 (0) 0 (0) 0.28
NICU admissions, n (%) 1 (8) 2 (9) 0 (0) 0.71
Glucocorticoid exposure, n (%) 0 (0) 1 (4) 0 (0) 0.66
Maternal smoking, n (%) 0 (0) 0 (0) 0 (0) –
Hypertension in pregnancy, n (%) 1 (8) 0 (0) 0 (0) 0.28
Mode of delivery, n (%)
Normal delivery 10 (83) 13 (57) 2 (29)
Instrumental 0 (0) 7 (30) 1 (14) 0.02
Cesarean 2 (17) 3 (13) 4 (57)
Labor
Spontaneous 6 (50) 14 (61) 2 (29)
Induced 5 (35) 8 (35) 1 (14) 0.01
No labor 1 (8) 1 (4) 4 (57)
Newborn characteristics
Gestational age (weeks) 38  1.0 39  1.3 39  1.1 0.18
Sex (girls/boys) 5/7 13/10 3/4 0.65
Birth weight (g) 2772  332 3354  469 4210  315 <0.0001
Length (cm) 48  1.8 50  2.5 54  1.7 <0.0001
Head circumference (cm) 33  1.1 35  1.5 36  0.5 <0.0001
Body fatness (%) 3  2 10  2 17  2 <0.0001
Body fatness (g) 98  57 356  101 728  89 <0.0001
Fat-free mass (%) 97  1.8 90  2 83  5 <0.0001
Fat-free mass (g) 2665  302 3010  400 3467  299 <0.0001
Data are presented as mean  SD for continuous data using one-way analysis of variance (ANOVA), and n (%) for categorical data, using chi-
square tests between newborn body fat percentiles. LBF; low body fat percentile, HBF; high body fat percentile, NICU; neonatal intensive care
unit.
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and high-frequency components between newborns born
late preterm and those born full-term, (Table 4).
We found no differences in overall dP/dtmax, dP/dtmax
variability or individual frequency components of dP/
dtmax variability between newborns born late preterm and
those born full-term. Similarly, the normalized units of
low- and high-frequency components were not different
between groups, (Table 4).
Baroreflex function
Spontaneous baroreflex sensitivity and baroreflex effec-
tiveness index appeared to be reduced in late preterm
newborns compared to full-term newborns; however, this
did not reach statistical significance, (Table 4).
Discussion
There is strong epidemiological evidence demonstrating
an inverse association between low birth weight and risk
of cardiovascular disease in later life (Barker et al. 2005;
Huxley et al. 2007). Recently, studies have also identified
that being born large for gestational age may also impact
cardio-metabolic health (Eriksson et al. 2001; Koklu et al.
2007; Skilton et al. 2014). Being born preterm is associated
with hypertension although studies have predominantly
focused on severe prematurity, and it is unclear whether
those born late preterm show similar cardiovascular mal-
adaptation. One of the major identified modifiers of car-
diovascular risk is altered autonomic function (Julius
1991; Parati and Esler 2012). We hypothesized that new-
borns with high or low body fat, or those born late pre-
term, may display changes in autonomic function that
predispose them to cardiovascular disease, compared to
term newborns with normal body fat. However, we found
no evidence for altered autonomic modulation of vasomo-
tor function and cardiac contractility at the extremes of
the fetal growth spectrum or in newborns born late pre-
term. The exception was a reduced baroreflex sensitivity in
newborns with high body fat, compared to those with nor-
mal body fat. This could be a factor that predisposes this
group to development of hypertension in later life
(Bristow et al. 1969).
Baroreflex function and SBP variability in
the newborn
In our study, newborns with HBF showed reduced sBRS
compared to those with normal body fat. Studies in obese
children and adults show a consistent reduction in barore-
flex sensitivity (Skrapari et al. 2007; Lazarova et al. 2009;
Calcaterra et al. 2013; Javorka et al. 2013), however, the
time of onset of this change is unclear. Our results extend
these findings by showing that reduced baroreflex sensitiv-
ity is also apparent in newborns with high body fat at just a
few days postpartum. Decreased baroreflex sensitivity is a
negative prognostic factor for cardiovascular morbidity and
sudden cardiac death (La Rovere et al. 1998; Honzıkova
et al. 2006; Lazarova et al. 2009). Reduced sensitivity may
be due to autonomic nervous system dysfunction (Spraul
et al. 1994; Chapleau et al. 1995; Miller et al. 1999; Grassi
et al. 2004) and or through changes in the mechanical
Table 2. Maternal and newborn characteristics of full-term and
preterm newborns.
Full term
(n = 40)
Preterm
(n = 8) P value
Maternal characteristics
Age (years) 33  4.2 33  5 0.66
Ethnicity, n (%)
Asian 8 (21) 3 (38)
Caucasian 23 (59) 4 (50)
Middle Eastern 1 (3) 0 (0) 0.82
South Asian 5 (13) 1 (13)
Other 2 (5) 0 (0)
Maternal prepregnancy
BMI (kg/m2)
22.9  3.4 24.4  9.2 0.67
Gestational diabetes
mellitus, n (%)
6 (15) 2 (25) 0.49
Preeclampsia, n (%) 0 (0) 0 (0) –
NICU admissions, n (%) 3 (8) 0 (0) 0.42
Glucocorticoid
exposure, n (%)
1 (3) 1 (13) 0.20
Maternal smoking, n (%) 0 (0) 0 (0) –
Hypertension in
pregnancy, n (%)
0 (0) 0 (0) –
Mode of delivery, n (%)
Normal delivery 23 (58) 6 (75)
Instrumental 9 (22) 1 (13) 0.65
Cesarean 8 (20) 1 (13)
Labor
Spontaneous 22 (55) 6 (75)
Induced 12 (30) 1 (13) 0.54
No Labor 6 (15) 1 (13)
Newborn characteristics
Gestational age (weeks) 39  1.1 36  0.5 <0.0001
Sex (girls/boys) 23/17 3/5 0.30
Birth weight (g) 3387  565 2737  406 0.003
Length (cm) 50  3 47  2 0.012
Head circumference (cm) 35  2 33  2 0.04
Body fat (%) 11  4 7.6  2 0.05
Body fatness (g) 378  183 204  93 <0.01
Fat-free mass (%) 89  4 92  2 0.05
Fat-free mass (g) 3033  423 2515  324 <0.01
Data are presented as mean  SD for continuous variables using
independent t-tests and n (%) for categorical variables, using chi-
square tests between full-term and late preterm groups. NICU,
neonatal intensive care unit.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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properties of the arterial wall (Tanaka et al. 2001; Hon-
zıkova et al. 2006). Increased carotid intima-media thick-
ness and stiffness have been found in obese children (Woo
et al. 2002; Iannuzzi et al. 2004; Skilton et al. 2014; Park
et al. 2015), but there are currently no studies that have
investigated the association of arterial stiffness with
increased adiposity in the newborn. Reduced sBRS in this
group may also be due to increased sympathetic activity as
a result of increased plasma insulin or circulating leptin
(Lazarova et al. 2009). Leptin has also been known to
impair the cardiac baroreflex centrally at the level of the
nucleus tractus solitarii (Arnold et al. 2009). We hypothe-
size that an imbalance in the autonomic nervous system,
with an impaired parasympathetic activity alone or with
sympathetic over activity may play an important role in the
reduced sBRS observed in our newborns with high body
fat. Interestingly, across our entire body fat spectrum, we
found a nonlinear association between newborn body fat
and sBRS, which was independent of birth weight. This
may indicate that newborn body fatness may be a better
predictor of spontaneous baroreflex sensitivity in the new-
born than birth weight.
We found no differences in BPV between body fat
groups, (Table 3). The magnitude of BPV in the low-fre-
quency band is regarded as an index of sympathetic mod-
ulation of the systemic vasculature and therefore total
peripheral resistance (Pagani et al. 1986; Yiallourou et al.
2012a). The role of the high-frequency component of
BPV in autonomic regulation is less clear, however, a
recent report indicated that it may be linked to respira-
tory modulation of sympathetic vasomotor tone (Menuet
et al. 2017). Although we failed to identify any clear dif-
ferences in BPV between groups, it is possible that differ-
ences may arise in later childhood. Currently there are no
studies that have investigated BPV in the neonate or chil-
dren with high adiposity. It therefore remains to be deter-
mined at what age autonomic dysfunction as observed
through analysis of BPV at different levels of body fat
may manifest.
Low birth weight is strongly, inversely associated with
later cardiovascular disease (Barker et al. 2005), but does
not discriminate between low birth weight due to fetal
growth restriction or prematurity. In our study, newborns
born full-term with LBF showed no differences in barore-
flex function or BPV. Studies in low birth weight children
and adolescents born at term have shown increased BPV,
measured in the time domain as the standard deviation
from discontinuous noninvasive BP monitoring or stan-
dard deviation, coefficient of variation and deviation
(Lurbe et al. 2001; Chen et al. 2012). These methodolo-
gies do not provide information on autonomic function
as does frequency analysis of beat-to-beat BP waveforms
and therefore cannot conclude whether the subjects of
these studies had altered autonomic regulation. Because
low birth weight is a strong predictor of later cardiovas-
cular disease it is important to review whether changes
seen in early life are due to prematurity or growth restric-
tion alone, and at what age changes in autonomic
Table 3. Autonomic indices across body fat percentiles.
LBF ≤10th percentile
(n = 12)
Control >25th to ≤75th percentile
(n = 23)
HBF >90th percentile
|(n = 7) P value
Systolic blood pressure variability
TP (mmHg2) 0.89 (2.98) 0.70 (1.50) 0.82 (1.29) 0.78
LF (mmHg2) 0.49 (1.60) 0.44 (0.95) 0.51 (0.77) 0.99
LF, NU 60.4  16.5 68.5  15.8 74.8  12.6 0.12
HF (mmHg2) 0.25 (1.41) 0.21 (0.34) 0.12 (0.22) 0.58
HF, NU 39.6  16.5 31.5  14.8 25.2  12.6 0.12
dP/dtmax variability
dP/dtmax (mmHg/sec) 144.9 (91.94) 105.1 (69.6) 115.9 (45.2) 0.47
TP (mmHg2/sec2) 9.6 (27.92) 5.8 (19.7) 6.2 (11.0) 0.71
LF (mmHg2/sec2) 3.2 (6.3) 2.6 (4.5) 3.1 (3.0) 0.91
LF, NU 36.9  15.8 38.3  18.0 39.0  16.3 0.96
HF (mmHg2/sec2) 5.3 (13.6) 3.1 (10.8) 3.1 (8.8) 0.78
HF, NU 63.1  15.8 61.7  18.0 61.0  16.3 0.96
Baroreflex function
sBRS (msec/mmHg) 18.4  6.0 20.1  9.4 11.0  6.0 0.04
BEI 0.09  0.05 0.15  0.08 0.13  0.08 0.09
Data presented as mean  SD for normally distributed data and median (interquartile range) for log-transformed data using one-way analysis
of variance (ANOVA). LBP; low body fat percentile, HBF; high body fat percentile, TP, total power; LF, low frequency; HF, high frequency; NU,
normalized units; sBRS, spontaneous baroreflex sensitivity; BEI, baroreflex effectiveness index.
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function detrimental to cardiovascular risk may manifest.
Future studies measuring BP waveforms in children and
adolescents born small for gestational age and late pre-
term will help to answer this question.
Baroreflex function and SBP variability in
late preterm newborns
In our study, although preterm newborns showed a lower
percentage body fat and low birth weight compared to
their term born counterparts, no differences were
observed in baroreflex or vasomotor function between
these groups. Studies in newborns born preterm (28–32
gestational age) found reduced baroreflex sensitivity at 2,
3, and 6 months age (Witcombe et al. 2012). Studies by
the same authors in children born preterm combined
with fetal growth restriction did not affect BPV or barore-
flex function; however, children born preterm alone
showed increased high-frequency BPV and no differences
in baroreflex function (Cohen et al. 2017). It is unclear
whether prematurity or growth restriction accounts for
these changes seen in these studies. In our study, we did
not look to separate fetal growth restriction within those
born late preterm.
Arterial dP/dtmax variability as an index of
autonomic regulation of cardiac
contractility
In our study, we found no differences in dP/dtmax vari-
ability across body fat percentiles or between full-term
and late preterm newborns. The dP/dtmax of left ventricu-
lar pressure is a well-validated measure of contractility
(Little 1985). Despite the dP/dtmax of the arterial pressure
waveform being affected by a number of factors such as
preload and arterial compliance (Adler et al. 1996), stud-
ies have shown good correlation between ventricular and
arterial dP/dtmax, and arterial dP/dtmax may offer a valu-
able methodology for noninvasive determination of
myocardial contractility (De Hert et al. 2006; Masutani
et al. 2009; Morimont et al. 2012).
A major influence on ventricular contractility is the
autonomic nervous system (Charkoudian and Rabbitts
2009). This study has introduced a possible new mea-
sure, dP/dtmax variability as an index of autonomic con-
trol of myocardial contractility. We suggest that
sympathetic modulation of the ventricular myocardium
may be reflected in the low-frequency component of dP/
dtmax variability in a similar manner to how sympathetic
modulation of heart rate and vascular resistance are
reflected in the low-frequency components of heart rate
variability and BPV (Pagani et al. 1997; Yiallourou et al.
2012a). These factors are not independent, and both
heart rate and blood pressure influence dP/dtmax because
of their influence on preload and afterload. It is unlikely
that the force-frequency relationship, where myocardial
contractility is observed to increase at higher heart rate,
influences dP/dtmax variability because these effects are
observed when heart rate increases over a sustained time
frame (Janssen 2010), rather than with cyclical variations
that are the hallmark of the dP/dtmax analysis. Moreover,
the force-frequency relationship appears to apply more
to small mammals than human, at least under normal
physiological conditions (Torres and Janssen 2011). Fur-
ther investigation and validation of dP/dtmax variability
independent of heart rate variability using specific ino-
tropic and chronotropic agents is important and the
subject of future studies. This added index of autonomic
regulation of the myocardium may be important in
evaluating pediatric and adult patients with autonomic
dysfunction.
The use of radial (used in the newborn in our study)
or finger arterial pressure derivative and its variability
may provide valuable data to monitor cardiac perfor-
mance noninvasively during daily activities. A limitation
of this technique in the newborn is that it is unclear how
accurate the radial arterial pressure derivative of dP/dtmax
is in comparison to gold standard measures of cardiac
Table 4. Frequency analysis of systolic blood pressure, dP/dtmax
variability, and baroreflex function in newborns born full term or
late preterm.
Late preterm
(34–36 weeks)
n = 8
Full term
37–42 weeks)
n = 40 P value
Systolic blood pressure variability
TP (mmHg2) 0.70 (1.99) 0.96 (1.67) 0.24
LF (mmHg2) 0.40 (0.63) 0.70 (1.17) 0.22
LF, NU 65.4  19.0) 69.6  15.0 0.50
HF (mmHg2) 0.21 (1.03) 0.23 (0.35) 0.46
HF, NU 34.6  19.0 30.4  15.0 0.50
dP/dtmax variability
dP/dtmax (mmHg/sec) 115.4 (55.2) 120.6 (91.5) 0.94
TP (mmHg2/sec2) 6.23 (14.51) 5.55 (12.24) 0.80
LF (mmHg2/sec2) 2.27 (5.85) 2.87 (4.1) 0.75
LF, NU 44.7  17.9 45.0  15.7 0.99
HF (mmHg2/sec2) 2.7 (7.06) 3.00 (7.42) 0.78
HF, NU 55.3  17.9 55.0  15.7 0.99
Baroreflex function
sBRS (msec/mmHg) 13.2  7.1 18.0  9.4 0.20
BEI 0.10  0.05 0.2  0.07 0.34
Data presented as mean  SD for normally distributed data and
median (interquartile range) for log-transformed data, indepen-
dent t-test between preterm versus full-term newborns. TP, total
power; LF, low frequency; HF, high frequency; NU, normalized
units; sBRS, spontaneous baroreflex sensitivity; BEI, baroreflex
effectiveness index.
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contractility. However, as with the use of the Finapres in
the newborn for determining BPV, beat-to-beat changes
in dP/dtmax may be accurate even if the absolute measure-
ment is not (Polson et al. 2006). It is the beat-to-beat
change, rather than the absolute value that is important
in the determination of dP/dtmax variability.
Limitations
Obtaining blood pressure waveform in the newborn non-
invasively using photoplethysmography is a technique that
offers potentially important advances in both research
and clinical settings (Andriessen et al. 2004; Polson et al.
2006; Yiallourou et al. 2012a, 2013; Cohen et al. 2017).
However, the methodology is technically challenging, and
often investigators are unable to obtain adequate blood
pressure signals in subjects. Moreover, the accuracy of the
measurements has been questioned (Drouin et al. 1997a,
b; Andriessen et al. 2004; Polson et al. 2006). We have
found previously that with appropriate cuff placement,
there is good agreement between photoplethysmography
and an arterial cannula in mean diastolic and systolic
blood pressure measurements made over several minutes,
however, on a beat-to-beat basis absolute measures of
blood pressure were not well validated (Polson et al.
2006). Importantly, however, we found that measurement
of the beat-to-beat changes in systolic blood pressure, and
therefore calculations of systolic BPV and spontaneous
BRS, were accurate (Polson et al. 2006).
This study is part of a wider study assessing early car-
diovascular risk which included measures of heart rate
variability obtain from the ECG, as another marker of
autonomic control. However, due to the technical diffi-
culties in measuring blood pressure waveform in the new-
born, we were only able to obtain continuous blood
pressure waveform data in a subset of participants. Thus,
the sample size in the present report is reduced compared
to heart rate variability measures. Given the large differ-
ence in the number of participants with available data,
measures of heart rate variability were not included in
this study and will be published elsewhere in conjunction
with other markers of cardiovascular risk. The sample size
in this study is, however, similar to, or higher than, other
studies that have assessed autonomic function in the
infant (Andriessen et al. 2004, 2005; Patural et al. 2004;
Polson et al. 2006).
Conclusions
There is strong evidence demonstrating that babies born
at the extremities of the birth weight spectrum are at
increased risk of developing cardiovascular disease in later
life, although the mechanisms remain unclear. Moreover,
the age at which predisposition for cardiovascular disease
can be demonstrated is not known. In this study, we
sought to ascertain whether babies born with high or low
body fat, or those born late preterm, showed changes in
autonomic function, compared to controls. We found lit-
tle evidence for altered autonomic function of vasomotor
function and cardiac contractility in these groups, with
the exception of newborn with high body fat who showed
reduced baroreflex sensitivity. Reduced baroreflex sensitiv-
ity observed in newborns with high body fat may be due
to impaired parasympathetic activity or sympathetic over
activity. Furthermore, across the entire body fat spectrum
(n = 62), there was a nonlinear association between new-
born body fat and baroreflex sensitivity which was inde-
pendent of birth weight (P = 0.04). This study has
introduced dP/dtmax variability as a possible new measure
of autonomic control of myocardial contractility. This
novel index, proposed as a measure of autonomic regula-
tion of the myocardium, may be of value in evaluating
pediatric and adult patients with autonomic dysfunction.
Further investigation and validation of dP/dtmax variabil-
ity using specific inotropic and chronotropic agents is
important and the subject of future studies.
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ABSTRACT  
Importance: Birth weight is associated with cardiovascular disease, with those at both ends of the 
spectrum at increased risk. Markers of cardiovascular risk are altered in both low and high birth 
weight infants. However, birth weight is a relatively crude surrogate of fetal growth, and it has been 
proposed that body composition of newborns, particularly body fatness, may more accurately 
identify “high risk” infants.  
Objective: Determine whether cardiac autonomic control, and cardiac structure and function differ 
in newborns with high or low body fatness compared to those with average body fatness.  
Design, Setting, and Participants: A cross-sectional study was conducted between 2015-2017 at 
Royal Prince Alfred Hospital, Sydney, Australia. 189 healthy singleton term born neonates were 
recruited from the maternity wards. Recruitment was stratified by predefined groups on the basis of 
body fat percentiles (sex and gestation-specific). Our prespecified analyses were comparisons of High 
body fatness (>90th percentile) and Low body fatness (≤10th) with Control (>25 to ≤75th).   
Main outcomes and measures: Outcome measures included were heart rate variability as a measure 
of cardiac autonomic control, and cardiac structure and function assessed by echocardiography. Body 
fat was assessed by air displacement plethysmography.  
Results: Infants with low body fat had lower heart rate variability (log, total power, -0.5 [95% CI -
0.8, -0.1, P = .008), and thicker ventricular walls (posterior wall thickness normalised to body 
surface area, 3.1 mm [95% CI 1.6, 4.6], P <0.001) compared to controls. Infants with high body fat 
showed reduced heart rate variability (log, total power, -0.8 [95% CI -1.1, -0.5], P < 0.001) and 
stroke volume (-0.3 ml/kg [95% CI -0.6, -0.0], P = .03). The non-linear association of body fatness 
with heart rate variability was independent of birth weight.  
Conclusions and relevance: Infants born with high or low body fat have altered markers of 
cardiovascular health and may represent groups at higher risk of future cardiovascular disease.  
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INTRODUCTION  
Cardiovascular disease remains the leading cause of death globally, accounting for 15 million 
deaths in 2015 [1]. There is an extensive and consistent body of epidemiologic evidence supporting 
an inverse association of birth weight with incidence of adult cardiovascular disease, such that for 
every 1kg higher birth weight, the risk of coronary artery disease is 10-20% lower [2]. However, 
this association is likely not linear, with people born with a high birth weight, also exhibiting 
evidence of altered cardio-metabolic health in childhood and adulthood, [3-5] and there is indirect 
evidence supporting a higher risk of subsequent cardiovascular disease events [2].  
Although cardiovascular disease presents clinically in adult life, evidence of structural and 
functional changes to the vasculature consistent with the earliest etiologic features of 
atherosclerosis are present in in infants with early life risk factors, [6], such as low birth weight [7] 
[8].  
These early physiological markers of cardiovascular risk are increasingly well described, and 
include cardiac structural and functional modification, and alterations in cardiac autonomic control. 
Studies have shown altered cardiac morphology and subclinical impairments of systolic and 
diastolic cardiac function in small for gestational age (SGA) infants,[9, 10] which persist into 
childhood [11] and late adolescence [12]. By mid-adulthood, the magnitude of these effects would 
appear to be of limited clinical relevance [13]. But even in the context of this presumed reversal by 
mid-adulthood, such temporary structural and functional cardiac impairments during the first two 
decades of life may theoretically predispose an individual to later cardiovascular disease via 
prolonged exposure to hemodynamic alterations, accelerating the onset and progression of 
arteriosclerosis and causing subclinical end-organ damage.  
Such alterations in cardiac function may etiologically relate to changes in cardiac autonomic 
control. The physiological variation in the heart rate is modified by the sympathetic and 
parasympathetic branches of the autonomic nervous system which act together to regulate blood 
pressure and cardiovascular function starting in fetal life. Autonomic activity is an important 
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mechanistic determinant of other health and disease outcomes [14].  Heart rate variability (HRV), a 
surrogate of cardiac autonomic control, can be assessed non-invasively, and is associated with risk 
of subsequent cardiovascular events [15]. There is evidence that cardiac autonomic control is 
altered in SGA infants from the prenatal period through to childhood and adult life [16].  
The vast majority of this body of evidence linking fetal growth with adult cardio-metabolic disease, 
and markers of pre-clinical disease in childhood, uses birth weight as the exposure of interest, as it 
is easily obtained and considered a useful, albeit rather crude, surrogate marker of fetal growth and 
nutrition. However, birth weight and birth weight percentiles are unable to differentiate between the 
constitutionally small but well-nourished infant who has met their genetic growth potential, from 
malnourished infants of the same weight with evidence of fetal growth restriction. Similarly, those 
who are large for gestational age may be constitutionally large or have excessive weight gain. It has 
been proposed that the groups of infants with restricted or excessive growth in response to their 
intrauterine environment are those with increased rates of adult cardiovascular disease,[17] 
although the use of clinically applied measures of such have failed to show consistent associations 
with cardio-metabolic changes consistent with high risk [18, 19]. One possible means by which to 
quantify newborn body composition is through the amount of lean and fat body mass. Lean body 
mass is relatively stable and largely reflects genetic and familial determinants, such as parental size 
[20]. Newborn fat mass is more variable and appears to reflect the intrauterine environment, 
including nutritional status of the mother [20-22].  
Accordingly, we sought to determine whether autonomic control and cardiac structure and function, 
differ in newborns with either high or low body fatness, when compared to those with “normal” 
body fatness. Furthermore, we aimed to identify whether BF% is a better predictor than birth weight 
of any such alterations in cardiac autonomic control, structure and function.  
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METHODS 
This study was approved prospectively by the Sydney Local Health District ethics committee and 
the University of Sydney Human Ethics committee. Participation was voluntary, and informed 
written consent was obtained for all participants. 
 
The study comprised two parts.  First, acquiring ECG data in quietly resting neonates for analysis of 
HRV, as an index of autonomic regulation of the heart.  Second, ultrasound examination of the 
structure and function of the heart.  
 
Subject Recruitment  
Recruitment consisted of a total of 189 newborns from the postnatal wards and the neonatal unit at 
Royal Prince Alfred Hospital, Sydney.  This is a major obstetric tertiary referral centre with 
approximately 5500 deliveries per year, and covers an inner-city, multicultural population. 
Newborns were recruited consecutively according to consent within the body fat percentile 
categories and according to gender balance within each subgroup. Eligible subjects were well 
singleton newborns between 37 and 42 completed weeks gestation who had undergone routine body 
composition measurements. Exclusions were major congenital abnormalities and ongoing need for 
respiratory support. Gestational age was calculated from first trimester ultrasounds.  
Recruitment and Study flow is shown in figure 1.  
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Figure 1: study flow  
 
 
Body composition and anthropometry  
Body composition was measured in infants in the first 48 hours postpartum using air-displacement 
plethysmography (PEA POD®, COSMED USA, Inc), as part of their routine clinical management.   
Air displacement plethysmography accurately measures body volume by the application of Boyle’s 
law to the displacement of air by the infant in a sealed chamber, with proprietary algorithms used to 
calculate fat mass and fat-free mass [23-25]. Infants were categorised according to published body 
fat percentiles [26] Birth weight, length and head circumference were measured concurrently by 
two trained midwives. Weight was measured with the integrated PEA POD® scales to the nearest 
gram, and head circumference to 0.1cm. Length was measured to the nearest 0.1cm with an Easy-
Glide Bearing Infantometer (Perspective Enterprises, USA) length board.  
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Maternal and infant demographics 
Demographic data on mothers and infants were collected from mothers using a standardised 
questionnaire and from mother and infant medical records. We collected current and previous 
health status, pregnancy and delivery details, including previous medical conditions, gestational 
diabetes, gestational hypertension, smoking status, physical activity and dietary profile.  
 
Heart rate variability  
ECG was recorded continuously for 15 minutes using standard neonatal 3-lead configuration whilst 
the infants were sleeping in a supine position. The ECG analog output was digitised at 500 Hz, and 
acquired using commercial hardware (Powerlab, ADInstruments, Sydney, Australia). Infants 
behaviour was observed closely; any periods of activity where the infant woke up were noted and 
these periods removed from subsequent analysis. Analysis of heart rate (HR) and HRV were 
performed using LabChart (HRV 1 module, version 7, ADInstruments) on up to three (average 
2.75) R-R interval epochs of exactly 4 minutes. Peak detection on ECG was used to create RR 
sequences. Time domain measures of HRV included total power the standard deviation of the 
normal-to-normal (NN) RR intervals as a measure of overall variability, and two short term 
measures: standard deviation of change in successive NN intervals (SDNN), and the root mean 
square of successive differences in NN interval (RMSSD) [15]. Frequency domain analysis was 
done by performing a fast Fourier transformation (256 point, Hanning window) with 50% overlap. 
The spectral bands for HRV were investigated in the range of 0-1.1 Hz based on previous studies 
[27, 28]. Low Frequency (LF) at 0.04 to 0.15 Hz, and high frequency (HF) at 0.15 to 1.1 Hz. The 
HF band was based on respiratory rates in infants at 0.5 to 1 Hz [29, 30]. VLF was not determined 
due to the short sampling times. 
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Cardiac Ultrasound  
2D cardiac ultrasound was performed with a Philips EPIQ 5 and S12-4 Phased Sector Array 
transducer using a standardised protocol, from day 2 after birth to allow for postpartum 
cardiovascular transition. Images were stored and analysis performed offline with Xcelera software 
V (Philips Medical Systems, Netherlands).  
 
Cardiac dimensions: Left and right ventricle base to apex length and diameter were measured in 
apical 4 chamber view at end-diastole, and sphericity index calculated as length/diameter. Left 
ventricular wall thickness was measured at end-diastole just distal to the mitral leaflets in M-mode 
from a parasternal long axis view.  
 
Systolic function: Fractional shortening was measured in M-mode from a parasternal long axis view 
and calculated as end-diastolic diameter – (end-systolic diameter/end-diastolic diameter). 
Ascending aortic velocity time integral was measured from an apical 5 chamber view with pulsed-
wave Doppler. Internal aortic diameter was measured at parasternal long axis view where the aortic 
valve leaflets were clearly visualized. Stroke volume was calculated as aortic area x heart rate and 
left ventricular output as aortic area x velocity time integral x heart rate. Mitral and tricuspid 
annular plane systolic excursion were measured using M-mode through respective lateral valve 
leaflets from apical 4 chamber view.[31] Peak systolic myocardial velocity was measured with 
tissue Doppler imaging at the lateral and septal mitral and lateral tricuspid valves utilising pulsed-
wave Doppler from the apical 4 chamber view.[32] 
 
Diastolic function: Ventricular inflow was measured using pulsed-wave Doppler of the 
atrioventricular valves from an apical 4 chamber view. Peak velocities of the E and A waves were 
measured and used to calculate the E: A ratio. E deceleration time was calculated as time from peak 
velocity of the E wave to the return to baseline. Isovolumetric relaxation time (IVRT) was 
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measured from an apical view, with the sample volume placed to simultaneously record both mitral 
and aortic flow. IVRT was calculated as the end of flow through the aortic valve to the beginning of 
flow through the mitral valve. Peak diastolic myocardial velocities (Eʹ and Aʹ) were measured with 
tissue Doppler imaging at the lateral and septal mitral and lateral tricuspid valves utilising pulsed-
wave Doppler from the apical 4 chamber view. Lateral and septal E: Eʹ were calculated.  
 
To determine intra-observer variability, blinded analyses were performed on two separate occasions 
at least one month apart for 20 randomly selected participants. Two anatomical and two 
physiological parameters were analysed utilising the coefficient of variation and the intra-observer 
intra-class correlation coefficient. Intra-class correlations ranged from 0.75 to 0.98 (Supplementary 
Table 1).  
 
Statistical analysis  
Continuous data are expressed as mean (SD) and categorical data as n (%). Data were tested for 
normality by plotting histograms, and log transformations applied as required. Log transformed data 
are presented as the geometric mean (interquartile range). Multivariable linear regression were used 
to compare HBF (>90th percentile) and LBF (≤10th percentile) infants with a control group of 
infants with average body fatness (>25th to ≤75th percentile). Chi–Square or Fisher’s Exact tests 
were utilised for categorical data. Nonlinear associations were determined by use of quadratic terms 
in multivariable regression models that included participants across the entire spectrum of body 
fatness. Statistical significance was inferred at 2P<0.05.  Statistical analysis was performed using 
IBM SPSS Statistics for Windows, version 23 (IBM Corp., Armonk, NY). 
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RESULTS  
Participant characteristics 
Maternal and infant characteristics are shown in (Table 1). Mothers of infants with LBF were more 
likely to identify as South Asian and less likely to identify as Caucasian, and maternal BMI was 
higher in mothers who gave birth to infants with HBF compared to infants in the control group. 
Infants with HBF were more likely to be delivered by elective caesarean section and presented with 
no labour, a greater proportion of control infants had a normal delivery with spontaneous onset of 
labour. There were no mothers on glucocorticoid intervention and prevalence of maternal smoking 
did not differ between test groups.  
As expected based on selection criteria, infants with LBF were lighter, shorter and had a reduced 
head circumference compared to controls, and infants with HBF were heavier, taller and had a 
larger head circumference. Maternal and infant characteristics for those infants between the >10th 
and 25th body fat percentiles, and between the >75th and ≤90th  body fat percentiles are provided 
in (Supplementary Table 2).  
 
Heart rate variability   
Heart rate was similar across body fat percentiles (Table 2). Measures of overall HRV both in the 
time (SDNN) and frequency domain (total power) were lower in LBF and HBF than control infants 
(Table 2). These associations remained statistically significant after adjustment for gestational age 
and sex (eg. for log, total power: LBF, -0.5 [95% CI -0.8, -0.1], P = .008; HBF, -0.8 ms2 [95% CI -
1.1, -0.5], P < 0.001; both compared to control).  
Furthermore, SDNN and RMSSD, both short term time domain measures, and the HF and LF 
power measures were all lower in HBF infants than controls (Table 2).  
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Across the entire body fat percent spectrum, there was a non-linear association between infant body 
fat percent and overall HRV (total power, figure 2; P = .001, adjusted for gestational age and sex), 
which was independent of birth weight (P = .01 after adjustment). Body fat percent accounted for 
8.6 % of the variance in overall HRV. In comparison, birth weight accounted for 8.2% of the 
variance in overall HRV. In a model which included birth weight, the introduction of body fat 
percent accounted for an additional 4.7% of the variance in overall HRV. Absolute heart rate 
variability indices across body fat percentiles shown in supplementary table 3.  
 
Cardiac structure and function 
Infants with LBF had significantly increased septal and posterior wall thicknesses and left 
ventricular chamber dilatation compared to control infants (Table 2). Physiological parameters were 
similar between LBF and control infants (Supplementary Table 4). Infants with HBF had increased 
ventricular base to apex length (Table 2) and lower left ventricular stroke volume compared to 
control infants (Supplementary Table 4), with no other differences observed in cardiac structure or 
measures of systolic or diastolic function.  
There were no statistically significant associations, linear or non-linear, between cardiac measures 
and body fat percent across the entire spectrum of body fat measures (results not shown). Six 
infants had a small ventricular septal defect or patent ductus arteriosus, which were asymptomatic 
with minimal shunt. There was no difference in incidence between groups, and sensitivity analyses 
indicated that results did not differ when these infants were excluded. Absolute cardiac structure 
and function indices across body fat percentiles are shown in supplementary table 5.   
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Table 1: Maternal and infant characteristics  
 
Control 
(>25th to ≤75th BF%) 
( n = 56) 
LBF 
(≤10th BF%) 
(n = 33) 
P value 
(LBF vs control) 
HBF 
(>90th BF%) 
(n =29) 
P value 
(HBF vs control) 
Maternal Characteristics 
Age, years 33 ± 4.2 32 ± 3.9 0.31 34.8 ± 4.6 0.17 
Ethnicity, n (%) 
Asian 11 (20) 5 (16) 
0.04 
4 (14) 
0.81 
Caucasian 39 (70) 14 (45) 22 (76) 
Middle Eastern 1 (2) 2 (7) 0 (0) 
South Asian 3 (5) 7 (23) 1 (3) 
Other 2 (4) 3 (10) 2 (7) 
Maternal pre-pregnancy BMI, Kg/m2 22.6 ± 3.7 22.1 ± 2.7 0.47 24.6 ± 3.6 0.03 
Gestational Diabetes Mellitus, n (%) 11 (20) 5 (15) 0.59 3 (10) 0.27 
Hypertension in pregnancy, n (%) 1 (3) 2 (4) 0.89 0 (0) 0.30 
Mode of delivery, n (%) 
Normal delivery 35 (63) 20 (61) 
0.97 
13 (45) 
0.01 Instrumental 12 (21) 7 (21) 3 (10) 
Caesarean 9 (16) 6 (18) 13 (45) 
Labour 
Spontaneous 34 (61) 17 (52) 
0.70 
10 (35) 
<0.001 Induced 18 (32) 13 (39) 6 (21) 
No Labour 4 (7) 3 (9) 13 (45) 
Infant Characteristics 
Postnatal age, days 2 ± 1 2 ± 2 0.22 2 ± 1 0.90 
Gender (girls/boys) 32/24 18/15 0.81 14/15 0.44 
Birth weight, g 3401 ± 415 2916 ± 360 <0.0001 3997 ± 437 <0.0001 
Length, cm 49.8 ± 1.9 47.6 ± 1.8 <0.0001 51.6 ± 1.9 <0.0001 
Head circumference, cm 34.6 ± 1.3 33.8 ± 1.2 <0.001 36.0 ± 1.3 <0.0001 
Body fat, %  10.6 ± 1.8 3.9 ± 1.8 <0.0001 17.9 ± 2.5 <0.0001 
Data are presented as mean (SD) for continuous variables using Independent t-test and n (%) for dichotomous variables using chi-square tests between groups. LBF, 
low body fat; HBF, high body fat. Control = 56; LBF = 33; HBF = 29 except BMI, n = 32 (LBF), n = 54 (control); maternal age n = 25 (HBF). 
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Table 2. Effect of infant body fat percent on aortic intima-media thickness, heart rate variability and cardiac 
structure 
 Control 
(>25th to ≤75th BF%) 
 
LBF 
(≤10th BF%) 
 
HBF 
(>90th BF%) 
 
  (95% CI)  (95% CI) P value  (95% CI) P value 
HRV (frequency domain) N = 39 N = 25 N = 26 
Ln Total Power 0 (referent) -0.5 (-0.8, -0.1) .01 -0.8 (-1.1, -0.5) < 0.001 
Ln LF 0 (referent) -0.3 (-0.7,0.1) .18 -0.8 (-1.1, -0.4) < 0.001 
Ln HF 0 (referent) -0.2 (-0.7,0.3) .51 -1.0 (-1.4, -0.4) < 0.001 
Ln LF: HF 0 (referent) -0.2 (-0.6,0.2) .38 0.3 (-0.1,0.8) .15 
HRV (time domain) N = 39 N = 25 N = 26 
HR, bpm 0 (referent) -0.5 (-9,8) .92 4 (-4,12) .32 
Mean NN, ms 0 (referent) 11 (-22,44) .48 -18 (-50,13) .25 
SDNN, ms 0 (referent) -7 (-13, -1) .02 -11 (-17, -5) < 0.001 
Ln SDNN 0 (referent) -0.1 (-0.4,0.2) .52 -0.5 (-0.7, -0.2) .02 
Ln RMSSD 0 (referent) -0.1 (-0.4,0.2) .39 -0.4 (-0.7, -0.1) .004 
Cardiac structure N = 46 N = 22 N = 23 
LV Base to apex length, mm 0 (referent) -1.34 (-3.1,0.3) .11 2.09 (0.3, 3.8) .02 
LV Diameter, mm 0 (referent) -0.88 (-2,0.3) .13 0.09 (-1.1,1.3) .89 
LV Sphericity index  0 (referent) 0.05(-0.1,0.2) .46 0.18 (-0.02,0.3) .09 
Septal wall thickness/BSA 0 (referent) 2.3 (0.5,4.1) .01 -0.01 (-1.8,1.7) .99 
Posterior wall thickness/BSA 0 (referent) 3.1 (1.6,4.6) <0.001 -1 (-2.4,0.5) .18 
End-diastolic dimension/BSA 0 (referent) 5.5 (1.4,9.7) .01 -3 (-7.1,1.0) .14 
Relative wall thickness 0 (referent) 0.03 (-0.01,0.7) .08 -0.01 (-0.04,0.3) .71 
RV Base to apex length, mm 0 (referent) -0.8 (-2.6,1.0) .36 2.0 (0.36,3.7) .02 
RV Diameter, mm 0 (referent) -0.7 (-1.7,0.35) .19 0.4 (-0.5,1.4) .38 
RV Sphericity index 0 (referent) 0.01 (-0.1,0.2) .87 0.09 (-0.1,0.2) .23 
Values are unstandardized -regression coefficients (95% CI) from multivariable models, adjusted for sex and 
gestational age. Ln, log transformed data.   
LBF: low body fat percent; HBF: high body fat percent; HRV, heart rate variability; LF, low frequency; HF, high 
frequency; LF: HF, low frequency/high frequency ratio; HR; heart rate, mean NN; mean of N wave to N wave variation 
normal; SDNN, the mean of the standard deviation of all normal RR intervals; SDNN, SD change in NN; RMSSD, 
square root of the mean squared differences of successive NN intervals; LV, left ventricle; RV, right ventricle; BSA, 
body surface area.  
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DISCUSSION  
Our findings indicate that infants with LBF have reduced cardiac autonomic control and altered 
cardiac structure, in particular having thicker ventricular walls and larger chamber size. At the other 
end of the body fatness spectrum, infants with HBF also showed reduced cardiac autonomic 
control, although this was accompanied by a different cardiac phenotype, specifically cardiac 
functional changes, including reduced stroke volume, but not structural changes. 
Furthermore, when compared to birth weight, the associations of body fatness with cardiac 
autonomic control were stronger, suggesting that the use of body fatness assessment may better 
identify those at risk of cardiovascular diseases than the use of birth weight alone.  
 
More precise identification of individuals at high risk of cardiovascular disease remains a priority in 
prevention initiatives. Early life factors are increasingly recognized as being associated with future 
risk of disease, however, they remain crudely described. A number of studies have now described 
altered autonomic functions to be present in people born with low birth weight, from infancy 
through adult life [16, 33, 34]. Spassov et al found reduced HRV at 2-10 days of age in SGA 
newborns [35], Galland et al found increased sympathetic activity and reduced parasympathetic 
activity at 1 and 3 months of age [36], whereas Cohen et al found no differences in resting HRV 
[37, 38] despite increased sympathetic response at 0-2 weeks [37]. We extend these previous 
findings by characterising infants based on their body fatness profile at birth, potentially a more 
relevant marker of an adverse fetal environment than birth weight. We found that infants with LBF 
had lower overall HRV (total power and SDNN), and that total power of HRV was independent of 
birth weight. Accordingly, reduced HRV may indicate a reduced ability to adapt to internal and 
external stimuli making these individuals mechanistically susceptible to future hemodynamic and 
cardiac diseases, particularly via autonomic nervous system pathways.     
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In our study, infants with HBF showed a marked reduction in HRV, seen in all frequency and time 
domain measures. Studies in obese children and adults show changes to autonomic function 
consistent with a reduced parasympathetic and increased sympathetic modulation to the heart [39-
42]. Previous literature on cardiac parasympathetic response to higher body fatness and obesity in 
children and adults are remarkably consistent. Children over 6 years of age with obesity show 
reduced parasympathetic activity, specifically a reduction in HF power is seen in children with 
obesity during 5 minute recordings [43], 24 hour Holter monitoring [44-46] and during a Valsalva 
manoeuvre [47]. Other studies in children reported a reduction in Total power, LF and HF power in 
children with obesity compared to those without, or a reduction in LF and HF power in children 
with diabetes mellitus and increased body weight [43, 48]. Consistent with the literature in children, 
our study showed that infants with high body fatness had reduced overall HRV (total power and 
SDNN), reduced LF, and a clear reduction in parasympathic modulation indicative of a reduced HF 
power, RMSSD, and SD  NN. However, no differences were seen in the LF: HF ratio, a marker of 
cardiac sympathetic drive. Collectively, the marked reduction in HRV seen in infants with high 
body fatness may indicate an overall reduction in parasympathetic modulation to the heart. This 
may be precipitated by both maternal factors and other intrauterine exposures. Our study did not 
look to elucidate these specific mechanistic pathways that link adiposity and HRV, although they 
may involve fetal glucose, insulin and adipocytokine levels.  
 
These reductions in HRV in infants with LBF or HBF may potentially be mechanistically involved 
in the higher risk of stillbirth at the extremes of the fetal growth spectrum, although further work 
would be required to develop and test this hypothesis.   
The most commonly reported structural adaptation that accompanies fetal growth restriction is a 
globular ventricle, as assessed by sphericity index [9, 49]. Whilst we did not observe a significant 
difference in sphericity index in the LBF group, we found that infants with LBF have thicker 
ventricular walls and larger chamber size, which is consistent with the general structural adaptations 
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previously described. These changes have been demonstrated to be related to the severity of growth 
restriction as defined by body weight and antenatal Doppler assessment. Interestingly, we found no 
added discriminatory benefit of using body fatness for identifying infants with these cardiac 
adaptations, beyond the use of birth weight alone. This hypertrophic phenotype of fetal origin persists 
into adolescence [11, 50, 51] and adulthood [13], although the cardiac phenotype becomes more 
subtle with age. Whether the associations of body fatness with this cardiac phenotype will persist, 
strengthen, or weaken over time remains unknown. Accompanying this structural phenotype are 
subtle changes in diastolic and systolic function.  
A key strength of our study is that we investigated infants at a very early age, on average 3-5 days 
old. The observation that cardiac autonomic, structural and functional changes seen are already 
established in the infant provides further insight into the cardiovascular adaptations that may be 
useful in assessing the effects of exposure to an adverse intrauterine environment. Future follow up 
of these infants will allow us to determine whether these changes seen in infancy persist into later 
life, or whether they are transient in infancy.  
 
Our study has a number of limitations. Although our measurements were taken during sleeping, 
studies have shown that HRV differs by sleep state (active vs quiet sleep), consistent with a greater 
cardiac sympathetic presence during active sleep. We did not confirm sleep state (active vs quiet 
sleep) via polysomnography, which may contribute to increased variability in HRV measures.  
All participants in our study did not have complete cardiac structural measures and autonomic data 
therefore it was hard to make associations between changes seen.  
 
Collectively, infants born with low or high body fatness show reduced HRV, an established marker 
of autonomic activity, although these groups have distinct cardiac structural and functional 
phenotypes. The immediate or long-term consequences of impaired autonomic function are 
unknown in the infant, particularly in the context of concurrent cardiac structural and functional 
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alterations, but in older people are associated with risk of cardiovascular, lipid and endocrine 
abnormalities, and may reflect a compromised ability of these infants to adapt to ongoing internal or 
external stimuli. 
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Supplemental methods and table.  
 
Cardiac dimensions: Left and right ventricle base to apex length and diameter were measured in apical 4 chamber view at end-diastole, and sphericity 
index calculated as length/diameter. Left ventricular wall thicknesses were measured at end-diastole just distal to the mitral leaflets in M-mode from a 
parasternal long axis view. Relative wall thickness was posterior wall thickness + septal thickness/left ventricular end diastolic dimension. Wall 
thicknesses were indexed to body surface area as calculated by the Haycock formula.[52] 
 
Systolic function: Fractional shortening was measured in M-mode from a parasternal long axis view, and calculated as end-diastolic diameter – (end-
systolic diameter/end-diastolic diameter). Ascending aortic velocity time integral was measured from an apical 5 chamber view with pulsed-wave 
Doppler. Internal aortic diameter was measured at parasternal long axis view where the aortic valve leaflets were clearly visualized. Stroke volume was 
calculated as aortic area x heart rate, and left ventricular output as aortic area x velocity time integral x heart rate. Mitral and tricuspid annular plane 
systolic excursion were measured using M-mode through respective lateral valve leaflets from apical 4 chamber view. Peak systolic myocardial 
velocity was measured with tissue Doppler imaging at the lateral and septal mitral and lateral tricuspid valves utilising pulsed-wave Doppler from the 
apical 4 chamber view.  
 
Diastolic function: Ventricular inflow was measured using pulsed-wave Doppler of the atrioventricular valves from an apical 4 chamber view. Peak 
velocities of the E and A waves were measured and used to calculate the E:A ratio. Isovolumetric relaxation time was measured from an apical view, 
with the sample volume placed to simultaneously record both mitral and aortic flow, and calculated as the end of flow through the aortic valve to the 
beginning of flow through the mitral valve. Peak diastolic myocardial velocities (Eʹ and Aʹ) were measured with tissue Doppler imaging at the lateral 
and septal mitral and lateral tricuspid valves utilising pulsed-wave Doppler from the apical 4 chamber view. Lateral and septal E: Eʹ were calculated.  
 
Supplementary Table 1. Intra-class correlation 
 Coefficient of variation ICC (95% CI) 
Left ventricle end-diastolic diameter 3.85 .93 (0.81-0.97) 
Left ventricle end-systolic diameter 4.0 .75 (0.47-0.89) 
Ascending aorta velocity time integral 3.73 .98 (0.95-0.99) 
Left ventricular output 15.1  .82 (0.57-0.92) 
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Supplementary Table 2: Maternal and infant characteristics for infants in >10th and 
25th and >75th and ≤90th  groups  
 
 
>10th and 25th 
(n = 23) 
>75th and ≤90th  
 (n = 27) 
Maternal Characteristics   
Age (years) 33 ± 5 33 ± 4  
Ethnicity, n (%) 
Asian 5 (23) 3 (11) 
Caucasian 12 (55) 21 (78) 
Hispanic  1 (5) 0 (0) 
Middle Eastern 1 (5) 1 (4) 
South Asian 3 (14) 2 (7) 
Other 0 (0) 0 (0) 
Maternal pre-pregnancy BMI, Kg/m2 24 ± 4  24 ± 4  
Gestational Diabetes Mellitus, n (%) 1 (4) 5 (19) 
Hypertension in pregnancy, n (%) 1 (4) 0 (0) 
Mode of delivery, n (%) 
Normal delivery 14 (61) 17 (63) 
Instrumental 5 (22) 2 (7) 
Caesarean 4 (17) 8 (30) 
Labour 
Spontaneous 14 (63) 16 (59) 
Induced 8 (35) 6 (22) 
No Labour 1 (4) 5 (19) 
Infant Characteristics 
Postnatal age, days 3 ± 1 3 ± 2  
Gender, girls/boys 10/13 14/13 
Birth weight, g 3083 ± 266  3676 ± 341 
Length, cm 50 ± 2  50 ± 2  
Head circumference, cm 34 ± 1 35 ± 1  
Body fat, % 7 ± 1 15 ± 2  
Data are presented as mean (SD) for continuous variables and n (%) for dichotomous variables. Independent t-test and chi-square tests 
between groups.
Hasthi U Dissanayake  Chapter Five 
 
120 
Supplementary Table 3. Heart rate variability indices across body fat percentiles  
 Control 
(>25th to ≤75th 
BF%) 
LBF 
(≤10th BF%) 
P value 
(LBF vs 
control) 
HBF 
(>90th 
BF%) 
P value 
(HBF vs 
control) 
Heart rate 
variability 
N = 39 n = 25  n = 26  
Frequency 
domain 
     
*Total Power, ms2 1556 (1312.6) 960 (1226.3) .01 702 (552.8) < 0.001 
*LF, ms2 374 (384.2) 288 (318.1) .18 176 (152.1) < 0.001 
*HF, ms2 196 (301.0) 157 (160.9) .40 79 (92.6) < 0.001 
*LF: HF 2.3 (2.3) 2.0 (2.7) .49 3.1 (2.1) .21 
Time domain       
HR, bpm 128 (17) 128 (20) .92 132 (14) .30 
Mean NN, ms 477 (60) 488 (78) .55 460 (48) .22 
SDNN, ms 44 (13) 36 (12) .02 33 (10)  < 0.001 
*SDNN, ms 19 (19.2) 17 (13.3) .40 12 (8.9)  .002 
*RMSSD, ms 19 (19.2) 17 (10.1) .31 13 (8.9)  .01 
Data presented as mean (SD) or *geometric mean (IQR) for log transformed data. Independent t-test between body fat percentile 
groups. LBF: low body fat percent; HBF: high body fat percent; LF, low frequency; HF, high frequency; LF: HF, low frequency/high 
frequency ratio; HR; heart rate, mean NN; mean of N wave to N wave variation normal; SDNN, the mean of the standard deviation of all 
normal RR intervals; SDNN, SD change in NN; RMSSD, square root of the mean squared differences of successive NN intervals 
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Supplementary 4. Indices of cardiac function in infants with low, high and control 
body fat. 
 Control 
(>25th to ≤75th 
BF%) 
 
LBF 
(≤10th BF%) 
 
HBF 
(>90th BF%) 
 
  (95% CI)  (95% CI) P 
value 
 (95% CI) P 
value 
Systolic function N = 46 N = 20 N = 19 
Heart rate 0 (referent) 0.8 (-11,12) .90 7.6 (-4,19) .21 
Fractional shortening, % 0 (referent) -0.2 (-3.8,3.3) .70 0.9 (-2.5,4.4) .60 
Left ventricular output, 
ml/kg/min 
0 (referent) -10.6 (-46,25) .56 -25 (-60,11) .17 
Stroke volume, ml/kg 0 (referent) -0.1 (-0.4,0.1) .33 -0.3 (-0.6,-0.03) .03 
MAPSE, mm 0 (referent) -0.4 (-1,0.3) .29 0.02 (-0.1,0.1) .56 
TAPSE, mm 0 (referent) -0.1 (-0.1,0.1) .77 0.1 (-0.01,0.2) .07 
Mitral lateral Sʹ, cm/s 0 (referent) 0.02 (-0.5,0.5) .94 0.4 (-0.1,1.0) .12 
Mitral septal Sʹ, cm/s 0 (referent) 0.01 (-0.4,0.4) .98 -0.7 0.9(-0.5,0.4) .78 
Tricuspid Sʹ, cm/s 0 (referent) -0.2 (-0.7,0.2) .34 -0.3 (-0.9,0.3) .28 
Diastolic function N = 37 N = 21 N = 15 
Mitral E wave, cm/s 0 (referent) 0.9 (-5.4,7.2) .78 4.5 (-2.5,11.5) .20 
Mitral A wave, cm/s 0 (referent) 1.9 (-4.2,8.0) .54 4.2 (-2.6,11.0) .22 
Mitral E:A 0 (referent) -8.8 (-27,9) .34 -8.2 (-28,12) .42 
Tricuspid E wave, cm/s 0 (referent) -2.5 (-8.8,3.8) .43 6.1 (-0.8,13) .08 
Tricuspid A wave, cm/s 0 (referent) -0.5 (-5.6,4.6) .85 5.9 (0.3,11.5) .04 
Tricuspid E:A 0 (referent) -0.05 (-0.1,0.2) .19 0.01 (-0.1,0.1) .72 
Left isovolumic relaxation 
time, ms 
0 (referent) -3.6 (-8.7,1.0) .12 -2.7 (-8.0,2.7) .32 
Mitral lateral Eʹ, cm/s 0 (referent) -0.7 (-1.5,1.5) .11 0.01 (-1,1) .99 
Mitral septal Eʹ, cm/s 0 (referent) -0.1 (-1,0.6) .75 0.6 (-0.2,1.5) .14 
Tricuspid Eʹ, cm/s 0 (referent) -1.1 (-2,-0.07) .04 -0.5 (-1.6,0.7) .43 
E:Eʹ lateral 0 (referent) 0.8 (-0.7,2.3) .29 0.9 (-0.8, 2.7) .29 
E:Eʹ septal 0 (referent) 0.3 (-1.4,2.0) .73 0.3 (-1.8,2.4) .80 
Values are unstandardized -regression coefficients (95% CI) from multivariable models, adjusted for sex and gestational age. LBF: low 
body fat percent; HBF: high body fat percent; MAPSE, mitral annular peak systolic excursion: TAPSE, tricuspid peak annular systolic 
excursion.  
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Supplementary 5. Cardiac structure and function across body fat percentiles  
 Control 
(>25th to ≤75th BF%) 
LBF 
(≤10th BF%) 
P value 
(LBF vs control) 
HBF 
(>90th BF%) 
P value 
(HBF vs control) 
Indices of cardiac structure         
 N  N   N   
PDA present n, % 48 0 (0) 23 2 (8.7) .14a 21 1 (4.8)  
VSD present n, % 48 1 (2.1) 23 1 (4.3) .80a 21 1 (4.8)  
Left ventricle 
Base to apex length, mm  36 27.1 (2.2) 20 25.5 (3.7) .04 19 29.0 (3.7) .02 
Diameter, mm 36 16.5 (1.4) 20 15.7 (2.7) .26 19 16.8 (2.2) .56 
Sphericity index 35 1.6 (0.2) 19 1.7 (0.3) .28 18 1.9 (0.7) .18 
Septal wall thickness/BSA, mm 
45 18.4 (2.7) 21 21.1 (3.8) .007 23 18.6 (4.4) .88 
Posterior wall thickness/BSA, mm 
45 15.5 (2.8) 22 18.5 (2.9) .000 22 14.4 (2.6) .13 
End-diastolic dimension/BSA 46 80.3 (8.3) 22 86.9 (8.8) .005 23 77.7 (7.2) .18 
Relative wall thickness 45 0.42 (.07) 21 0.46 (.07) .09 22 0.42 (.07) .63 
Right ventricle 
Base to apex length, mm 33 23.4 (2.4) 14 22.4 (2.9) .25 17 25.3 (3.4) .02 
Diameter, mm 33 13.8 (1.8) 14 13 (1.4) .18 17 14.2 (1.6) .40 
Sphericity index 33 1.7 (0.2) 14 1.7 (0.2) .48 16 1.8 (0.2) .11 
Indices of cardiac function         
 N  N   N   
 Systolic function         
Heart rate 46 135 (22) 20 136 (18) .87 19 142 (23) .23 
Fractional shortening, % 46 34.6 (7.2) 22 34.3 (5.8) .83 23 35.6 (6.2) .60 
Left ventricular output  
 
 
(ml/kg/min(ml/kg/min) 
46 230 (69) 19 214 (55) .39 18 203 (61) .15 
Stroke volume, ml/kg 45 1.8 (0.52) 19 1.6 (0.44) .27 18 1.4 (0.43) .03 
MAPSE, mm 35 7.0 (1.0) 15 6.6 (0.8) .20 14 7.1 (1.1) .62 
TAPSE, mm 39 8.7 (1.3) 16 8.4 (1.2) .52 15 9.4 (1.8) .11 
Mitral lateral Sʹ, cm/s 30 5.4 (0.7) 15 5.5 (0.9) .68 10 5.9 (0.8) .07 
Mitral septal Sʹ, cm/s 36 4.9 (0.6) 15 4.9 (0.6) .89 9 4.8 (0.6) .81 
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Tricuspid Sʹ, cm/s 24 6.2 (0.6) 15 5.9 (0.9) .21 9 5.9 (0.8) .30 
 
Control 
(>25th to ≤75th BF%) 
LBF 
(≤10th BF%) 
P value 
(LBF vs control) 
HBF 
(>90th BF%) 
P value 
(HBF vs control) 
Diastolic function         
 N  N   N   
Mitral E wave, cm/s 36 51 ± 11 21 51 ± 13 .95 15 55 (11) .21 
Mitral A wave, cm/s 36 51 ± 10 21 52 ± 13 .71 15 55 (13) .25 
Mitral E/A 37 1.0 ± 0.1 21 1.0 ± 0.1 .45 15 1.0 (0.1) .53 
Tricuspid E wave, cm/s 40 46 ± 10 20 43 ± 12 .31 15 52 (13) .11 
Tricuspid A wave, cm/s 40 52 ± 8 20 52 ± 9 .70 15 57 (11) .10 
Tricuspid E/A 40 0.9 ± 0.1 20 0.8 ± 0.1 .17 15 0.9 (0.1) .77 
IVRT, ms 32 58 ± 8 18 54 ± 9 .12 13 55 (5.4) .27 
Mitral lateral Eʹ, cm/s 30 6.8 ± 1.3 15 6.1 ± 1 .08 10 6.8 (1.4) .98 
Mitral septal Eʹ, cm/s 36 5.5 ± 1 15 5.2 ± 1 .48 9 6.0 (1.7) .17 
Tricuspid Eʹ, cm/s 24 7 ± 1.6 15 5.9 ± 1.1 .02 9 6.7 (1.6) .54 
E/Eʹ lateral 28 7.3 ± 2.5 15 8.2 ± 2.5 .28 10 8.1 (1.8) .37 
E/Eʹ septal 31 9.1 ± 2.6 15 9.5 ± 2.9 .64 8 9.3 (2.1) .88 
Data presented as mean (SD). Frequency data No. (%).  Independent t-test between body fat percentile groups. All cardiac structure and function P values adjusted for sex and gestational age. a Fisher’s 
Exact test 
PDA: patent ductus arteriosus; VSD: ventricular septal defect; BSA: body surface area. MAPSE: Mitral annular plane systolic excursion; TAPSE: Tricuspid annular plane systolic excursion; IVRT: 
Isovolumetric relaxation time.
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ABSTRACT  
Background: Late preterm newborns make up approximately 74% of all preterm births and 
8% of total births. There is an increasing body of evidence demonstrating that babies born 
late preterm are at an increased risk of neonatal morbidity and mortality. The autonomic 
nervous system is central in controlling heart rate, effecting rapid changes in heart rate 
response to stimuli. Such changes enable the newborn to response adequately to changes in 
the internal and external environment.  
Aim: The aim of this study is to investigate whether changes in cardiac autonomic function 
measured by heart rate variability were present in the late preterm newborn. 
Methods: This study included 26 late preterm newborns at 34 and 37 completed week’s 
gestation and a control group of 114 newborns at 37-42 week’s gestation. Heart rate 
variability was assessed in 4-minute epochs repeated up to three times, using time and 
frequency analysis.  
Results: Heart rate variability (total power) was approximately 39% lower in those born late 
preterm (P = 0.003), similarly cardiac parasympathetic activity was approximately 51% lower 
in those born late preterm (P = 0.02). The LF to HF ratio was higher in late preterm newborn 
compared to full term newborns (P = 0.04). Heart rate and low frequency component of heart 
rate variability did not differ between groups, P > 0.05. These associations were independent 
of newborn sex, birth weight, body fatness and maternal pre-pregnancy body mass index.     
Conclusion: Cardiac autonomic control is altered in late preterm newborns compared to term 
born newborns. This reduced autonomic control during the neonatal period may contribute to 
increased neonatal morbidity and mortality in late preterm newborns, in addition to 
potentially predisposing these individuals to higher risk of cardiovascular disease in 
adulthood.  
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INTRODUCTION 
Eleven percent of all births worldwide are preterm[1]. Approximately, 74% of these preterm 
infants are born ‘late preterm’, after 34 weeks gestation, comprising 6-8% of all livebirths [2, 
3]. Those born late preterm are often managed during the neonatal phase in the same way as 
term infants, because they may be appropriate size at birth and appear mature [4]. However, 
late preterm infants are at a greater risk of medical complications compared to their full-term 
counterparts[5, 6], including neonatal morbidity and mortality[2, 7, 8] and negative 
neurologic sequelae [9-11]. Fetal brain growth and development is highest in the last 6 weeks 
of gestation. At 34 weeks, brain weight is only 65% of that of a brain at 40 weeks [4], 
Furthermore, between, 34 and 40 weeks gestation cortical volume increases by 50%, and 
25% of cerebellar development occurs during this period.     
 
Those born preterm are at increased risk of Sudden infant Death Syndrome during infancy as 
well as developing high blood pressure as adults [12]. The exact cause of this is unknown; 
however it is thought that impaired maturation of the autonomic nervous system either via 
increased sympathetic activity or reduced sympathetic and/or parasympathetic activity may 
be implicated. Heart rate variability is a widely used non-invasive tool for evaluating cardiac 
autonomic function. Heart rate variability represents the variation between consecutive heart 
beat modified by the sympathetic and parasympathetic nervous system. Measures of heart 
rate variability reflects the hearts ability to respond and adapt to ongoing changes from the 
internal and external environment [13].  
 
Previous studies in those born preterm show reduced cardiac autonomic activity, specifically 
a reduction in cardiac parasympathetic activity from infancy to adulthood [13-17]. However, 
the late preterm infant is less well studied. Given that late preterm newborns make up the 
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fastest growing subset of neonates [4], the identification of altered risk profile in this group 
would be of considerable public health relevance. Therefore, we sought to determine whether 
cardiac autonomic control is reduced in late preterm newborns, compared to those born at 
term.  
 
METHODS 
Ethical approval   
This study was conducted in accordance with the NHMRC National Statement of Ethical 
Conduct in Human Research and was approved by the Sydney Local Health District ethics 
committee and The University of Sydney Human Ethics committee (HRECH/14RPAH/478). 
Participation was voluntary, and informed written consent was collected from the 
parents/guardians.  
 
Subjects  
Participants were recruited from the postnatal wards and the neonatal unit at Royal Prince 
Alfred Hospital, Sydney. This was a pre-specified analysis within a larger prospective cohort 
study that sought to determine the associations of body composition with cardiovascular 
health in newborns. Eligible subjects were healthy singleton newborns between 34 and 42 
completed weeks gestation. Exclusion criteria for this study was major congenital 
abnormalities and ongoing need for respiratory support in the newborn. We recruited 33 
newborns between 34 and 36  completed week’s gestation and 189 term newborns between 37 
to 41 week’s gestation (Figure 1) as determined by first trimester ultrasound. The control 
group consisted of 114 newborns. To ensure equal spread across body fat percentiles for 
comparisons between the full term and late preterm group. The full-term group was selected 
so that 10% of the newborns were ≤10th body fat percentile, 15% between >10th to ≤25th, 25% 
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between >25th to ≤50th, 25% between >50th to ≤75th, 15% between >75th to ≤90th and 10% of 
newborns >90th percentile body fat percentile. Individuals within body fat percentiles were 
chosen at random (Figure 1).  
 
Data collection 
Demographic data on mothers and newborns were collected directly from mothers using a 
standardised questionnaire and mother and newborn medical records. We collected current 
and previous health status, pregnancy and delivery details, and smoking and other lifestyle 
information.  
 
Body composition and anthropometry  
Body composition was measured in newborns in the first 24 hours of life with air-
displacement plethysmography (PEA POD®, COSMED, CA, USA, Inc), as part of routine 
clinical practice. Air-displacement plethysmography is an age-appropriate method for 
assessing body composition [18], and has been validated in both term and preterm infants 
[19-21]. This technique accurately measures body volume by the application of Boyle’s law 
to the displacement of air by the infants in a sealed chamber. Fat mass and fat-free mass are 
calculated by proprietary algorithms. Anthropometry was measured concurrently by two 
trained midwives. Weight is measured with the integrated PEA POD® scales to the nearest 
gram, and head circumference to 0.1cm. Length is measured with a length board to the 
nearest 0.1cm (Easy-Glide Bearing infantometer, Perspective Enterprises, USA). Newborns 
were categorized according to published gender and gestational age specific body fat 
percentiles [22].  
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Heart rate variability  
An electrocardiogram (ECG) was recorded continuously for 15 minutes using standard 
neonatal 3-lead configuration whilst the newborns were sleeping in a supine position. The 
ECG analogue output was digitised at 500 Hz, and acquired using commercial hardware 
(Powerlab, ADInstruments, Sydney, Australia). Newborn behaviour was observed closely. 
Any periods of activity where the newborn woke up were noted and these periods removed 
from subsequent analysis. Analysis of heart rate and HRV were performed using LabChart 
(HRV 1 module, version 7, ADInstruments, Sydney, Australia) on up to 3 R-R interval 
epochs of exactly 4 minutes. Peak detection on ECG was used to create RR sequences. Time 
domain measures of HRV included the standard deviation of the normal-to-normal (NN) RR 
intervals as a measure of overall variability, and two short term measures: standard deviation 
of change in successive NN intervals (SDNN), and the root mean square of successive 
differences in NN interval (RMSSD) [23]. Frequency domain analysis was done by 
performing a fast Fourier transformation on the RR interval waveform (256 point, Hanning 
window) with 50% overlap.  This provided a resolution (bin width) of 10 Hz. The spectral 
bands for HRV were investigated in the range of 0-1.1 Hz based on previous studies [12, 24]. 
Low Frequency at 0.04 to 0.15 Hz, and high frequency at 0.15 to 1.1 Hz. The high frequency 
band was based on respiratory rates in newborns at 0.5 to 1 Hz.[25, 26]  VLF was not 
determined due to the short sampling times. 
 
Statistical analysis  
Statistical analysis was performed using SPSS (IBM Corp, Armonk, NY version 23). Data 
are expressed as mean and standard deviation (SD) or number and percentage (%). Data were 
tested for normality by plotting histograms. Log transformations were applied to non-
normally distributed data, and normality of the transformed variable was confirmed visually.  
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Between-group comparisons were performed with independent-samples T-test for continuous 
data, and Chi-Square or Fisher’s Exact tests were utilised for categorical data. Multivariable 
linear regressions were utilised to compare whether associations were independent of known 
confounders.  
 
RESULTS 
Patient characteristics 
Maternal and newborn characteristics are show in Table 1. Mothers in the preterm group 
were more likely to have a higher pre-pregnancy body mass index compared to mothers in 
the term group. Maternal characteristics and health were otherwise comparable between 
groups. Prevalence of maternal smoking and steroid exposure did not differ significantly 
between groups (Table 1). As expected late preterm newborns were lighter, shorter, had 
reduced head circumference, body fat and reduced fat free mass compared to full term 
newborns, Table 1. Rates of admission to the Neonatal Intensive Care (NICU) were not 
different between groups, highlighting that our preterm group was a healthy group, with the 
majority managed on the postnatal ward.  
 
Heart rate variability 
Heart rate was similar between groups, Table 2. Measures of overall HRV both in the time 
(SDNN) and frequency domain (total power) were lower in late preterm newborns, being 
approximately 39% lower for total power. Short-term time domain measures SDNN and 
RMSSD were lower in late preterm compared to full term newborns. For frequency domain 
measures, there was no difference in LF power between late preterm and term born 
newborns, but HF power was 51% lower in in the late preterm group, Table 2. Furthermore, 
the LF:HF ratio was higher in late preterm newborns compared to those born full term.  
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These associations were independent of newborn sex, body fatness, birth weight and maternal 
pre-pregnancy BMI (data not shown).  
 
DISCUSSION 
Our findings indicate that newborns born late preterm show reduced cardiac autonomic 
control. Infants born late-preterm often are the same weight and size as those born at term. 
However, they are physiologically and metabolically immature[27] and may be at an 
increased risk of developing medical conditions in the immediate postnatal life. To date there 
have been no studies that have investigated autonomic control in the late preterm newborn, 
however studies in infants and children born preterm (28 to 37 weeks’ gestation) show 
reduced HRV, as well as reduced parasympathetic modulation to the heart [13-17, 28]. In our 
study, newborns born late preterm had lower overall HRV (total power and SDNN) and 
lower parasympathetic modulation of the heart indicated by reduced HF power, RMSSD, 
SDNN, all markers of parasympathetic modulation of the heart. Furthermore, in this study, 
late preterm newborns showed an increased low frequency:high frequency ratio, thought to 
be a marker of cardiac sympathetic drive.  
 
These cardiac autonomic changes seen in the late preterm newborn may be exacerbated by 
maternal and intrauterine exposures. This study did not look to elucidate mechanistic 
pathways linking late prematurity with cardiac autonomic control. However, we hypothesise 
that these changes may arise due to impaired development of autonomic regulatory systems 
even in the late preterm newborn. Studies indicate fetal brain growth and development is 
highest during the last 6 weeks of gestation. It is possible key brain regions associated with 
blood pressure control may therefore be impaired, leading to altered cardiac autonomic 
control[4].  
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The autonomic nervous system rapidly changes during the last trimester, these changes 
ensure that the newborn is able to breath, regulate body temperature and obtain food. These 
progressive changes are critical for normal physiological and behavioural state of the 
newborn [29]. Furthermore, myelination of the vagus nerve increases significantly between 
33-35 weeks’ gestation [30]. The vagus nerve is the principal mediator of parasympathetic 
outflow to the heart, and is central to effecting rapid changes in heart rate in response to 
stimuli [15].  
 
The reduced overall HRV and parasympathetic modulation to the heart in these late preterm 
may indicate an impaired inability to adapt to ongoing changes in the internal and external 
environment. This compromised state obligates the preterm newborn to rely on the 
sympathetic nervous system to increase heart rate in response to stimuli rather than a vagal 
withdrawal. This compromised profile may contribute to altered blood pressure control in the 
immediate postnatal period as well as the long-term control of blood pressure. Indeed, a 
number of studies show altered blood pressure control in preterm infants [12] and elevated 
blood pressure in children and adults born preterm [31, 32], it is possible these adverse 
cardiovascular outcomes may extend to those born late preterm.  
 
CONCLUSIONS  
In this study, newborns born late preterm showed evidence of altered cardiac autonomic 
control, specifically reduced cardiac parasympathetic modulation and increased cardiac 
sympathetic modulation. The altered cardiac autonomic regulation seen in these late preterm 
newborns may be associated with increased neonatal morbidity and mortality seen in these 
newborns, and if these changes persist long-term, may potentially confer increased risk of 
raised blood pressure in later life. 
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Figure 1:  study flow diagram  
 
 
 
Term infants recruited
(n = 189)
Late preterm infants recruited 
(n = 33) 
Excluded (n = 24)
 - Declined to have autonomic 
   assessments  (n = 21, full term)
-  Declined to have to have autonomic 
   assessments (n = 3, late preterm)
Full term data 
Analysed autonomic data (n = 114)
Excluded from analysis (n = 54)
-18 excluded to ensure equal gender & birth 
weight percentiles 
-11 discharged before measurement 
performed
- 17 failed to settle during recording 
- 8 excluded due to inadequate ECG quality 
to analyse
Preterm data 
Analysed autonomic data (n = 26)
Excluded from analysis (n = 4)
 
- 2 failed to settle during recording
- 2 excluded due to inadequate ECG quality 
to analyse
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Table 1: Maternal and newborn characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are presented as mean ± SD for continuous variables using independent t-tests and n (%) for categorical variables, using chi-square 
tests between full term and late preterm groups. NICU; neonatal intensive care unit. Full term n = 114, late preterm n = 26 except maternal 
BMI n = 102 (full term). 
 
Full term  
N = 114  
Late preterm  
N = 26 
P value 
Maternal Characteristics  
Age, years 33.2 ± 4.6 34.6 ± 5.0 0.17 
Ethnicity, n (%) 
Asian 19 (17) 10 (39)  
Caucasian 74 (66) 12 (46)  
Middle Eastern 4 (1) 0 (0) 0.15 
South Asian 8 (7) 1 (4)  
Other 6 (5) 3 (12)  
Maternal pre-pregnancy BMI, Kg/m2 23.1 ± 3.7 25.0 ± 6.1 0.05 
Gestational Diabetes Mellitus, n (%) 17 (15) 6 (23) 0.38 
Preeclampsia, n (%) 5 (4) 1 (4) 1.00 
NICU admissions, n (%) 6 (6) 3 (12) 0.37 
Steroid intake, n (%) 4 (4) 1 (4) 0.93 
Maternal smoking, n (%) 3 (3) 3 (12) 0.14 
Hypertension in pregnancy, n (%) 4 (4) 1 (4) 1.00 
Mode of delivery, n (%) 
Normal delivery 67 (59) 18 (69)  
Instrumental 20 (18) 6 (23) 0.19 
Caesarean 27 (24) 2 (8)  
Labour 
Spontaneous 62 (54) 19 (73)  
Induced 38 (33) 5 (19) 0.22 
No Labour 14 (12) 2 (8)  
Newborn Characteristics 
Gestational age, weeks 39.2 ± 1.1 35.8 ± 0.4 < 0.0001 
Postnatal age, days 4.5  ± 4.7  4.1 ± 3.2  0.70 
Sex (girls/boys) 62/52 15/11 0.76 
Birth weight, g 3436.3 ± 502.1 2806.7 ± 319.8 < 0.0001 
Length, cm 49.8 ± 2.3 47.0 ± 2.0 < 0.0001 
Head circumference, cm 34.8 ± 33.1 33. 1 ± 1.1 < 0.0001 
Body fat, % 11.0 ± 5.1 9.3 ± 3.1 0.03 
Body fatness, g 422.0 ± 358.6  259.1 ± 103.8 < 0.0001 
Fat free mass, % 89.0 ± 5.1 90.7 ± 3.1 0.10 
Fat free mass, g 3017.0 ± 401.7 2548.5 ± 282.6  < 0.0001 
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Table 2. Frequency and time domain measures of heart rate variability between full term and late 
preterm newborns 
 
 
 
 
 
 
 
 
 
 
 
Data presented as mean (SD) or *geometric mean (IQR) for log transformed data. Independent t-test between groups. LF, low frequency; 
HF, high frequency; LF: HF, low frequency/high frequency ratio; HR; heart rate; SDNN, the mean of the standard deviation of all normal 
RR intervals; RMSSD, square root of the mean squared differences of successive NN intervals.  
 
Full term 
 (n = 114) 
Late preterm 
 (n = 26) 
P value 
(control vs late preterm) 
Frequency domain    
*Total Power, ms2 1051.7 (1114.3) 661.2 (606.5) 0.003 
*LF, ms2 2660.0 (279.7) 232.8 (187.1) 0.43 
*HF, ms2 135.9 (174.0) 82.2 (93.3) 0.02 
*LF: HF 2.3 (2.2) 3.1 (2.7) 0.04 
Time domain    
HR, bpm 127.5 ± 16.6 132.9 ± 12.2 0.12 
Mean NN, ms 477.6 ± 55.8 455.0 ± 42.1 0.06 
SDNN, ms 38.0 ± 12.1 29.5 ± 10.4  0.001 
*SDNN, ms 16.3 (13.1) 12.4 (7.5) 0.01 
RMSSD, ms 18.7 ± 10.2 13.4 ± 6.1 0.01 
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ABSTRACT 
Background: Over the past four-decade childhood and adolescent obesity has increased by 
tenfold, a major contributor to increased cardiovascular risk. The autonomic nervous system 
has been implicated in the pathophysiology of obesity showing an association between 
increased adiposity and altered autonomic function.  
 
Aim/Methods: The aim of this study was to investigate the association between body 
composition and autonomic function in children and adolescents 2 to 20 years of age (n = 72) 
at rest and in response to an exercise test. Body composition was assessed by air 
displacement plethysomography using the BOD POD (COSMED). Markers of autonomic 
function include, heart rate variability (HRV), systolic blood pressure variability (SBPV), 
baroreflex function and dp/dtmax variability measured for 5 minutes during rest and 4 minutes 
during moderate exercise (70% of age predicted heart rate maximum) on a cycle ergometer.  
 
Results: Body fat and fat free mass was not associated with markers autonomic function at 
rest (P > 0.05). However, some associations found after adjustment for the interaction 
between age and body fatness as well as age and fat free mass. A positive association 
between body fatness (%) and high frequency component of SBPV was dependent on the 
interaction between age and body fatness (P interaction < 0.001). In addition, a positive 
association between fat free mass and heart rate and HRV was dependent on the interaction 
between age and body fatness (P interaction < 0.0001, P interaction = 0.01, respectively).  
There was a significant difference between rest and exercise for all markers of autonomic 
function (P < 0.001 for all). Furthermore, there was a significant association between body 
fatness, fat free mass and HRV during exercise, (total power, 0.063 [95% CI 0.002, 0.124], P 
= 0.04), (total power, -0.123 [95% CI -0.213, -0.033, P = 0.01, respectively). The change in 
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HRV from resting to exercise was associated with fat free mass (total power, -0.165 [95% CI 
-0.279, -0.051], P = 0.006) which was unaffected after adjusting for resting HRV (total 
power, -0.124 [95% CI -0.219, -0.029], P = 0.013). Fat free mass was not associated with 
other markers of autonomic function during exercise (P > 0.05 for all).  
 
Conclusions: At rest, the association between body fat percent and high frequency SBPV 
was significantly modified by age such that the association was strongest among older 
participants. Investigating the associations between fat free mass and autonomic function 
revealed that leaner subjects showed increased HRV, increased cardiac parasympathetic drive 
and lower heart rates, these associations were strongest among younger participants, 2-9 
years of age.  
During exercise, individuals with higher body fatness showed increased HRV whereas those 
with higher fat free mass had lower heart rate variability during exercise. The change in heart 
rate variability from resting to exercise was only associated with fat free mass, such that a 
higher fat free mass was associated with a lower change in HRV. This may indicate that those 
with higher fat free mass (lean body mass) show a reduced response to exercise measured by 
heart rate variability.  
These results are somewhat in line with previous studies indicating that leaner subjects have 
favourable autonomic function and are at reduced risk or obesity related diseases. 
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INTRODUCTION  
Childhood and adolescent obesity is a major public health concern worldwide. Over the last 
four decade obesity among children and adolescents has increased by 10-fold [1].  The 
increasing prevalence of childhood and adolescent obesity is a major concern as children with 
obesity are more likely to have obesity as adults, increasing their risk of developing 
cardiovascular disease [2]. Children and adolescents today, compared to those in the last two 
decade have a higher predicted risk of heart disease in adulthood [3].  
 
Altered autonomic function is implicated as a potential mechanistic link between obesity and 
cardiovascular disease. The majority of studies in children and adults indicate that obesity 
alters the cardiac sympatho-vagal balance towards an increased sympathetic modulation and 
reduced parasympathetic modulation [2]. Analysis of blood pressure variability provides 
information on vascular autonomic control and an assessment of end-organ autonomic 
activity [4-6]. Studies in adults show altered vascular autonomic control consistent with an 
increased sympathetic modulation to the vasculature [6]. Impaired baroreceptor reflex 
function has also been associated with obesity [7-9]. In addition, studies show altered stress 
reactivity in obesity [6].   
 
Cardiovascular disease is becoming more prevalent among children and adolescents as rates 
of obesity increase [10]. A number of studies show obesity is often accompanied by 
concurrent cardiovascular and metabolic abnormalities. Therefore, immediate attention to 
understand the underlying mechanistic pathways and prevent cardiovascular damage in 
children and adolescents is a priority [11-15]. Utilizing body composition measures 
comprising lean and fat mass may better identify those at increased risk. Accordingly, we 
sought to determine whether baroreflex function, dP/dtmax  variability (as a possible new 
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measure of autonomic regulation of the myocardium), and cardiac and vascular autonomic 
functions are associated with lean and fat mass in children and adolescents at rest. 
Furthermore, we sought to determine how these autonomic indices change in response to an 
exercise test with altered body composition.  
 
METHODS  
Ethical Approval  
This study was conducted in accordance with the standards set by the 2013 version of the 
declaration of Helsinki, the National Statement on Ethical Conduct in Human Research 2007 
and was approved by the Sydney Local Health district ethics committee 
(HREC/16/RPAH/80).  
 
Subject selection  
Children and adolescents aged 2-20 years of age were recruited via various media including 
flyers, local newspapers, school newsletters, and The University of Sydney and Royal Prince 
Alfred Hospital intranet and newsletters. Including/exclusion criteria for the study were that 
children must be aged 2 – 20 years of age to be included in the study with no specific 
exclusion criteria. All investigation was undertaken as part of a single visit to the Charles 
Perkins Centre Royal Prince Alfred Clinic. We recruited a total of 72 children and 
adolescents for this study, Figure 1.   
 
Body composition and anthropometry  
The BOD POD (COSMED, Concord, CA, USA), is a validated non-invasive device that 
measures body fat percentage and fat free mass in children and adults [16, 17]. This 
technique accurately measures body volume by the application of Boyle’s law to the 
Hasthi U Dissanayake  Chapter Seven 
 
150 
displacement of air by the child or adolescent in a sealed chamber, which together with body 
weight, is used to determine body density.  Validated proprietary algorithms are then used to 
calculate fat mass and fat free mass. Body composition measurements were carried out in a 
temperature-controlled room (23-25° C). Participants wore minimal, form-fitting clothing 
and a swim cap to reduce air pockets during the measurement.  
Birth weight, length, and head circumference were collected from the participants’ ‘My 
Personal Health Record’ (the Blue Book) or similar. 
 
Demographics and medical history  
Participant characteristics, maternal perinatal details and caregiver characteristics were 
collected using standardised questionnaires. Information on pregnancy complications was 
collected from the participants ‘My Personal Health Record’ (the Blue Book) or similar.  
 
Continuous heart rate and blood pressure measurement 
Continuous blood pressure waveform was measured with the human non-invasive blood 
pressure system (ADInstruments, Sydney, Australia). An appropriate size blood pressure cuff 
was placed around the middle phalanx of right index finger of the subject. Electrodes were 
placed for measurement of heart rate via a 3-lead electrocardiogram. A respiratory belt 
transducer (ADInstruments, Sydney, Australia) containing a piezo electric device was placed 
around the chest of the subject to measure respiratory rate. The blood pressure, ECG and 
respiration analogue outputs were digitised at 500 Hz and acquired (Powerlab, 
ADInstruments, Sydney, Australia). Blood pressure, ECG and respiration were measured 
during two phases: phase 1 (resting), and phase 2 (exercise test). Participants who did not 
comfortably reach the foot pedals of the cycle ergometer did not take part in the exercise test, 
generally children 9 years and below.  
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Resting phase - phase 1. Participants rested quietly in a supine position for 5 minutes prior to 
ECG recording.   To maintain resting behaviour and reduce the likelihood of younger 
children moving, a standardized cartoon was offered. Autonomic function analysis was 
performed over a 5-minute period in each participant during the resting phase.  
Exercise test – phase 2. Exercise measurements were made during moderate exercise on a 
cycle ergometer (Corival cpet, Lode B.V, Groningen, Netherlands). Moderate exercise was 
defined as 70% of maximum heart rate. Participant maximum heart rate was determined by 
age-predicted maximum heart rate (maximum heart rate = 220 – age). Maintaining 60-70 rpm 
on the ergometer, the work load was gradually increased till the participant reached their 70% 
age predicted heart rate maximum. The participant then continued to maintain this heart rate 
for a total of 4 minutes. Autonomic function measures were derived from this 4 minute 
period. Typically, the entire recording period for the exercise test took 8-10 minutes, Figure 
2. 
 
Baroreflex function analysis  
Spontaneous baroreflex sensitivity (sBRS) was determined using the sequence method which 
incorporates the identification of sequences of consecutive increases in SBP (pressor ramps) 
or decreases in SBP (depressor ramps) that are followed by a progressive lengthening (or 
shortening) of pulse interval (PI) [18]. Spontaneously occurring changes in SBP over a period 
of 4 or more beats were identified and the relationship with the corresponding pulse interval, 
with zero delay were plotted. The slope and r2 value of the linear regression for these plots 
were calculated and a baroreceptor mediated change in heart rate was only considered to have 
occurred when the slope was positive and r2 was >0.8 for each delay.  
In addition to sBRS, baroreflex effectiveness index (BEI) was used as an additional measure 
of baroreflex function in the newborn. This is a measure of barorflex recruitment and was 
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determined as the ratio of the number of identified baroreflex sequences against the total 
number of SBP ramps observed for a given period of time [19], calculated using the formula 
below:  
 
𝐵𝐸𝐼 =
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑢𝑙𝑠𝑒 𝑖𝑛𝑡𝑒𝑟𝑣𝑎𝑙/𝑆𝐵𝑃 𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒𝑠 
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑒𝑟 𝑜𝑓 𝑆𝐵𝑃 𝑟𝑎𝑚𝑝𝑠 
 
 
Systolic blood pressure variability  
Power spectral analysis of the systolic blood pressure (SBP) waveform provides a non-
invasive method for the analysis of autonomic nervous system modulation to vasculature. 
SBPV was calculated using frequency domain methodology on the SBP waveform sampled 
at 5 Hz, with linear trend removal and by performing a Fast Fourier transform (FFT; 512 
point, Hanning window, zero percent overlap) using customised algorithms in Spike2. The 
FFT was performed on SBP waveform duration of 5 minutes during phase 1 and 4 minutes 
during phase 2 in each participant. Spectral bands of SBPV during phase 1 (resting) were 
defined at 0.04 to 0.15 Hz for low frequency and 0.15 to 0.5 Hz for high frequency. Spectral 
bands of SBPV during phase 2 (exercise testing) were defined at 0.04 to 0.15 Hz for low 
frequency and 0.15 to 1.1 Hz for high frequency. The very low frequency band was not 
analysed because of the short time period of the recordings.  The high frequency band was 
based on respiratory rates of the participants during resting and exercise. The total frequency 
band was defined as the range between 0 to 1.1 Hz.  
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Heart rate variability  
Time and frequency domain analysis of heart rate variability (HRV) were performed using 
LabChart (HRV 1 module, version 8, AD Instruments, Sydney, Australia). Analysis was 
performed over 5 minutes during phase 1 and 4 minutes during phase 2.  
The Spectral bands of HRV during phase 1 (resting) were defined at 0.04 to 0.15 Hz for low 
frequency and 0.15 to 0.5 Hz for high frequency. Spectral bands of HPV during phase 2 
(exercise testing) were defined at 0.04 to 0.15 Hz for low frequency and 0.15 to 1.1 Hz for 
high frequency. The very low frequency band was not analysed because of the short time 
period of the recordings.  The high frequency band was based on respiratory rates of the 
participants during resting and exercise. The total frequency band was defined as the range 
between 0 to 1.1 Hz [20]. 
Time domain measures of HRV included the standard deviation of the normal-to-normal 
(NN) RR intervals as a measure of overall variability (total power), and two short term 
measures: standard deviation of change in successive NN intervals (SDNN), and the root 
mean square of successive differences in NN interval (RMSSD) [21].  
 
Spectral analysis of dP/dtmax variability  
Estimated arterial dP/dtmax has been reported to be a surrogate measure for evaluating 
changes in left ventricular contractility [22], and dP/dtmax variability may represent autonomic 
modulation of ventricular myocardial contractility. The arterial pressure dP/dt is determined 
by the first differential of the blood pressure waveform, and dP/dtmax, the peak rise in blood 
pressure was identified using a peak detection algorithm in Spike2. Frequency analysis of 
dP/dtmax variability was then performed similar to SBPV.  The dP/dtmax waveform was 
resampled at 5 Hz, and linear trend removal and FFT (512 point, Hanning window) was 
performed.  As the maximum rate of change in arterial pressure is related to the force of 
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ventricular contraction, the low frequency component of dP/dtmax variability may reflect the 
sympathetic modulation of the myocardium during systole.  
 
Statistical analysis  
Statistical analysis was performed using SPSS Statistics, version 23 (IBM Corp, Armonk, 
N.Y., USA). Continuous data were expressed as mean (standard deviation), and categorical 
data as count (percentage). Data were visually inspected for normality, and non-normally 
distributed data were transformed appropriately. 
The relationship between body composition and autonomic function at rest and in response to 
exercise were compared using multivariable linear regression. Models were adjusted for age 
and gender. All exercise test models were adjusted for resting measures. Interaction terms 
were used to determine whether the associations of body composition with autonomic 
function differ by age.  
 
RESULTS  
Participant characteristics are shown in Table 1. None of the participants were smokers, 
whilst 3 participants were regular users of asthma inhalers. Exclusion of these 3 participants 
did not materially affect results (data not shown), and as such were included in all analyses.  
 
Body composition and autonomic function at rest  
There were no associations between body fat percent, fat free mass or fat mass with any 
markers of autonomic function; heart rate variability (HRV), blood pressure variability 
(SBPV), baroreflex function or dP/dtmax variability at rest (P > 0.05 for all, adjusting for sex 
and age, Table 2).  
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The associations of body fat percent with heart rate variability and baroreflex function did not 
differ by age (P  interaction > 0.05). However, the association between body fat percent and 
high frequency SBPV was significantly modified by age (P interaction < 0.001), such that 
there was a positive association amongst older participants, which was not observed in 
younger participants, Figure 3.  
The associations of fat mass with heart rate variability, blood pressure variability, baroreflex 
function and dp/dtmax variability were not modified by age (P interaction > 0.05, for all). 
However, the association between fat mass with and heart rate was significantly modified by 
age (P interaction = 0.02), following effect modification we found no association between the 
two age groups, Figure 4. 
The association between fat free mass with time and frequency domain measures of HRV 
was significantly modified by age. These include total power (HRV), high frequency (HRV), 
SDRR and heart rate, (P interaction = 0.01, P interaction = 0.003, P interaction = 0.02, P 
interaction < 0.0001, respectively), such that these associations were strongest among 
younger participants, which was not observed in older participants, Figure 5.  
 
Autonomic function during rest and during an exercise test  
There was a significant difference between rest and exercise for all markers of autonomic 
function, Table 3. Overall heart rate variability (total power and SDRR), LF, HF, RMSSD, 
baroreflex sensitivity and baroreflex effectiveness index decreased significantly in response 
to exercise. However the LF:HF ratio of heart rate variability increased in response to 
exercise. Conversely, blood pressure variability and dp/dtmax variability significantly 
increased in response to exercise, Table 3.  
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Body composition and autonomic function during exercise  
There was a significant association between body fat percent and heart rate variability (HRV) 
during exercise, (total power, 0.063 [95% CI 0.002, 0.124], P = 0.04), adjusted for age and 
gender. However, the change in HRV from resting to exercise was not associated with body 
fat percent (total power, 0.075 [95% CI -0.004, 0.154], (P = 0.06) and adjusting for HRV at 
rest did not materially affect this association (total power, 0.062 [95% CI -0.000, 0.125], P = 
0.05). Body fat percent was not associated with other markers of autonomic function during 
exercise (P > 0.05 for all).  
 
Similarly, there was a significant association between fat free mass and overall heart rate 
variability during exercise, (total power, -0.123 [95% CI -0.213, -0.033], P = 0.01), adjusted 
for age and gender. Furthermore, the change in HRV from resting to exercise was associated 
with fat free mass (total power, -0.165 [95% CI -0.279, -0.051], P = 0.006) which was 
unaffected by adjustment for resting HRV (total power, -0.124 [95% CI -0.219, -0.029], P = 
0.013). Fat free mass was not associated with other markers of autonomic function during 
exercise (P > 0.05 for all).  
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Table 1: Participant characteristics  
Participant characteristics  
N = 72 
Value 
Age, y 10 (5) 
Weight, kg 37 (18) 
Height, cm 140 (25) 
Gender, male/female  33/39 
BMI, kg/m2 18 (3) 
Body fat, % 20 (8) 
Fat free mass, % 80 (8) 
Fat mass, kg 8 (6) 
Fat free mass, kg 38 (15) 
Steroid exposure n, % 3 (4) 
Smoking, n (%) 0 (0) 
Birth details  Value 
Birth weight, (g)  3334 (454) 
Birth length (cm) 51 (2) 
Head circumference, (cm) 34 (1) 
Data presented as mean (SD) N = 72, except for birth weight (n = 67), 
birth length (n = 61), head circumference (n = 49), body fat (n = 70), 
fat mass (n = 70), fat free mass (n = 70).  
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Table 2: Association of body fatness, fat free mass and fat mass with markers of autonomic function in children and adolescents at rest  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are unstandardized -regression coefficients (95% CI) from multivariable models, adjusted for sex and gestational age. Ln log transformed data. HRV, heart rate 
variability; LF, low frequency; HF, high frequency; LF: HF, low frequency/high frequency ratio; HR; heart rate, mean NN; mean of N wave to N wave variation normal; 
SDRR, the mean of the standard deviation of all normal RR intervals; SDNN, SD change in NN; RMSSD, square root of the mean squared differences of successive NN 
intervals; SBPV, blood pressure variability; sBRS, spontaneous baroreflex sensitivity; BEI, baroreflex effectiveness index.  
 
Body fatness (%) Fat free mass (kg) Fat mass (kg) 
  (95% CI) P value  (95% CI) P value  (95% CI) P value 
Respiratory rate, br/min 0.05 (-0.06, 0.15) 0.40 -0.14 (-0.3, -0.03) 0.01 0.9 (0.7, 1.0) 0.20 
HRV (frequency domain) N = 61 N = 61 N = 61 
Ln Total Power  - 0.01 (-0.03, 0.03) 0.70 0.01 (-0.02, 0.04) 0.64 0.003 (-0.05, 0.06) 0.90 
Ln LF  - 0.001 (-0.03, 0.03)  1.00 0.02 (-0.02, 0.05) 0.53 0.01 (-0.04, 0.06) 0.69 
Ln HF  -0.01 (-0.05, 0.03) 0.59 0.004 (-0.04, 0.04) 0.85 -0.01 (-0.07, 0.06) 0.85 
Ln LF: HF 0.01 (-0.1, 0.03) 0.36 0.01 (-0.01, 0.03) 0.29 0.02 (-0.02, 0.05)  0.35 
HRV (time domain) N = 61 N = 61 N = 61 
HR, bpm 0.1 (-0.2, 0.5) 0.62 -0.2 (-0.6, 0.2) 0.31 -0.1 (-0.7,0.5) 0.80 
SDRR, ms -0.2 (-1.3, 0.8) 0.67 0.09 (-1.0,1.2) 0.88 -0.1 (-2.0,1.7) 0.88 
Ln RMSSD  -0.003 (-0.02, 0.02) 0.73 -0.001 (-0.02, 0.02) 0.95 -0.002 (-0.04, 0.03) 1.0 
SBPV (frequency domain) N = 58 N = 58 N = 58 
Ln Total Power -0.01 (-0.03, 0.01) 0.44 0.01 (-0.01, 0.3) 0.40 -0.004 (-0.04, 0.03) 0.83 
Ln LF -0.01 (-0.04, 0.01) 0.36 0.01 (-0.01, 0.04) 0.35 -0.01 (-0.05, 0.03) 0.64 
Ln HF  -0.01 (-0.02, 0.03) 0.57 -0.01 (-0.03, 0.02) 0.62 0.03 (-0.01, 0.07) 0.19 
Baroreflex function  N = 58 N = 58 N = 58 
sBRS -0.02 (-0.2, 0.2) 0.84 0.18 (-0.05, 0.40)  0.13 0.08 (-0.2, 0.4) 0.64 
Ln BEI -0.02 (-0.04, 0.01) 0.29 0.02 (-0.01, 0.05) 0.16 -0.01 (-0.05, 0.04) 0.77 
dP/dtmax variability N = 58 N = 58 N = 58 
Ln dP/dtmax -0.004 (-0.02, 0.01) 0.64 -0.01 (-0.03, 0.01) 0.20 -0.01 (-0.03, 0.02) 0.63 
Ln Total power  -0.02 (-0.06, 0.02) 0.25 0.0001 (-0.04, 0.04) 1.00 -0.02 (-0.09, 0.04) 0.54 
Ln LF  -0.03 (-0.08, 0.02) 0.19 0.01 (-0.04, 0.05) 0.81 -0.03 (-0.1, 0.04) 0.46 
Hasthi U Dissanayake      Chapter Seven 
 
159 
Figure 1: study flow diagram  
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Figure 2: Blood pressure, ECG, respiratory waveform recording and derived parameters during resting and exercise test  
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2-9 year: R2 = 0.07, P = 0.20 
10-20 years: R2 = 0.27, P = 0.003 
 
Figure 3: Correlation of body fat percent and ln HF (BPV). HF, high frequency; BPV, blood 
pressure variability  
2-9 year: R2 = 0.08, P = 0.12 
10-20 years: R2 = 0.006, P = 0.70 
 
Figure 4: Correlation of fat mass and heart rate.   
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Figure 5: Correlation of fat free mass and ln total power (a), ln HF (b), SDRR (c), heart rate (d)  
HRV, heart rate variability; SDRR, standard deviation of RR interval; HF, high frequency  
 
 
2-9 year: R2 = 0.20, P = 0.01 
10-20 years: R2 = 0.04, P = 0.28 
 
 
2-9 year: R2 = 0.19, P = 0.01 
10-20 years: R2 = 0.10, P = 0.10 
 
 
2-9 year: R2 = 0.13, P = 0.04 
10-20 years: R2 = 0.07, P = 0.17 
 
 
2-9 year: R2 = 0.60, P < 0.001 
10-20 years: R2 = 0.001, P = 0.84 
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Table 3: Autonomic parameters at rest and at exercise test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data presented as mean (SD) or *geometric mean (IQR) for log transformed data. Paired t-test between rest and 
exercise phase.  HRV, heart rate variability, LF, low frequency; HF, high frequency; LF: HF, low 
frequency/high frequency ratio; HR; heart rate; SDRR, the mean of the standard deviation of all normal RR 
intervals; RMSSD, square root of the mean squared differences of successive NN intervals; SBPV, blood 
pressure variability; sBRS, spontaneous baroreflex sensitivity; BEI, baroreflex effective index 
 
 Rest 
 (phase 1)  
Exercise test 
(phase 2) 
 
P value 
Respiratory rate, br/min 17 (4) 29 (6) <0.0001 
HRV (frequency domain) N = 29 N = 29  
*Total Power, ms2 5010 (5412) 449 (1245) <0.0001 
*LF, ms2 1360 (1662) 76 (129) <0.0001 
*HF, ms2 2327 (3373) 59 (328) <0.0001 
*LF: HF 0.5 (0.5) 1.3 (2.6) <0.0001 
HRV (time domain) N = 26 N = 26  
HR, bpm 65 (8) 124 (18) <0.0001 
SDRR, ms 75 (30) 26 (16) <0.0001 
*RMSSD, ms 71 (57) 12 (22) <0.0001 
SBPV (frequency domain) N = 26 N = 26  
*Total Power, mmHg2 0.4 (0.5) 1.8 (1.9) 0.002 
*LF, mmHg2 0.2 (0.3) 0.6 (0.5) <0.0001 
*HF, mmHg2 0.1 (0.1) 0.7 (0.7) 0.01 
*LF: HF 3.2 (7.1) 0.9 (1.0) < 0.0001 
Baroreflex function  N = 26 N = 26  
sBRS (ms/mmHg) 12.5 (5.0) *1.8 (1.3) < 0.0001 
*BEI 0.1 (0.1) 0.06 (0.04) 0.03 
dP/dtmax variability N = 26 N = 26  
dP/dtmax, mmHg/s 1026 (298) 1523 (873) <0.0001 
Total power, mmHg2/s2 109 (114) 694 (832) <0.0001 
LF, mmHg2/s2 39 (69) 186 (286) <0.0001 
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DISCUSSION  
The aim of this study was to investigate the association between body composition and 
autonomic function in children and adolescents at rest and in response to an exercise test.  
At rest, the association between body fat percent and high frequency SBPV was significantly 
modified by age such that the association was strongest among older participants. 
Investigating the associations between fat free mass and autonomic function revealed that 
leaner subjects showed increased HRV, increased cardiac parasympathetic drive and lower 
heart rates, these associations were strongest among younger participants, 2-9 years of age.  
During exercise, individuals with higher body fatness showed increased HRV whereas those 
with higher fat free mass had lower heart rate variability during exercise. The change in heart 
rate variability from resting to exercise was only associated with fat free mass, such that a 
higher fat free mass was associated with a lower change in HRV. This may indicate that those 
with higher fat free mass (lean body mass) show a reduced response to exercise measured by 
heart rate variability.  
 
Obesity among children and adolescents has been increasing over the past four decades and 
the autonomic nervous system has been implicated in the disease progression [2]. This study 
found that the association between body fat percent and high frequency SBPV was 
significantly modified by age such that a positive association was observed among older 
participants. The high frequency component of SBPV in autonomic regulation is thought to 
be linked to respiratory modulation of sympathetic vasomotor tone. This rhythmic drive in 
phase with respiration producing high frequency oscillations in blood pressure are known as 
Traube-Herine waves and involve intrinsic central coupling between neurons that generate 
vasomotor and respiratory activities [23]. Studies indicate amplified sympathetic nerve 
activity as the respiratory frequency contributes to the development rather than the 
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maintenance of hypertension [24]. Furthermore, studies in humans show amplified Traube-
Herine waves in young, normotensive adults at risk of developing hypertension [23]. The 
exact cause of increased high frequency SBPV in those with high body fat is unclear, 
however a strong association between increased adiposity and increased sympathetic drive 
has been shown previously [25]. It is possible that those with increased body fatness as young 
as 10-20 years of age are already showing altered autonomic function illustrated by increased 
high frequency SBPV. We found no other associations between body fatness and other 
markers of autonomic function.  
Investigating the associations between fat free mass and autonomic function revealed that 
leaner subjects showed increased HRV (total power and SDRR), increased high frequency 
HRV (marker of cardiac parasympathetic drive) and lower heart rates; these associations 
were only evident among younger participants, 2-9 years of age. HRV reflects the heart’s 
ability to adapt to ongoing changes in the internal and external environment and a lower HRV 
is a prognostic for adverse cardiovascular events [26, 27]. Our study findings indicate that 
children who have increased fat free mass (lean subjects) show favourable cardiac autonomic 
function with increased HRV, increased cardiac parasympathetic drive and lower heart rates.  
 
We found no other associations between body fatness, fat mass or fat free mass and other 
autonomic function indices.  
 
Autonomic function during exercise  
It is possible that a disease phenotype may only be unveiled when individuals are challenged 
with an acute stressor, such as moderate exercise. To date only a few studies have 
investigated the pattern of autonomic variables during exercise.  
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 In our study, overall HRV and cardiac parasympathetic activity and baroreflex function was 
significantly reduced in response to exercise, however the LF : HF ratio of HRV was 
significantly increased during exercise. The LF : HF ratio is often considered as a marker of 
autonomic nervous system balance and a higher ratio is thought to be associated with 
increased cardiac sympathetic balance [27]. Conversely, SBPV and individual frequency 
components, low and high frequency were significantly increased in response to exercise 
indicating vascular autonomic control and end organ autonomic function is significantly 
elevated. Similarly, cardiac contractility measured by dP/dtmax was significantly increased 
along with dP/dtmax total variability and low frequency dP/dtmax variability.  
 
Body composition and autonomic function during exercise  
We further investigated the effect of body composition on markers of autonomic function 
during exercise. A normal cardiovascular adaptation to exercise in healthy individuals is a 
parasympathetic withdrawal, resulting in increased heart rate and a pronounced reduction in 
HRV [28, 29]. In our study individuals with higher body fatness showed increased HRV 
whereas those with higher fat free mass had lower heart rate variability during exercise. The 
change in heart rate variability from resting to exercise was only associated with fat free 
mass, such that a higher fat free mass was associated with a lower change in HRV. This 
suggests that those with higher body fatness respond to exercise with greater variability in 
heart rate possibly indicating an exacerbated response to exercise. Conversely, those with 
increased fat free mass showed reduced HRV, and the change from resting to exercise was 
lower. This may indicate that those with higher fat free mass (lean body mass) show a 
reduced response to exercise measured by heart rate variability. These results are somewhat 
in line with previous studies indicating that leaner subjects possess favourable autonomic 
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function and are at reduced risk or obesity related diseases. We found no other associations 
between body fatness and other markers of autonomic function during exercise.  
 
Strengths and Limitations  
One of the strengths in our study is that we have successfully recorded and analysed a 
number of key markers of autonomic function across a broad cross-section of childhood and 
adolescence, from 2 to 20 years of age. Many studies only assess heart rate variability, which 
is a measure of cardiac autonomic function alone, and does not represent autonomic activity 
to other regions including the vasculature. Furthermore, it is increasingly accepted that 
measures of blood pressure variability and baroreflex function are also associated with 
disease pathology, therefore, optimising these markers and measuring them in younger 
individuals is important in the understanding of disease progression.  
There are a number of limitations in this study. Firstly, we were unable to obtain exercise 
stress tests data in all participants, particularly the younger 2-9-year olds, as they were unable 
to pedal the cycle ergometer safely. Although autonomic function was significantly altered 
from resting to exercise, not all participants reached their 70% of heart rate max. We believe 
this is because not all subjects were accustomed to cycling, therefore premature muscular 
fatigue may have prevented these individuals from reaching their maximal effort. Future 
studies should look to evaluate individual physical capacity and effort tolerance.  
 
CONCLUSION  
At rest, the association between body fat percent and high frequency SBPV was significantly 
modified by age such that there was a direct association amongst older participants (aged 9- 
10 years). Investigating the associations between fat free mass and autonomic function 
revealed that those with higher fat free mass showed increased HRV, increased cardiac 
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parasympathetic drive and lower heart rates, these associations were strongest among 
younger participants, 2-9 years of age.  
During exercise, individuals with higher body fatness showed increased HRV whereas those 
with higher fat free mass had lower heart rate variability during exercise. The change in heart 
rate variability from resting to exercise was only associated with fat free mass, such that a 
higher fat free mass was associated with a lower change in HRV. This may indicate that those 
with higher fat free mass (lean body mass) show a reduced response to exercise measured by 
heart rate variability. This suggests that worsening of autonomic control due to adiposity may 
develop over time during childhood and adolescence.  
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CONCLUSIONS AND IMPLICATIONS OF THIS RESEARCH  
 
Role of the placenta in fetal growth - neonatal study  
In chapter three we assessed associations between maternal factors, placental function 
and inflammation with newborn body composition. We further examined whether placental 
weight mediated the association of maternal factors (pre-pregnancy weight and age) with 
newborn body composition. Over recent years there has been an increasing interest in the role 
of the placenta and factors which affect birthweight. However, little is known about the 
factors that control newborn body composition, fat mass and fat free mass, or the effects of 
newborn body composition on neonatal health parameters. In this study, we found maternal 
factors that were associated with newborn fat mass and fat free mass differed, suggesting 
different mechanisms controlling fat mass and fat free mass in the newborn. In addition, this 
study showed that placental weight and surface area were strongly associated with both fat 
mass and fat free mass.  
 
Studies indicate that early life inflammatory events may be important in programming 
later cardiovascular disease, contributing to causal pathways that underpin epidemiological 
associations between perinatal factors such as poor intrauterine growth. Therefore, this study 
also sought to determine whether there was an association between an early life inflammatory 
exposure and body composition. Contrary to our hypothesis we found little evidence for this. 
However, it is possible the low statistical power of the study to examine these relationships 
have meant that an effect may have gone undetected. Furthermore, placental weight partly 
mediated the association of maternal factors with newborn body composition. We believe 
that this study is the first to assess associations between maternal factors, placental function 
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and inflammation with newborn body composition and attempt to delineate direct and 
indirect associations.  
 
Newborn body composition, born late preterm and vasomotor function – neonatal study  
In chapter four we describe experiments where we examined the effect of newborn 
body composition on newborn autonomic control of vasomotor function, specifically, blood 
pressure variability and baroreflex function. Furthermore, we introduced a possible new non-
invasive measure of autonomic regulation of the myocardium, dP/dtmax variability of arterial 
pressure.  In this study we found blood pressure variability was similar across body fat 
percentiles, and between those born at term and those born late preterm. However, baroreflex 
sensitivity was significantly reduced in those with high body fatness. Furthermore, there was 
a non-linear association of newborn body fat with baroreflex sensitivity, which was 
independent of birthweight.  
 
Previous studies in children and adults with obesity have consistently shown a 
reduced baroreflex sensitivity. Our results extend these findings indicating that reduced 
baroreflex sensitivity is apparent in the newborn with increased body fatness. To date there 
are a number of studies that indicate babies born at the extremities of the birthweight 
spectrum are at increased risk of developing cardiovascular disease, although the mechanisms 
remain unclear. It is possible that the autonomic nervous system may be implicated in this 
increased risk. To our knowledge this is the first study that has investigated newborn body 
composition and vasomotor function in the newborn.  
 
This novel index, dP/dtmax variability proposed as a measure of autonomic regulation 
of the myocardium, may be of value in evaluating paediatric and adult patients with 
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autonomic dysfunction. Further investigation and validation of dP/dtmax variability using 
specific iontropic and chronotropic agents is important and the subject of future studies. 
 
Newborn body composition and cardiac autonomic function – neonatal study  
Birthweight is associated with cardiovascular disease, such that those at both end of 
the birthweight spectrum are at increased risk. However, birthweight is only a crude marker 
of fetal growth and may not accurately differentiate between the constitutionally small infant 
who has met their genetic growth potential from those of the same weight but who are 
pathologically growth restricted. Similarly, those who are large may have reached their 
predetermined growth potential or may be disproportionately large. In an attempt to 
distinguish between these groups of infants we assessed infant body composition, and 
measured heart rate variability, a widely used tool to assess cardiac autonomic function. We 
demonstrated that infants with low body fatness have significantly reduced heart rate 
variability.  
 
Previous studies show altered autonomic function in people born with low 
birthweight, from infancy thought to adult life. However, our findings are the first to detail 
associations with body fatness. We also report for the first time that infants with high body 
fatness have lower overall heart rate variability, consistent with an overall reduction in 
parasympathetic modulation to the heart. The influence of adiposity on overall heart rate 
variability and parasympathetic activity in children and adults with increased adiposity is 
remarkably consistent with our study, showing reduced heart rate variability and vagal 
withdrawal in these individuals. Furthermore, the association of body fatness with heart rate 
variability was independent of birthweight and more strongly associated with body fatness 
than birthweight.  
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This study suggests that body fatness may provide information beyond that obtained 
from birthweight assessments alone and may be an important factor in identifying individuals 
at risk of later cardiovascular disease.  
 
Late preterm newborns and cardiac autonomic function – neonatal study  
Findings from this study indicate those born late preterm show reduced overall heart 
rate variability and reduced parasympathetic modulation to the heart. In addition, late preterm 
infants showed an increased low frequency: high frequency ratio, thought to be a marker of 
cardiac sympathetic drive. Previous studies in preterm infants show altered blood pressure 
control and elevated blood pressure in children and adults born preterm. Our findings indicate 
altered cardiovascular outcomes extend to those born late preterm.  
 
Body composition and autonomic function – child & adolescent study  
At rest, the association between body fat percent and high frequency SBPV was 
significantly modified by age such that there was a direct association amongst older 
participants (aged 9- 10 years). Investigating the associations between fat free mass and 
autonomic function revealed that those with higher fat free mass showed increased HRV, 
increased cardiac parasympathetic drive and lower heart rates, these associations were 
strongest among younger participants, 2-9 years of age.  
During exercise, individuals with higher body fatness showed increased HRV whereas those 
with higher fat free mass had lower heart rate variability during exercise. The change in heart 
rate variability from resting to exercise was only associated with fat free mass, such that a 
higher fat free mass was associated with a lower change in HRV. This may indicate that those 
with higher fat free mass (lean body mass) show a reduced response to exercise measured by 
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heart rate variability. This suggests that worsening of autonomic control due to adiposity may 
develop over time during childhood and adolescence. 
 
Taken together, the series of studies conducted as part of this thesis has identified groups 
with altered autonomic function. This thesis also highlights that body composition maybe an 
important additional predictor of cardiovascular risk.  
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FUTURE DIRECTIONS  
 
Newborn body composition  
 We investigated several predictors (maternal and placental factors) of newborn body 
composition and examined the effects of newborn body composition on a number of 
noninvasive markers of autonomic function. Following the investigations in this thesis, there 
are a number of future directions into the research of newborn body composition that should 
be addressed. Firstly, studies concerning fetal programming should consider neonatal body 
composition as an additional predictor of nutritional status in utero rather than birthweight 
alone. However, it is important to note that neonatal body fatness is better reflective of 
nutritional status in the last trimester of pregnancy, and therefore body fatness may identify 
specific aspects of cardiovascular risk modulated in the last trimester. Identifying individuals 
at risk of later cardiovascular disease remains a priority. Therefore, to characterize if these 
changes seen in infancy persist to later life, follow up studies are required.  
 
Using birthweight percentiles and body fat percentiles will allow us to identify newborns at 
risk of cardiovascular morbidity and mortality in the immediate neonatal period as well as in 
later life. However, there are infants within the low and high ends of birthweight and body fat 
percentiles that have autonomic function comparable to those in the normal categories. 
Perhaps a “risk score” which incorporates several factors including maternal and placental 
factors may better identify the high risk infant.  
 
The immune system is a key mediator in the development of cardiovascular disease. Early 
life inflammatory events which affect the placenta may be important in programming later 
cardiovascular disease. However, only a few studies have investigated the possible 
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contributory role of prenatal inflammation on cardiovascular risk. Therefore, whether a 
prenatal inflammatory exposure may contribute to increased cardiovascular risk in later life is 
yet to be investigated comprehensively.  
 
Noninvasive markers of autonomic function  
Over the recent years a significant relationship between the autonomic nervous 
system and cardiovascular mortality has been recognized with an established relationship 
between increased sympathetic nerve activity and cardiovascular disease in the adult.  
Given that those born at the extreme ends of the birthweight spectrum are at an 
increased risk of cardiovascular disease, it is important to understand the origins of altered 
autonomic function beginning in the newborn. To date it is unclear how autonomic function 
throughout the lifespan may change and modulate risk of later cardiovascular disease. 
Measures of heart rate variability represents a promising marker of autonomic function and is 
now used in clinical practice by cardiologists, and as an important research tool. However, 
heart rate variability is concerned with cardiac autonomic function only and does not 
discriminate cardiac from global autonomic activity. Autonomic modulation of the 
vasculature, including the kidney and the baroreflex, may play a crucial role in the 
development of the disease. The significance of blood pressure variability on cardiovascular 
risk has also been recently recognized. Future longitudinal and intervention studies 
incorporating autonomic function measures across the lifecourse may improve risk 
stratification.  
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Editorial
Hypertension, a disease of deregulation of blood pressure control, is
a major risk factor for cardiovascular and cerebrovascular diseases [1]
and is reported to affect approximately 40% of people [2]. In addition
to the high prevalence and predicted increases incidence of
hypertension, successful treatment remains poor and it has been
argued that this is partly due to the poor understanding of causative
mechanisms. The autonomic nervous system is central to the control of
blood pressure and a neurogenic component of hypertension is
becoming increasingly realised as several lines of evidence in humans
and animal models show convincingly that abnormalities in autonomic
control of blood pressure plays a major role in the etiology of disease
and cardiovascular mortality. The mammalian nervous system begins
its development during fetal life and continues after birth. Therefore, it
is thought that both intrauterine and postnatal insults may sensitise
and alter the development of different components of the nervous
system.
There is a robust body of evidence indicating that a number of
different nutritional manipulations or other adverse variations in the
prenatal environment program hypertension; this has been shown
convincingly in a number of animal models [3]. Whilst the resultant
pathophysiology underlying programmed hypertension is uncertain
and may be varied, there is evidence for autonomic dysfunction as a
possible causative pathophysiological mechanism underlying the
development of fetal programming of hypertension.
To date there has been limited interest in autonomic dysfunction as
a potential mechanism in programmed hypertension which may be
due to historical reasons as well as technical limitations associated with
autonomic measurements.
Historically, the kidney was considered the sole contributor of long
term blood pressure control, this theory stems from the teachings of
the highly influential Guyton model of blood pressure control.
Therefore, many of the work investigating programmed hypertension
explored kidney dysfunction as a plausible mechanism in determining
the etiology of programmed hypertension. Studies investigating the
kidney have indeed shown windows of susceptibility to blood pressure
programming that appear to occur during the early stages of kidney
development, showing a reduction in glomeruli and nephron number
[4-6]. However, there is conflicting evidence as studies show
hypertension in the absence of reduced nephron number [7] and
reduced nephron number with no apparent hypertension [8].
Although it is physiologically plausible that abnormalities in the
kidney may be of importance to the etiology of programmed
hypertension, the data indicate that while nephron deficit may play a
permissive role, it is not the primary cause of programmed
hypertension.
Over the last decade technological advancement have greatly
improved our ability to accurately quantify or measure autonomic
function. Earlier studies investigating blood pressure of programmed
rats used more invasive techniques, such as tail cuff plethysmography.
It has been postulated that these types of invasive techniques may be
inducing a stress response and therefore the observed increased blood
pressures may not be reflective of resting hypertension but that of an
exaggerated stress response. Animal models have been used extensively
to investigate programmed hypertension using a variety of maternal
manipulations [3] however only a few have investigated autonomic
dysfunction as a potential mechanism. A study by Samuelsson and
colleagues [9] showed hypertension and increased sympathetic activity
in rat offspring from mothers fed an obesogenic diet during pregnancy.
In addition, hypertension and changes to sympathetic activity was
established in the juvenile rate indicating that hypertension and
changes in autonomic activity arise as a direct consequence of in utero
exposure to a maternal obesogenic diet. Similarly, a study investigating
a high fat diet in the absence of maternal obesity in rats showed
increased sympathetic activity and blood pressure only in response to a
stressor [10]. Studies in rabbits also show increased blood pressure and
renal sympathetic nerve activity in offspring from mothers that were
fed a high fat diet. Furthermore, an exaggerated sympathetic response
was seen when these rabbits were exposed to an acute stressor [11].
Non-invasive measures of autonomic function are imperative when
translating these effects into human studies. Recent techniques of heart
rate variability and blood pressure variability have facilitated the
exploration of autonomic dysfunction as a potential mechanism in
programmed hypertension. Several studies of growth-restricted
children show changes to cardiovascular control, these include altered
blood pressure [12], increased pulse rate [13] and change in heart rate
fluctuations [14]. Assessment of heart rate variability has shown that
infants born small-for-gestational-age (SGA) exhibit increased
sympathetic activity at one and three months of age compared to
infants born appropriate-for-gestational age [15]. Beyond childhood,
in adults born SGA, direct recording of sympathetic nerve traffic using
microneurography showed increased sympathetic nerve activity
compared to their control counterparts, who did not differ by central
adiposity, body mass index or glucose tolerance; therefore metabolic
factors did not attribute to the increased sympathetic activity seen in
these SGA individuals [16]. Furthermore, a strong association between
low birth weight and a shorter pre ejection period, indicative of a
stronger sympathetic control of heart rate [17,18] and increased
sympathetic activation of the heart has also been reported [17].
In line with these findings, studies have also shown an association
between diminished parasympathetic control and increased risk of
malignant cardiac arrhythmias and hypertension [19].
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Young adults born with extremely low birth weight exhibit a
significantly decreased parasympathetic regulatory capacity compared
to their control counterparts during their second and third decade of
life [19]. Collectively, these studies suggest that increased sympathetic
and reduced parasympathetic activity may manifest during early
development, and that autonomic dysfunction is a plausible
mechanism underlying the increased risk of hypertension in
individuals who had intrauterine growth restriction [16,20].
There is increasing evidence for autonomic dysfunction as a
potential mechanism in programmed hypertension. However, to
explore the exact mechanism by which this occurs requires further
experimental investigation incorporating recent techniques in
measuring autonomic function.
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Key Points
• The potential for ‘deprogramming’ of hypertension and the underlying mechanisms are poorly 
understood.
• Animal studies indicate that long-chain omega-3 polyunsaturated fatty acid insufficiency in the 
perinatal period is associated with raised blood pressure in later life.
• Overall evidence for maternal omega-3 polyunsaturated fatty acid intake influencing offspring 
blood pressure in humans is inconclusive.
• Some cohort studies suggest an association between higher maternal omega-3 polyunsaturated 
fatty acid intake in late pregnancy with lower offspring blood pressure in childhood.
• Post hoc analyses of dietary interventions increasing maternal omega-3 polyunsaturated fatty acid 
intake during gestation or lactation have shown no effect on offspring blood pressure.
• There is a lack of evidence from prospective randomised trials of maternal omega-3 polyunsatu-
rated fatty acid with offspring blood pressure as a prespecified outcome.
• There is a lack of evidence for associations of maternal omega-3 polyunsaturated fatty acid intake 
with offspring blood pressure in high-risk populations.
Keywords Omega-3 polyunsaturated fatty acids • Blood pressure • Developmental origins • 
Pregnancy • Lactation • Fetal programming • Life course
Abbreviations
ALA Alpha-linolenic acid
BP Blood pressure
DBP Diastolic blood pressure
DHA Docosahexaenoic acid
EPA Eicosapentaenoic acid
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GA Gestational age
LCPUFA Long chain polyunsaturated fatty acids
MAP Mean arterial pressure
n-3 PUFA Omega-3 polyunsaturated fatty acids
n-6 Omega-6 polyunsaturated fatty acids
SBP Systolic blood pressure
 Introduction
High blood pressure (BP) is a major risk factor for cardiovascular and cerebrovascular diseases, which 
in turn are the leading cause of morbidity and mortality worldwide [1]. For each 20 mmHg increase 
in systolic BP (SBP) or 10 mmHg increase in diastolic BP (DBP) the risk of cardiovascular disease 
increases by twofold [2].
Physiological control of BP involves the complex, yet precise, interaction between different organs 
and the continuous actions of the cardiovascular, renal, neural and endocrine systems. Under normal 
function, BP is tightly regulated, maintaining sufficient pressure to ensure constant perfusion of end 
organs and tissues, without causing pressure related structural damage [3]. This tight regulation of BP is 
achieved through combination of local and systemic mechanisms, whereby local mechanisms acutely 
regulate blood flow via vasoconstriction and dilatation, and global mechanisms act via the autonomic 
nervous system. The sympathetic branch of the autonomic nervous system affects BP control via direct 
adjustments to cardiac output and total peripheral resistance, and indirect adjustments to blood volume 
via changes in renal function. In contrast, the renal endocrine system is a powerful long-term regulator 
of BP, principally achieved via water and salt excretion related changes in blood volume.
 Pathophysiology of Programmed Hypertension
There is now an extensive body of experimental and clinical work demonstrating that the intrauterine 
environment is a predictor of BP, and describing the underlying mechanisms. Mechanisms implicated 
include the kidney – with evidence for critical periods of exposure [4]; the vasculature – with exten-
sive evidence that various forms of maternal malnutrition can affect nitric oxide dependent vasodilata-
tion and microvascular density [5], key local mechanisms influencing total peripheral resistance and 
thus BP; and the autonomic nervous system. A number of studies show increased sympathetic activity [6], 
decreased parasympathetic activity [7], and changes to autonomic function [8] in children born small 
for gestation age, a group with at risk of elevated BP from childhood through adulthood [9]. This is 
supported by experimental models showing autonomic and baroreflex dysfunction induced by a num-
ber of maternal nutritional manipulations [10]. Nonetheless, the fine details of these mechanisms 
driving programmed hypertension remain elusive, although may provide an indication of potential 
targets for interventions.
 Programmed Hypertension: Potential for Prevention or Early Treatment
High BP is one of the most modifiable risk factors and strong evidence supports that it can be affected 
by pharmacological agents and lifestyle interventions, including dietary strategies [11]. Effective 
strategies to counter programmed hypertension remain poorly described. Due to potential risks to the 
H.U.W. Dissanayake et al.
281
developing fetus and infant, safety is a key consideration for interventions during this period. 
Accordingly, maternal nutritional interventions are likely a practicable means by which to prevent 
programmed hypertension, with omega-3 polyunsaturated fatty acids (n-3 PUFA) being one such 
nutritional hemodynamic agent.
 n-3 PUFA, Metabolism and Physiology
Embedded in the phospholipids of cellular membranes, fatty acids play vital biochemical and physiolog-
ical roles serving as lipid platforms to drive mechanistic and signalling pathways. In particular, the 
essential PUFAs, namely n-3 α-linolenic acid (ALA; C18:3n-3) and n-6 linoleic acid (C18:2n-6), which 
cannot be synthesised by mammalian cells and are essential for normal physiological function. ALA is 
on average the most readily consumed n-3 PUFA, obtained predominantly from plant sources, and can 
be endogenously converted into longer chain n-3 PUFAs, including eicosapentaenoic acid (EPA; 
C20:5n-3) and docosahexaenoic acid (DHA; C22:6n-3) via desaturase-mediated desaturation and elon-
gation. Linoleic acid and ALA compete for the same enzyme systems for biosynthesis to long-chain 
PUFA (LCPUFA) and, importantly, for incorporation into membranes. Nonetheless, the conversation of 
ALA to EPA & DHA is relatively inefficient in humans, partly due to competition with n-6 linoleic acid 
for the rate-limiting enzyme for conversion into arachidonic acid [12]. Alternatively, EPA and DHA can 
be obtained directly from the diet by consuming oily fish such as salmon, tuna and mackerel.
LCPUFAs are precursors for eicosanoids which act as local and systemic mediators for coagu-
lation, immune, allergic and inflammatory responses as well as having effects on BP and vascular 
 reactivity. EPA is metabolized by the cyclooxygenase pathway into 3-series eicosanoids (prostaglan-
dins, thromboxanes) and by 5-lipoxygenase into 5-series leukotrienes which have antagonistic physi-
ological effects to the 2-series eicosanoids derived from arachidonic acid. DHA also gives rise to 
anti- inflammatory lipid mediators [13]. Leukotrienes and lipoxins derived from EPA and arachidonic 
acid are additional lipid mediators that modulate inflammation and serve as endogenous regulators of 
vascular tone and BP. Importantly, those derived from arachidonic acid are pro-inflammatory and pro- 
aggregatory agonists while those derived from EPA have opposing effects including anti-arrhythmic, 
hypolipidemic and hypotensive effects [14].
The beneficial effects of n-3 PUFAs have been explained by some authors in terms of a balance 
between total n-6 and n-3 FAs, rather than the absolute amount of each [15]. A high n-6/n-3 ratio has 
been hypothesized as being detrimental for human health, while conversely a ratio of ~1, estimated to 
be that consumed by our paleolithic forebears, is considered cardioprotective. During the last 
150 years, a dramatic increase in the Western diet towards consumption of n-6 PUFAs paralleled with 
a decrease of n-3 PUFAs intake has resulted in a drastic shift resulting in average n-6/n-3 ratio between 
15:1 and 20:1 [15].
Thus the dietary imbalance of LCPUFAs in favour of n-6 FAs can drive vascular and inflammatory 
responses, with consequent elevations of BP and other chronic diseases. Other vascular actions of n-3 
PUFA are relatively poorly understood, but include changes in membrane structures, gene expression, 
and direct interactions with ion channels.
 Anti-hypertensive Actions of n-3 PUFA
Studies have shown a number of antihypertensive effects of n-3 PUFA (Fig. 21.1). Consumption of 
n-3 PUFA reduces systolic and diastolic BP as well as resting heart rate in adults [16]. The reduced 
heart rate is thought to be due to direct effects on cardiac electrophysiology as well as indirect 
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pathways [16], which include augmenting vagal tone and improving left ventricular diastolic filing 
[17]. Short-term trials indicate a number of vascular mechanisms of n-3 PUFAs including increased 
nitric oxide production, enhanced vasodilatory responses, attenuation of vasoconstrictive responses to 
angiotensin II and norepinephrine, improved arterial compliance and flow-mediated dilatation, a non- 
invasive marker of endothelial function [16]. N-3 LCPUFAs have beneficial effects on other aspects 
of endothelial health, including evidence that DHA decreases the expression of adhesion molecules 
on endothelial cells and monocytes, including E-selectin, intercellular cell-adhesion molecule-1 and 
vascular cell adhesion molecule-1. The magnitude of this effect is directly associated with the degree 
of incorporation of DHA into cellular phospholipids [18]. In human umbilical vein endothelial cells 
exposed to oxidized-LDL, EPA improves the balance between nitric oxide and reactive oxygen spe-
cies [19]. Incubation with EPA also attenuates saturated fatty acid-induced generation of reactive 
oxygen species, expression of adhesion molecules and cytokines, activation of apoptosis-related 
 proteins, and apoptosis in endothelial cells [20].
More recently, the cytochrome P450 enzymes have been proposed as targets of n-3 PUFAs to 
modulate vascular tone. It has become evident from several in vitro studies that n-3 PUFAs may exert 
potent vasodilatory effects as fatty epoxides metabolized by cytochrome P450 epoxygenase in the 
endothelium [21]. In isolated coronary arterial cells, DHA-derived epoxides were shown to activate 
calcium-activated potassium currents producing vasodilatation. Furthermore, the DHA-mediated dil-
atory effects were dose-dependent, increasing calcium-activated potassium currents by 5%, 170%, 
and 220% at 0.1, 0.3, and 1.0 mM DHA, respectively [22]. In recent experiments, n-3 PUFA-derived 
mono-epoxides was also reported to possess nearly 1000-fold greater potency than their precursors 
EPA or DHA in reducing effects of calcium overload in neonatal rat cardiomyocytes [23].
Fig. 21.1 Antihypertensive effects of omega-3 fatty acids: mechanistic evidence. n-3 polyunsaturated fatty acids have 
a number of antihypertensive effects, including improved arterial health, increased vagal activity and improved cardiac 
health. ICAM-1 intercellular adhesion molecule-1, NO nitric oxide, HR heart rate, VCAM-1 vascular cellular adhesion 
molecule-1
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Observational studies and small trials suggest n-3 PUFA may improve autonomic function via 
augmentation of vagal activity or tone, although further studies are required to determine the appro-
priate dose required as either supplementation or as a component of dietary intake [16].
Taken together, these vascular and central mechanisms likely underpin the blood pressure lowering 
actions of n-3 PUFA.
 Maternal n-3 PUFA and Offspring BP
The “fetal origins” hypothesis proposes that alterations in fetal nutrition result in developmental adap-
tations that permanently change structure, physiology, and metabolism, most likely influencing sus-
ceptibility to develop metabolic disorders, such as type 2 diabetes, cardiovascular disease, obesity and 
hypertension in later life [24]. It has been postulated that a deficiency in n-3 PUFAs in the perinatal 
period may be one such early life “insult” with hypertensive consequences.
Indeed, maternal DHA is readily transferred via the placenta, is an important component of breast 
milk, and is rapidly accumulated in the synapses during fetal development and early postnatal life. 
DHA comprise 30% of the phospholipid fatty acids within the cortex and 15% within the hypothala-
mus, a key brain centre that controls BP.
 Maternal n-3 PUFA and Offspring BP: Experimental Animal Studies
To date, there is limited evidence from animal studies regarding the relationship between maternal n-3 
PUFA and offspring BP. Armitage and colleagues [25] investigated the effects of maternal n-3 PUFA 
deficiency, in addition to the effects of post-weaning repletion of n-3 PUFA in the offspring, with 
subsequent offspring BP. Pregnant dams were given a diet either deficient in n-3 PUFA or supple-
mented with n-3 PUFA, throughout pregnancy and until weaning. At 9 weeks of age, half the supple-
mented offspring were crossed to the deficient diet and half the deficient offspring were subsequently 
supplemented, while the remainder continued to consume the diet to which their mother was origi-
nally allocated. In the adult offspring, mean arterial pressure (MAP) was highest in those fed the n-3 
PUFA deficient diet throughout development and during post-weaning life (Fig. 21.2). Interestingly, 
the two groups with the lowest BP were those who were supplemented with n-3 PUFA throughout and 
those who were supplemented during pregnancy, but not post-weaning. This suggests that prenatal 
and early infancy is a critical period during which n-3 PUFA may modify adult BP in the rat, puta-
tively via accumulation of n-3 PUFA in the developing nervous system.
A similar study investigating n-3 and n-6 PUFA, and their ratios, found that BP was elevated in the 
offspring of those dams fed either a diet enriched in n-3 or n-6 PUFA prenatally [26]. Only male off-
spring from dams given the diet containing both n-6 and n-3 PUFA had elevated blood pressure, suggest-
ing that prenatal fatty acid balance may be important in influencing BP in a gender-specific manner.
Observations from Armitage and colleagues offer some clues as to mechanisms by which PUFA 
and its composition affect early development and BP control. Rats exposed to n-3 PUFA deficiency 
while in utero and during infancy were found to over ingest sodium and consequently consume lower 
amounts of water, as part of a sodium and water deprivation challenge [27]. Such behaviour is consis-
tent with abnormalities in sodium and osmoreceptors as well as the renin angiotensin mechanism, 
both of which influence BP and hydromineral balance. N-3 PUFA deficiency is also found to affect 
phototransduction in the retina, which share similar receptor morphology as the angiotensin II recep-
tor [25]. These changes may have emerged due to developmental changes in the membrane bound 
receptors.
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 Maternal n-3 PUFA During Pregnancy and Offspring BP: Human Studies
All of the n-3 and n-6 PUFAs accumulated by the fetus must ultimately be derived from the mother 
by placental transfer and studies have demonstrated the preferential selectivity in the placental mem-
brane binding sites for LCPUFAs, in particular DHA [28].
Despite the functions of n-3 PUFAs in fetal and newborn neurodevelopment and inflammation, 
there is only a relatively small body of evidence describing the associations of maternal n-3 PUFA 
intake with BP or measures of cardiovascular health in the offspring (Table 21.1).
In the Generation R Study, an observational cohort of 4455 mothers and children [29], higher 
maternal n-3 PUFA and lower n-6 PUFA concentration in the second trimester of pregnancy was 
associated with lower SBP but not with DBP in the offspring during childhood. In models adjusted for 
gestational age at sampling, pregnancy and childhood factors, and sex and age of the child, both 
higher total maternal n-3 PUFA concentration and DHA concentration were found to be associated 
with lower SBP in the children at 6 years of age (differences: −0.28 [95% CI −0.54, −0.03] and 
−0.29 mmHg [95% CI −0.54, −0.03] per SD increase of n-3 PUFAs [one SD is 1.5 wt%] and DHA 
[one SD is 1.1 wt%] respectively) [29]. Conversely, a higher maternal n-6 PUFA was associated with 
a higher childhood SBP (difference: 0.36 mmHg [95% CI 0.09, 0.62] per SD increase of total n-6 
PUFA [2.5 wt%]). Furthermore, a higher n-6/n-3 ratio was associated with an increased childhood 
SBP, but not with DBP. In separate analyses of the Generation R cohort, a higher maternal n-6/n-3 
PUFA ratio was associated with a higher childhood total body fat mass percentage, android:gynoid fat 
Fig. 21.2 Effect of dietary fatty acid supply on mean arterial blood pressure (MAP). Cross over diet was implemented 
at 9 weeks of age, where half the supplemented (CON) offspring were crossed to the deficient diet (CON-DEF) and half 
the DEF offspring were crossed to the control diet (DEF-CON). The remaining rats continued on their initial diets 
(CON-CON and DEF-DEF). This study demonstrated that (1) the highest MAP occurred in animals raised and main-
tained on a diet deficient in n-3 PUFA (DEF-DEF); and that (2) early n-3 PUFA deficiency with subsequent n-3 PUFA 
supplementation at 9 weeks of age (DEF-CON) still resulted in raised blood pressure when compared to those who 
received PUFA supplementation throughout (CON-CON). This is consistent with a deficiency in n-3 PUFA during the 
prenatal and perinatal period affecting adult hemodynamics. *Significantly higher than all other groups (P < 0.05); ‡ 
significantly higher than CON-CON (P  <  0.05). n-3 PUFA, omega-3 polyunsaturated fatty acids (Reprinted from 
Armitage et al. [25] Copyright © 2003 by AOCS Press, with permission of Springer)
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mass ratio, and abdominal preperitoneal fat mass area adiposity at 3, 4 and 6  years of age [30], 
 potentially driving the observed association with BP.
The Avon Longitudinal Study of Parents and Children reported an inverse association between 
maternal n-3 PUFA intake assessed during the third trimester of pregnancy with offspring SBP at 
7.5 years of age in 6944 mother-child pairs (P = 0.04), although this effect was lost after adjusting for 
current anthropometry, maternal and social factors, birth weight and gestation (P = 0.7) [31]. There 
were no significant associations between maternal dietary n-3 PUFA intake and offspring DBP.
More recently, the Southampton Women’s Survey reported that higher oily fish consumption in late 
pregnancy was associated with reduced aortic stiffness, assessed by pulse wave velocity, in the child 
at 9 years of age (−0.084 m/s per portion of oily fish consumed per week; 95% CI −0.137, −0.031) 
independent of the child’s current oily fish consumption [32]; however there was no association with 
offspring BP or heart rate.
Promising findings on DHA supplementation and fetal heart rate have been reported. A randomised 
controlled trial involving maternal supplementation of 600 mg/day of DHA commenced at 14 weeks 
gestation was found to lower heart rate at 24, 32 and 36 weeks gestational age compared to placebo 
(P = 0.095) [33]. Furthermore, there was evidence that DHA intake during the last two trimesters of 
pregnancy results in more responsive autonomic function in the offspring.
Follow-up studies examining effects in adolescence have also yielded discrepant findings. A ran-
domised controlled trial in which 180 pregnant women were supplemented with marine n-3 LCPUFAs 
in the last trimester of pregnancy showed no association with BP, heart rate or heart rate variability, a 
marker of autonomic function, in the offspring at 19 years or age [34]. Similarly, marine-derived 
dietary n-3 LCPUFA expressed as quintiles of energy-adjusted intake during the second trimester of 
pregnancy showed no association with SBP, DBP, heart rate or heart rate variability in 443 offspring 
at 20 years of age in a Danish cohort [35].
 Maternal n-3 PUFA During Lactation and Offspring BP: Human Studies
For the infant, PUFAs are essential during the perinatal period where there is rapid growth and devel-
opment of new tissues and organ systems, and is primarily sourced from breast milk in nursing infants. 
The lactating mammary tissue synthesises FAs intracellularly from a supply of substrates extracted 
from the maternal plasma. The lipid drops formed in the mammary epithelial cells are secreted into 
the milk by exocytosis or association with the plasma membrane bilayer [36]. While the level of n-6 
arachidonic acid is relatively constant in human milk, the EPA and DHA levels are variable and 
dependent on the maternal nutritional habits [37], with maternal intake of fish oil, DHA, or DHA- 
enriched foods effectively increasing both maternal and neonatal n-3 PUFA status [38].
Studies linking breast milk intake in infancy to lower BP during childhood have been reported. 
Breastfeeding has also been associated with consistent reduction in obesity risk later in childhood 
[39], with likely benefits for BP, although the n-3 PUFA content of breast milk is likely not a major 
factor contributing to this lower risk of offspring adiposity. LCPUFAs are present in breast milk but 
were not routinely available in infant formula until the early 2000s. As infants have limited ability 
to synthesise DHA, infants fed unsupplemented formula may experience a relative deficiency of 
LCPUFAs compared to breast-fed infants [40].
Longitudinal observational studies in term infants have demonstrated that children who were 
breast-fed for at least 3 months have lower SBP and DBP during later childhood and adolescence 
compared to children who were formula fed [41, 42]. Fifteen year old children born preterm and ran-
domised during infancy to being fed banked breast milk, had lower SBP and DBP compared to those 
who were randomised to infant formula [43].
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Increased heart rate and decreased heart rate variability were found in infants fed a DHA-deficient 
milk formula compared to those fed DHA-supplemented formula or breast-fed infants [44]. In con-
trast, maternal supplementation with marine n-3 PUFAs during the first 4 months of lactation had no 
effect on BP, arterial stiffness or heart rate variability of the offspring at 2.5 years of age [45].
Postpartum intervention in infancy has proven effective in some randomised trials. A study of 71 
newborn infants who were randomised to a formula with LCPUFAs reported a significantly lower 
DBP at 6 years of age compared to those children who were fed a nutritionally similar formula in 
infancy but devoid of LCPUFAs (mean difference −3.0 mmHg [95% CI −5.4, −0.5 mmHg]) [46]. 
The association was weaker for SBP (mean difference −2.3 mmHg [95% CI −5.3, 0.7 mmHg])]. In 
late infancy supplementation with marine n-3 LCPUFA (924  mg/day) in 9  month old infants for 
3 months resulted in a lower SBP compared to those infants that did not receive n-3 PUFA (mean 
 difference −6.3 mmHg [95% CI −11.7, −0.9,mmHg]). No effects were observed for DBP or MAP 
[47]. Although these do not directly study the effect of maternal n-3 PUFA intake, these trials of for-
mula supplemented with n-3 PUFA compared with deficient formula, can be used as proof-of-concept 
of the potential haemodynamic effects of n-3 PUFA intake during infancy per se. It is not unreason-
able to posit that similar findings could result in breast-fed infants of mothers consuming an appropri-
ate amount of n-3 PUFA. Importantly, these infants would also obtain the other well-described health 
benefits of being breast-fed, including reduced risk of later obesity (Fig. 21.3).
While there are currently no widely recognised guidelines for intake of n-3 PUFA during preg-
nancy and lactation, there are well established recommendations for the general population of two 
servings of oily fish per week providing an average of ~100 to 250 mg per day n-3 PUFAs of which 
Fig. 21.3 Summary of evidence of maternal n-3 PUFA intake and offspring BP across the life course. Current evidence 
linking maternal intake of n-3 PUFA and lower offspring blood pressure is inconclusive. While some observational 
studies have shown inverse associations, others have not, and intervention studies have reported no effect. There is a 
lack of evidence from prospective randomised trials of maternal n-3 PUFA with offspring blood pressure as a prespeci-
fied outcome. BP blood pressure, DHA docosahexaenoic acid, n-3 PUFA omega-3 polyunsaturated fatty acids, SBP 
systolic blood pressure
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50–100 mg is from DHA [48]. It is likely that there are increased n-3 PUFA requirements during 
pregnancy, however most pregnant women likely do not meet the increased demand in part due to 
competing recommendations to limit oily fish consumption to a maximum of two servings per week 
due to concerns of their mercury content. For women consuming a solely or predominantly plant- 
based diet, there are other concerns in meeting these requirements. While plant-based foods can be 
rich in ALA, only a small amount of these short-chain n-3 PUFA appear to be endogenously converted 
to LCPUFA, and these dietary patterns provide only small amounts of EPA and DHA [48]. Accordingly, 
the use of supplements may be warranted in some women during pregnancy and lactation, who are 
otherwise unable to obtain sufficient n-3 LCPUFA from dietary sources.
The ability of n-3 PUFA in the fetus or during early infancy to reduce later BP may also depend on 
the background risk of the individual, particularly relating to the presence of other early life risk 
 factors for hypertension. A recent randomized trial of fish oil supplementation over the first 5 years of 
life in children who were not considered to be at risk of cardiovascular disease, found evidence of 
interaction by birth weight, such that those with the lowest birth weight had less severe subclinical 
atherosclerosis if they had been allocated to receive the fish oil supplement [49]. Similar findings have 
since been demonstrated for BP, with intake of both plant and marine-derived n-3 PUFA being associ-
ated with lower BP [50]. It is plausible that those born with impaired fetal growth in particular, are a 
group in which sustained n-3 PUFA intake postnatally may be beneficial, given that birth weight is 
inversely associated with later BP, that on average children born with impaired fetal growth are more 
likely to have been exposed to lower n-3 PUFA in utero, and that impaired fetal growth is associated 
with lower serum DHA and EPA levels later in life [50] (Fig. 21.4). Indeed, the above studies  reporting 
Fig. 21.4 Schematic proposed pathways linking n-3 deficiency with hypertensive disorders: potential timing for n-3 
PUFA interventions. Theoretical time points, including while in utero and postnatal, during which n-3 PUFA interventions 
could be applied to reduce or prevent the chronic disease outcomes of fetal programming. ANS autonomic nervous system, 
CVD cardiovascular disease, n-3 PUFA omega-3 polyunsaturated fatty acids, n-6 omega-6 polyunsaturated fatty acids
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the association of n-3 PUFA intake and BP lowering properties in those born with impaired fetal 
growth, found that similar associations were either not present or markedly weaker in those born with 
healthy birth weight [50].
 Conclusions
Accordingly, while a link between maternal intake of n-3 PUFAs and lower offspring BP is mechanis-
tically plausible, the evidence thus far is mixed and inconclusive, and limited principally by the lack 
of prospective randomised trials with BP as a pre-specified outcome.
There are a number of issues that will need to be duly considered in the design of such trials, and 
any recommendations that flow therefrom. What is the best vehicle for n-3 PUFA interventions in 
pregnant women? Consuming oily fish is generally recommended outside of pregnancy, for cardio-
vascular disease prevention, predominantly due to the inherent substitution of such a meal for a likely 
less healthsome meal. However, mercury levels in consumed fish are an important consideration, 
particularly during pregnancy, and as such consumption of species including swordfish and shark 
should be limited.
Fish oil supplements may be more amenable to some women, due to food preferences and toler-
ances, and most of the widely available supplements are low-mercury or mercury-free. Algae-derived 
DHA preparations overcome these concerns, and are also a suitable source of n-3 LCPUFA for women 
adhering to a plant-based diet. People adhering to such diets have higher ALA intake on average, the 
role of which during pregnancy remains poorly described.
Finally, identifying groups of women whose offspring will have the greatest likelihood of achiev-
ing clinically meaningful reductions in BP resulting from n-3 PUFA intake during pregnancy is an 
on-going challenge. As noted, such offspring are likely to be those at the highest risk of elevated BP 
due to an adverse maternal-fetal environment, including but not limited to those born premature or 
with fetal growth restriction, although clinical identification of women at risk of these outcomes early 
enough in pregnancy to enable the intervention to have a meaningful effect, remains challenging.
Yet despite these challenges, given the global burden of hypertensive-disorders and the strong 
evidence for developmental origins of hypertension, maternal n-3 intake is a potentially powerful and 
meaningful strategy to normalize offspring BP which warrants further careful and robust evaluation.
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